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Thesis summary 
 
Data suggest that for TG2 to be secreted, an intact N-terminal FN binding site (for 
which TG2 has high affinity) is required, however  interaction of TG2 with its high affinity 
binding partners presents both in the intracellular and extracellular space as well as with 
specific cell surface receptors may also be involved in this process.  
 
Using a site-directed mutagenesis approach, the effects of specific mutations of TG2 
on its translocation to the cell surface and secretion into the ECM have been investigated. 
Mutations include those affecting FN binding (FN1), HSPGs binding (HS1, HS2) GTP/GDP 
binding site (GTP1, 2) as well as N-terminal and C-terminal domains (TG2 deletion 
mutants N, and C). By performing transglutaminase activity assays, cell surface protein 
biotinylation and verifying distribution of TG2 mutants in the ECM we demonstrated that 
one of the potential heparan sulfate binding site mutants (HS2 mutant) is secreted at the 
cell surface in a much reduced manner and is less deposited into the ECM than the HS1 
mutant. The HS2 mutant showed a low affinity for binding to a heparin sepharose column 
demonstrating this mutation site may be a potential heparan binding site of TG2. 
Analogous peptides to this site were shown to have some efficiency in the inhibition of 
the binding of the FN-TG2 complex to cell surface heparan sulfates in a cell adhesion 
assay indicating the peptide to be representative of the novel heparin binding site within 
TG2. 
 
The GTP binding site mutants GTP1 and GTP2 exhibited low specific activity however, 
GTP2 showed more secretion to the cell surface in comparison to GTP1. The FN1 binding 
mutant did not greatly affect TG2 activity nor did it alter TG2 secretion at the cell surface 
and deposition into the ECM indicating that fibronectin binding at this site on the enzyme 
is not an important factor. Interestingly an intact N-terminus (Δ1-15) appeared to be 
essential for enzyme externalisation. Removal of the first 15 amino acids (N-terminal 
mutant) abolished TG2 secretion to the cell surface as well as deposition into the ECM. In 
addition it reduced the enzymes affinity for binding to heparin. In contrast, deletion of 
the C-terminal TG2 domain (Δ594-687) increased enzyme secretion to the cell surface.  
  
     Consistent with the data presented in this thesis we speculate that TG2 must fulfill two 
requirements to be successfully secreted from cells. The findings indicate that the closed 
conformation of the enzyme as well as intact N-terminal tail and a novel HS binding site 
within the TG2 molecule are key elements for the enzyme’s localisation at the cell surface 
and its deposition into the extracellular matrix. The importance of understanding the 
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interactions between TG2, heparan sulfates and other TG2 binding partners at the cell 
surface could have an impact on the design of novel strategies for enzyme inhibition 
which could be important in the control of extracellular TG2 related diseases.  
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                       P2 synthetic peptide 
Figure 5.3.4A Visualisation of 8 different images representing HOB cell adhesion in   
                         the presence of two different concentrations of P2 peptide alone  
                         or/and in the presence of RGD peptide, respectively 
Figure 5.3.4B Effect of P2 peptide in the absence or presence of RGD peptide on   
                         the attachment and spreading of HOB cells 
Figure 5.3.5 Effect of soluble P3 peptide on the adhesion of HOB cells to FN and  
                      FN-TG2 matrices in the presence of RGD peptide 
Figure 5.3.5A Illustration of eight independent images of HOB cells on FN and FN-  
                         TG2 matrices treated with P3 alone and with the same peptide but  
                         additionally supplemented with RGD peptide 
Figure 5.3.5B Effect of P3 peptide on TG2 mediated RGD-independent HOB cell   
                         adhesion on FN and FN-TG2 matrices 
Figure 5.3.6 Effect of P1 scrambled analogue (P1s) on the attachment and     
  spreading on HOB cells on FN and FN-TG2 matrices 
Figure 5.3.6A Visualisation of different images of HOB cells on FN and FN-TG2 in  
                             the presence of scrambled peptide alone and with addition of RGD  
                            peptide 
Figure 5.3.6B Effect of P1s on TG2 mediated RGD-independent HOB cells  
                         adhesion on both matrices 
Figure 5.3.7 Analysis for competition between the P1 peptide and the wild type   
                       TG2 for binding to Heparin 
Figure 5.3.8A Western blot analysis of TG2 eluted fractions from Heparin  
                         sepharose column demonstrating negligible competition between  
                         the wild type TG2 and the short peptide P3 (GRDCSRRSS) 
Figure 5.3.9B Comparison of showing TG2 binding to the Heparin Sepharose  
                          column in  the presence of P3 and P1 peptides and the scrambled P1  
                         counterpart 
Figure 6.1 Cellular distribution of wild type TG2 and TG2 constructs including HS1  
                   (K600A, R601A, K602A), HS2 (K205A, R209A), GTP1 (S171E), GTP2  
                   (K173L), FN1 (D94A, D97A), N (Δ1-15), and C (Δ594-687) 
Figure 6.2 TG2 sequence alignment. Alignment is showing conserved (green)           
                   positively charged amino acids and non-conserved (red) residues. 
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1.1 INTRODUCTION 
 
1.2 Transglutaminases and post-translational modification of proteins  
 
 Transglutaminases are multifunctional enzymes that possess more than one 
enzymatic feature acting on a wide range of different substrates. The first data reporting 
a TG were obtained from guinea pig liver by Clarke and his collaborators in 1957 (Clarke 
et al., 1957). Two years later an official name of ‘transglutaminase’ was used to describe 
this enzyme in a scientific report of Mycek (Mycek et al., 1959). All together, nine proteins 
have been characterised within the transglutaminase family. Eight of them are 
functionally and structurally connected with the TGase’s functions (the TGase 1-7 and 
Factor XIIIA). However the ninth one which is band 4.2 lacks a catalytic active site and 
remains only structurally related with the rest of the group (Griffin et al., 2002; Lorand 
and Graham, 2003). 
Transglutaminases are particularly interesting enzymes because of their ability to 
function in many physiological processes. It was reported that TGases can catalyse a 
number of different reactions which may affect either protein structure or the signal 
transduction process across the cell membrane. Some of these enzymatic reactions are 
chemically similar. Although there can be a difference in terms of substrate specificity or 
the kinetics of the reaction (Facchiano and Facchiano, 2009).  
The main function of TGases which are characterised as Ca2+ dependent thiol enzymes 
is to catalyse the post-translational modification between proteins resulting in their cross-
linking (Griffin and Wilson, 1984; Griffin et al., 2002; Fesus and Piacentini, 2002; Lorand 
and Graham, 2003; figure 1; Zemskov et al., 2006). The transamidating activity involves 
forming an Nε(γ-glutamyl)lysine isopeptide bond between the glutamine γ-carboxamide 
group of one polypeptide (acceptor) and the lysine ε-amino group of another polypeptide 
(donor) (Griffin et al., 2002; Zemskov et al., 2006) (Figure 1.1a). The reaction is strictly 
dependent on the presence of calcium which exposes a cysteine in the TGases active site 
resulting in the formation of cross-linked proteins which are highly protected against 
proteolytic degradation resulting in increased tissue strength (Folk and Finlayson, 1977; 
Griffin and Wilson, 1984). The transamidating activity can also lead to the amine 
incorporation (putrescine, spermine, histamine) which is based on replacing neutral 
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glutamine (Gln) residues by a positively charged one resulting in the formation of (γ-
glutamyl)-polyamine bonds (Folk and Finlayson, 1977) (Figure 1.1b). Another intriguing 
property of TGases is to create ester bonds. In particularly TGase 1 enzyme has been 
shown to mediate an esterification reaction between specific glutaminyl residues of 
human involucrin and a synthetic analogue of ω-hydroxyceramides (Nemes et al., 1999) 
(Figure 1.1d). This specific function plays an important role in maintaining the epidermal 
barrier of the skin.  It has also been reported that TGases can modify protein structure by 
catalysing the hydrolysis of peptide bound glutamine residues to glutamic peptide bond 
glutamate (Mycek and Waelsh, 1960). It was shown that deamidation of glutamine 
residues, catalysed by transglutaminases can influence the mechanism of the 
autoimmune diseases e.g. celiac disease (Aleanzi et al., 2001; Shan et al., 2002; Falini et 
al., 2008). This specific function of TGases is due to its ability to modify gluten proteins 
(Shan et al., 2002; Mazzeo et al., 2003). Briefly, TG2 mediated deamidation of gliadin 
favors the antigen presentation for activating T cells in celiac disease (Shan et al., 2002; 
Falini et al., 2008). Further analysis of TGases specificities, has revealed information about 
their potential in vitro to break the isopeptide bonds with high affinities for γ-branched 
peptides. TG2 as well as FXIIIa  exhibit isopeptide activity and has been reported to 
hydrolyse Nε(γ-glutamyl)lysine isopeptide bonds indicating the transglutaminase 
involvement in cell biology by both catalysing the formation and breaking of  Nε(γ-
glutamyl)lysine isopeptide bonds ( Parameswaran et al., 1997). 
Another function that these multifunctional enzymes exhibit is acting as a protein 
disulphide isomerase which is totally independent on the presence of calcium as well as 
their transamidation activity (Hasegawa et al., 2003).  
Although it seems easy to outline all reactions that transglutaminases catalyse, their 
enzymatic pathways are much more complex. When the acceptor carrying a glutaminyl 
residue is recognised by enzyme, the γ-glutamylthioester bond is formed with the 
cysteine residue of the TG active site which is known as the acylenzyme intermediate. 
This results in the release of ammonia (Figure 1.1a-e) or amine (Figure 1.1f). Meanwhile 
the donor amine reacts with the acyl-enzyme complex which attacks the thioester bond 
causing the cysteine residue of the enzyme to reverse back to its original form. Having an 
active site again, the enzyme is allowed to participate in another reaction and depending  
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Figure 1.1 Post-translational reactions catalysed by transglutaminases adopted from 
Lorand and Graham, 2003. Schematic illustration of different reactions mediated by 
transglutaminases a cross-linking between the lysine (Lys) residue of the targeted donor 
protein (purple ellipse) and acceptor glutamine (Gln) residue of another protein (blue 
rectangle) b incorporation of an amine (H2N) into the Gln residue c acylation of the Lys 
residue in donor protein. Additionally to transamidation TGases can catalyse d 
esteryfication between the Gln residue of protein and a ceramide (HOR”) and protein 
hydrolysis e deamidation, and f isopeptide cleveage. R corresponds to the side chain in a 
primary amine; R` a Gln containing peptide; R`” and R”” the side chains in ispoeptides. 
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on the donors’ nature, generate different reaction products (Lorand and Graham, 2003, 
figure 1). 
 The substrate specificity related to a specific Tgase activity still remains under the 
investigation (Kim et al., 1994; Nemes et al., 1999; Taguchi et al., 2000). It is known that 
only specific glutamine and lysine residues can act in proteins both as acyl donors and 
acyl acceptors (Facchiano and Facchiano, 2009). Many researchers have been exploring 
the specificity of these residues. Finally the consensus sequences pQx(P,T,S)1 – (where x, 
p and 1 suggests any amino acid , polar and aliphatic amino acids, respectively) which 
includes the reactive glutamines was found (Keresztessy et al., 2006). Meanwhile it was 
reported that  TG2 catalyses the cross-linking reaction within a specific sequence patterns 
as well QxPhD, QxPh, and QxxhDP (where x can be any amino acid and h can be an 
hydrophobic amino acid) (Sugimura et al., 2006; Facchiano and Facchiano, 2009). 
Furthermore another work revealed that substrate specificity is not only restricted by the 
consensus sequence but is more flexible which explains its ability to be cross-linked by 
TGases (Fontana et al., 2008).  
 
1.3 Classification of transglutaminases 
 
So far, nine members of the transglutaminase family have been identified at the 
genomic level in humans (Grenard et al., 2001a). As summarized in Table1.1, the 
transglutaminase family consist of: the keratinocyte transglutaminase (TG1), the tissue 
transglutaminase (TG2), the epidermal transglutaminase (TG3), the prostate 
transglutaminase (TG4), the circulating zymogen FXIII, (the inactive form of the enzyme is 
converted into the active FXIIIa subunit during thrombin-dependent proteolysis), the 
recently characterised  transglutaminase X, Y, and Z (TG5, TG6, TG7) and erythrocyte band 
4.2 (Aeschlimann et al., 1998; Griffin et al., 2002). 
Eight of the nine TG genes encode catalytically active enzymes while one encodes a 
catalytically inactive protein called band 4.2.  
Within the transglutamianse family a high level of structural homology has been 
observed. It is known that all the active members of this family share a four domain 
tertiary structure with a catalytic triad of Cys-His-Asp or Cys-His-Asn (Ikura et al., 1988; 
Griffin et al., 2002).  
 
 Table 1.1 Classification of TGases, adopted from Lorand and Graham, 2003 and Facchiano and Facchiano, 2009. 
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Moreover the common feature for all the members is lack of carbohydrate modifications 
regardless of the presence of N-glycosylation sites, as well as cysteine residue at the 
active site. 
 So far, the importance of transglutaminase catalytic activity in physiology, 
development of many human organs (heart, lung, salivary gland, and nervous system) as 
well as maintaining tissue stability and integrity has been reported (Lorand and Graham, 
2003; Telci and Griffin, 2006). Thus, it is not surprising that alteration of TG expression or 
activity has been implicated in a wide variety of diseases and pathologies. For example 
pathological conditions like skin disorders contribute to overexpression of TGases (TG1, 
TG2) whereas decrease of TG2 expression is involved in tumour growth following 
disruption of cell-matrix interactions leading to cancer-cell metastasis (Belkin et al., 2001; 
Lorand and Graham, 2003; Jones et al., 2006). 
 
1.4 Activation of FXIII and role of FXIIIA in mammalian cells 
 
It is known, that the other transglutaminase (FXIIIA) widely employed in maintaining 
the cell surface homeostasis, appears in a zymogen form requiring proteolytic activation 
of the pro-enzyme FXIII which occurs by thrombin cleavage (Muszbek et al., 1999; Al-
Jallad et al., 2006). FXIII (blood coagulation factor) exists as heterotetramer in plasma or 
homodimer in cells (Shwartz et al., 1973; Ariёns et al., 2002; Shwartz et al., 2007). Being a 
tetramer (A2B2), FXIII is composed of two proenzyme subunits (A2) surrounded by two 
carrier subunits (B2) while existing as homodimer (A2), FXIII is made exclusively of two 
subunits A (Shwartz et al., 2007; Shwartz et al., 2009). Subunit A contains the catalytic 
active site, an activation peptide, a calcium binding site and free sulfhydryl groups, while 
the carrier subunit B is a glycoprotein that stabilises subunit A, binds it to fibrinogen and 
influences FXIII activation (Lorand et al., 2001; Ariёns et al., 2002).  
The Factor XIII A subunit is synthesised by hematopoetic cells such as 
megakarryocytes, monocytes and macrophages, while the B subunit is synthesised by 
liver (Muszbek et al., 1995, 1996). FXIIIA has also been found in the placenta, prostate, 
uterus and liver (Henriksson et al., 1985; Greenberg et al., 1991; Adany, 1996). The 
secretion mechanism of FXIII A subunit still remains unknown. Some data indicates that 
FXIIIA is released as a consequence of cell destruction and is thought to unite with FXIII B  
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in the circulation (Kaetsu et al., 1996).  However there is some other data suggesting that 
similarly to other mammalian transglutaminases (TG2 and TG4), FXIII A subunit is secreted 
through an unconventional pathway. It has been shown that FXIII A can be externalised 
separately from its carrier subunit FXIII B that undergoes secretion through an ER/Golgi 
dependent mechanism (Al-Jallad et al., 2006). It was found in monocytes, osteoblasts, and 
osteocytes and was reported to be secreted from differentiating osteoblasts (Al-Jallad et 
al., 2006; Nakano et al., 2007).  
The gene coding for the FXIII A subunit is mapped to chromosome 6p 24-25 and is 
composed of 15 exons interrupted by 14 introns encoding a mature protein of 731 amino 
acids (Board et al., 1988; Hsieh and Nugent, 2008). Following analysis of cDNA sequences 
of FXIII, it was reported that FXIIIA shares sequence homology with TG2, TG3 and band 
4.2 (Ichinose, 1986; Ichinose and Kaetsu 1993). The FXIII B subunit gene is located on 
chromosome 1q31-32.1 and comprises 12 exons interrupted by 11 introns which encodes 
a mature protein of 641 amino acids (Webb et al., 1989; Bottenus et al., 1990).   
 Upon activation by thrombin which is the final step of blood clotting cascade and in 
the presence of Ca2+, the inactive enzyme (plasma FXIIIA) becomes activated (Fox et al., 
1999; Casadio et al., 1999). Studies on FXIIIA structure including x-ray crystallography and 
computer modeling analysis has additionally shown that the presence of calcium is not 
only required for activation but also enhances the physical stability of FXIIIA (Fox et al., 
1999; Casadio et al., 1999).  Triggered by thrombin cleavage of an N-terminal peptide on 
the A-subunits, dissociation of the A-subunits from the B-subunits exposes the active 
cysteine binding site of plasma FXIIIA (Ariёns et al., 2002; Lorand and Graham, 2003). The 
enzymatically active transglutaminase catalyses the cross linking leading to the formation 
of covalent bonds between proteins (adjacent fibrin monomers) which contain 
appropriate lysine and glutamine residues (Muszbek et al., 1999) (Figure1.2). Activated 
FXIII catalyses a transamidation reaction between two different fibrin molecules through 
an ε-(γ-glutamyl) lysine bonds (Shwartz et al., 1973). This reaction enhances the strength 
of the blood clot by providing a network for cell migration and new tissue formation 
(Shainoff et al., 1991; Telci and Griffin 2006).  Moreover, the cross-linking reaction 
catalysed by FXIII influences fibrin breakdown by incorporation of fibrinolysis resistant 
inhibitors (α2-antiplasmin, PAI-2) (Richie et al., 2000; Ariёns et al., 2002). FXIII forms 
covalent bonds with α2-antiplasmin, (the main inactivator of plasmin) (Booth, 1999;  
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Board et al., 1993) and thrombin (activatable fibrynolysis inhibitor) which increases the 
resistance of the clot to proteolytic degradation by plasmin (Mosesson et al., 2008; Hsieh 
and Nugent, 2008). Additionally FXIII A  can play a wider role by cross-linking several other 
protein substrates including the blood coagulation factor V (Francis et al., 1986), 
fibrinogen (Dyr et al., 1989), von Willebrand factor (Hada et al., 1986) , type-2 
plasminogen activator inhibitor (Richie et al., 2000). Also plasma fibronectin present on 
the fibroblasts surface as well as fibronectin synthesised by these cells were suggested to 
be cross-linked by FXIII A (Barry and Mosher, 1990).  
Other studies suggest that in tissues not expressing thrombin the inactive FXIII subunit 
can still be activated, by other serine proteases including endogenous platelet acid 
protease and calpain through cleavage of the Arg-37, Gly-38 (Lynch and Pfueller, 1988; 
Ando et al., 1987). Additionally FXIIIA can also be activated for example in bone by 
membrane bound protease (MMP-2) or cell surface endopeptidase PHEX (Belkin et al., 
2004; Miao et al., 2001). However in the intracellular environment where calcium levels 
rise in the presence of an appropriate substrate platelet FXIII may undergo a non 
proteolytic conformation change leading to its activation (Polgar et al., 1990).  
 
 
 
Figure 1.2. Activation of FXIII and cross-linking of insoluble fibrin.  Adopted from Lorand 
et al., 2001, and Shwartz et al., 2009.  
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FXIII was defined in early papers as a fibrin stabilising factor, however recent papers 
indicate its involvement in many processes which result from its ability to crosslink 
plasma proteins as well as proteins within the vascular matrix, endothelial cells, maturing 
monocytes and platelets.  So far, it has been reported that FXIIIA plays an important role 
in many processes including wound healing (Telci and Griffin, 2006; Jones et al., 2005), 
cell proliferation (Ádany et al., 2001; Schwartz et al. 2009), cell motility (Jayo et al., 2009) 
osteoblast and chondrocyte differentiation (Al Jallad et al., 2006; Johnson et al., 2008) 
and bone formation (Nakano et al., 2007), chromatin structure remodeling and even cell 
death (Ádany et al., 2001; Schwartz et al., 2009). In addition, FXIII has been reported to be 
involved in angiogenesis through interaction with factors that possess proangiogenic 
features (fibronectin, thrombospondin1) or interaction with β3 integrins and the VEGF 
receptor (Dardik et al., 2004; Dardik et al., 2005). Moreover it was suggested that FXIII can 
play other important roles outside of homeostasis by enhancing the metastasis by a 
mechanism linked to NK cells (Palumbo et al., 2008).  
The deficiency in FXIII activity has been correlated with many diseases mainly affecting 
homeostasis, normal wound healing as well as healthy pregnancy. It was demonstrated 
that severe FXIIIA deficiency can lead to bleeding diathesis, delays in wound healing and 
tissue repair, bleeding during pregnancy which increases the possibility of early 
miscarriage (Anwar and Miloszewski, 1999; Hsieh and Nugent, 2008). 
 
1.5 Keratinocyte transglutaminase (TG1) 
 
Keratinocyte transglutaminase (transglutamianse type 1) was identified as an 
intracellular, epidermal specific enzyme (Thacher and Rice, 1985; Philips et al., 1990). TG1 
was reported to be primarily expressed in stratified squamous epithelia, however as 
measured by in situ hybridization, it was noted its expression seemed dependent on 
keratinocyte proliferation and differentiation (Ta et al., 1990; Michel et al., 1992; Kim et 
al., 1995). In the skin epidermis it is expressed in the upper spinous and granular layers 
and is involved in the formation of the outermost skin protection barrier the so called 
cornified cell envelope (CE) (Thacher and Rice, 1985; Schroeder et al., 1992; Kim et al., 
1995). The presence of this insoluble outer cell layer on the cell surface of the epidermis 
acts as the main barrier against chemical or mechanical injury as well as biological  
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invasion. Additionally it was reported to be formed of ε-(γ-glutamyl) lysine cross-linked 
proteins present on the intracellular surface of the plasma membrane due to 
transamidation activity (Ta et al., 1990). Immunochistochemistry evidence suggests that 
TG1 appears to be very important in catalysing cross-linking of a range of substrates 
including involucrin (Simon and Green, 1988), loricrin (Mehrel et al., 1990), 
cornifins/small proline-rich proteins (Marvin et  al., 1992; Gibbs et al., 1993), cystatin-α 
(Takahashi et al., 1992), keratin intermediate filaments, filaggrin (Steiner and Marekov, 
1995), envoplakin (Ruhrberg et al., 1996) and other proteins (Robinson et al., 1997). 
Initially keratinocyte transglutaminase from human and rat was shown to be the 
largest from the whole transglutaminase family with a molecular mass of 90 kDa (Philips 
et al., 1990). Further studies on proliferating cells revealed the full length of the enzyme 
to be 106kD (Kim et al., 1994 and 1995). However this discovery was related to the 
cytoplasmic TG1 which was associated to the inner surface of keratinocyte membrane 
through mirystyl and palmityl anchors (Philips et al., 1993). Further work showed that 
keratinocyte differentiation causes increased proteolysis of cytoplasmic TG1 to yield 
fragments of 10, 33, 67 kDa (Steiner et al., 1996, Kim et al., 1995) which was suggested by 
in vitro studies to result in increased TG1 activity (Kim et al., 1994, Kim et al., 1995). 
The gene coding for human TG1 is located on the 14q11.2 chromosome and encodes a 
mature protein composed of 816 amino acids (Kim et al., 1992; Yamanishi et al., 1992). 
Studies on the TGM1 gene have revealed that the TGM1 locus is connected to the 
autosomal skin disease as Lamellar ichthyosis (Russell et al., 1994). Lamellar ichthyosis is a 
disorder which affects both skin and hair which results from the mutation in the TG1 gene 
causing thickening of the epidermis with high risk of dehydration (Huber et al., 1995; 
Russell et al., 1995; Eckert et al., 2005). This finding indicates that disruptions in TG1 
activity are the main source of the disease. Additional research on TG1 deficient mice 
showed that this enzyme is essential in the development of the stratum corneum and in 
neonatal adaptation to the environment (Matsuki et al., 1998). Briefly, it was 
demonstrated that TG1 -/- mice died 4-5 hours after birth due to the abnormal skin 
keratinisation and an impaired skin barrier (Matsuki et al., 1998). 
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 1.6 Epidermal transglutaminase (TG3) 
 
 
Epidermal transglutaminase was first characterised in 1975 by Buxman and Wuepper 
as a soluble protein of around 50kDa (Buxman and Wuepper, 1975) and purified from 
human and bovine skin (Buxman and Wuepper, 1976; Ogawa and Goldsmith 1976). 
Further studies revealed that TG3 is synthesised as an inactive zymogen form with a 
molecular weight of 77 kDa which undergoes limited proteolysis resulting in its activation. 
The proteolytic activation requires cleavage of the zymogen form into two fragments of 
30 kDa and 47 kDa in the region between the catalytic core and the β-barrel 1 and takes 
place during keratinocyte differentiation (Kim et al., 1990; Kim et al., 1993). Upon 
proteolysis TG3 like all mammalian TGases requires the presence of calcium ions which 
influences enzyme activity (Ahvazi et al., 2002; Ahvazi et al., 2003). In addition its activity 
can also be regulated by binding guanine nucleotides (Ahvazi et al., 2004). 
Even though the protease activation of epidermal transglutaminase in vivo still remains 
elusive, cathepsin-L (Cheng et al., 2006) and the bacterial enzyme dispase (Hitomi et al., 
1999) has been reported to proteolyse and activate the enzyme in vitro. Additionally, 
recent studies showed that the protease inhibitor cystatin M/E can act as an inhibitor of 
cathepsin-L thus negatively regulate TG3 activation at least during skin morphogenesis in 
the neonatal phase (Cheng et al., 2006).  
Epidermal transglutaminase is expressed mainly as a proenzyme in the brain, testis, 
small intestine as well as in the skin, generally in its granular and cornified layers (Hitomi 
et al., 2001; 2003). Additionally it can be localised in the cytoplasm of differentiating 
keratinocytes as shown by Hitomi et al., (2003). Similar to TG1, TG3 was reported to be 
involved in the formation of the cornified cell envelope (Buxman and Wuepper, 1975). 
When activated, TG3 crosslink proteins including loriclin and small proline rich proteins 
present in the cytoplasm of keratinocytes. In contrary to TG1, TG3 forms mostly 
intramolecular cross-links between certain lysine and glutamine residues while TG1 
favours intermolecular reactions (Candi et al., 1995). Moreover, TG3 cross-links one of the 
small proline rich proteins in a consecutive manner while TG1 forms large oligomers 
(Hitomi et al., 2005).  
The physiological role of epidermal transglutaminase is still elusive. However it is 
known to play role in the diagnosis of dermatitis herpetiformis (cutanous form of celiac 
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disease). The detection of autoimmune IgA antibodies directed against epidermal 
transglutaminase was revealed to be a very sensitive test for the detection of dermatitis 
herpetiformis (Sardy et al., 2002; Rose et al., 2009). 
 
1.7 Prostate transglutaminase (TG4) 
 
Prostatic transglutaminase (TG4) is a unique member within the whole 
transglutaminase family. It was described for the first time in the dorsal prostate and 
coagulation gland of rats and characterised as a homodimeric protein of 150 kDa 
composed of two polypeptide chains each with molecular weight of 75 kDa (Seitz et al., 
1990; 1991). So far it is known to be found mainly in the prostate gland and on a very low 
level in other tissues (Gentile et al., 1995; Dubbink et al., 1996).  
As shown by in situ hybridization the gene encoding human TG4 is located on the 
3p21.33-p22 chromosome (Gentile et al., 1995) and encodes a protein consisting of 684 
amino acids with a predicted molecular mass of 77 kDa (Dubbink et al., 1996). In the 
prostate, the expression of human TG4 is limited to luminal epithelial cells of the gland 
(Dubbink et al., 1999), however recent studies on a cancerous human cell lines revealed a 
much broader expression of this enzyme. Colon, lung and prostate cancerous cells 
showed a wide range of prostate transglutaminase expression level (Davies et al., 2007). 
Yet very little information has been provided regarding the mechanism of its 
externalisation. It has been revealed that the 30kDa and 100 kDa GTPase enzymatic 
activities are linked to the prostatic secretion with the TG4 (Spina et al., 1999). Additional 
information relates to albumin, which was reported to facilitate TG4 translocation 
through the membrane (Wiche et al., 2003). 
Little is known with regard to the physiological and pathological functions of this 
enzyme. In rodents, the rat prostate transglutaminase has been demonstrated to be 
involved in the formation of the copulatory plug (Williams-Ashman, 1984). In addition 
TG4 has been suggested to play a role in sperm cell motility, immunogenicity and 
immunoregulation (Ablin and Whyard, 1991). Moreover it has been reported that TG4 
may influence the invasiveness of the prostate cancer by being up regulated in some 
prostate cancer cell lines (Dubbink et al., 1996) and down-regulated in most metastatic 
prostate cancers (An et al., 1999). Another data base using prostate cancer cells (CAHPV- 
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10 cells) indicates that when the prostate TG4 is lost from these cells they become less 
invasive (Davies et al., 2007). Recent studies discovered that over expression of TG4 in 
prostate cancer cells enhances their capability to adhere to endothelial cells leading to 
the disturbance of the barrier function of the endothelial cells (Jiang et al., 2009).  
 
1.8 Erythrocyte Band 4.2 
 
The membrane protein, erythrocyte band 4.2, is one of the most abundant proteins 
within the erythrocyte membrane cytoskeleton, accounting for approximately 5% of the 
membrane components (Yawata, 2003). Analysis of the genomic organisation of human 
band 4.2 has revealed that the gene coding for band 4.2 is composed of 13 exons and 12 
introns (Korsgen and Cohen, 1991) giving rise to two different isoforms, a minor one with 
molecular weight of 74 kDa and a major isoform with molecular weight of 72 kDa 
(Korsgen et al., 1990; Sung et al., 1990; Satchwell et al., 2009). The human band 4.2 
protein has been reported to share a sequence homology with other members within the 
transglutaminase family even though it does not possess the active cysteine site required 
for the cross-linking activity (Korsgen et al., 1990) thus suggesting that band 4.2 is strictly 
a structural protein (Cohen et al., 1993).  
Studies on the amino acid sequence of the human band 4.2 (Korsgen et al., 1990; Sung 
et al., 1990) demonstrated that band 4.2 contains an N-terminal glycine residue following 
the initial methionine which becomes myristylated (Risinger et al., 1992). In addition the 
human protein was also reported to be palmitoylated on cysteine 203 (Das et al., 1994). 
Both of these processes have been shown to be required for the direct interaction of 
band 4.2 with the erythrocyte inner membrane space. 
The exact role of protein band 4.2 has not been fully discovered. It is known that band 
4.2 associates with the N- terminal cytoplasmic domain of the erythrocyte membrane by 
binding to the anion exchanger band 3 (Korsgen and Cohen, 1986). In addition it interacts 
with membrane structural proteins including ankyrin, protein band 4.1 (Korsgen and 
Cohen, 1988), and spectrin (Mandal et al., 2002) in solution. This interaction influences 
the structural integrity of the erythrocyte membrane. Moreover band 4.2 has been 
proposed to be involved in the anchoring of the Rh complex into the red blood cell 
skeleton by interaction with CD47 which is one of the proteins belonging to the Rh 
complex (Mouro-Chanteloup et al., 2003; Satchwell et al., 2009) Thus erythrocyte band 
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4.2 plays an important role in assisting the survival of red blood cells in circulation 
(Satchwell et al., 2009). 
The absence of protein band 4.2, caused by natural mutations in humans or  deficiency 
in its expression by mice can lead to haemolytic anaemia (Bruce et al., 2002; Dahl et al., 
2004) for example Hereditary spherocytosis, which is one of the most common anaemic 
disorders affecting red blood cells in many humans (Satchwell et al., 2009). In addition the 
deficiency of band 4.2 protein in mouse influences physiological functions of the 
erythrocytes membrane (Peters et al., 1999) indicating the importance of this protein in 
maintaining the stability of the red blood cell membrane.  
 
1.9 Transglutaminases 5, 6, and 7 (X, Y, and Z) 
 
Within the transglutaminase family, three transglutaminases including 
transglutaminase X (TG5), transglutaminase Y (TG6) and transglutaminase Z (TG7) have 
now been discovered and therefore they are less characterised at the functional level. 
However, genomic analysis within all the family members revealed a high degree of 
sequence homology (Aeschlimann et al., 1998; Grenard et al., 2001a). 
 Native Transglutaminase X, as characterised for the first time by Aeschlimann et al., 
1998 is composed of 720 amino acids with a molecular mass of approximately 82kDa. 
When compared to the other family members, novel transglutaminase showed an overall 
35% sequence homology with the conserved domain structure, active site and calcium 
binding site (Aeschlimann et al., 1998). Further investigation revealed that similar to TG2, 
and TG3, TG5 is regulated by adenine-guanine nucleotides with a capability of hydrolysing 
GTP (Candi et al., 2004), however it still remains unknown how its GTP activity influences 
cell function (Eckert et al., 2005). Recent studies reported that TG5 undergoes proteolysis 
in mammalian epithelial cells which activates the enzyme itself (Pietroni et al., 2008). 
The gene encoding TG5 is located on the 15q15.2 chromosome and consists of 13 
exons separated by 12 introns (Grenard et al., 2001a). Originally TG5 was described in the 
spinous and granular layers of the human epidermis and further analysis revealed its 
presence in differentiating keratinocytes (Candi et al., 2001; Candi et al., 2002).  As shown 
by in vitro experiments TG5 can cross-link small proline rich proteins, involucrin and 
loricrin indicating that similar to TG1 and TG3, TG5 can be involved in the formation of  
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the cornified cell envelope (Candi et al., 2001). The abolishment of the activity of TG5 in 
the skin caused by mutations in the human TG5 gene has been linked to acral peeling skin 
syndrome (Cassidy et al., 2005).  
Mapping of the chromosomal segment encoding for TG2 and TG3, revealed the 
presence of another novel gene transglutaminase Y (TG6) located on the 20q11 region of 
chromosome 20 (Grenard et al., 2001a). 
Additionally during extensive investigations another novel transglutaminase has been 
discovered in a human prostate carcinoma tissue. Transglutaminase Z, (TG7) has been 
reported to consist of 710 amino acids with a molecular weight of 80 kDa. When 
compared to the existing mammalian transglutaminases, TG7 has been shown to possess 
similarities and a high level of conservation for the TGase active and calcium binding sites 
as well as the core domain containing the catalytic amino acid triad. In addition 
sequencing analysis revealed genes encoding for TG7 and TG5 to be localised in tandem 
with the band 4.2 protein on chromosome 15 (Grenard et al., 2001a). 
 
1.10 Tissue transglutaminase (TG2) 
 
To date tissue transglutaminase (TG2) appears to be the most studied and the best 
characterised enzyme within the whole transglutaminase family. Under normal 
conditions, inside the cell the enzyme is mainly localised in the cytoplasm. Moreover its 
presence was also found in the nucleus, nuclear membrane, mitochondria, at the cell 
surface and in the extracellular matrix (Lesort et al, 1998; Upchurch et al, 1991; Griffin et 
al., 2002; Piacentini et al., 2005; Collighan and Griffin, 2009). 
TG2 is a unique member of the family widely distributed in both the intracellular and 
extracellular cell environment in tissues and in brain; however its expression levels differ 
dependent on the cell and tissue type (Thomazy and Fesus, 1989). There are cells that 
show high expression of TG2 (endothelial, epithelial cells and macrophages), which 
sometimes remains at a constitutive level (endothelium) or is up- regulated by specific 
stimuli such as inflammatory cytokines (INF-γ in rat intestinal cells and IL-6 in human 
Hepatoblastoma cells) as well as steroids, vitamin D, and growth factors including TGF-β1 
by the potential TGF-β1/BMP4 response element in TG2 gene (Suto et al., 1993; Ritter and  
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Davies, 1998; Kim et al., 2002; reviewed by Zemskov et al., 2006). Additionally tissue 
specific TG2 expression can be influenced by retinoic acid. Analysis of the TG2 gene 
revealed the presence of a retinoid response element within the functional promoter of 
the enzyme (Moor et al., 1984; Gentile et al., 1991).This specific retinoid response 
element (mTGRRE1) when coupled with short DNA (HR-1) triggers promoter activation by 
retinoic acid (Nagy et al., 1996). Furthermore, differences in TG2 expression can be 
caused by variations in methylation of its gene promoter. As shown for Ras-transformed 
fibroblastic cells, hypermethylation of the promoter region can play an important role in 
the transcriptional regulation of TG2 gene (Lu and Davies, 1997).  
 
1.10.1 Structure of TG2 
 
Following cloning studies of the TG2 cDNA sequence from guinea pig liver (Ikura et. al., 
1988), mouse macrophages (Gentile et al., 1991), chicken erythrocytes (Weraarchakul-
Boonmark et al., 1992), bovine aorta (Nakanishi et al., 1991), and human endothelial cells 
(Gentile et al., 1991) the structure of TG2 has been identified. The TG2 is a monomeric 
protein of 685-691 amino acids with a molecular mass of 76-85 kDa (Aeschlimann and 
Paulson, 1994) and is allosterically regulated by binding calcium or GTP (Liu et al., 2002; 
Fesus and Piacentini, 2002; Lorand and Graham, 2003). The gene encoding human TG2 
has been mapped to the chromosome 20 and is composed of 13 exons separated by 12 
introns (Fraj et al., 1992; Gentile et al., 1994). Exon 13 is made up around 50% of the 
enzyme cDNA and contains both the C-terminal coding region and the 3’ end of the cDNA 
(Fraj et al., 1992). Analysis of the amino acid sequence of the guinea pig liver has shown a 
cysteine residue to be present at position 276 (Ikura et al., 1988) while 277 in human TG2 
(Gentile et al., 1991). The calcium binding site thought to regulate TG2 transamidation 
activity has been localised in the core domain around 138 and 185 aminoacids (Figure 
1.3a) while recent studies has additionally demonstrated the presence of a few negatively 
charged amino acids localised in TG2 among the whole core domain which can influence 
TG2 activity by their ability to binding calcium (Király et al., 2009). 
Human tissue transglutaminase has been crystallized in two different conformations 
(Liu et al., 2002; Pinkas et al., 2007). When in a GDP-bound form, TG2 exists in a closed 
conformation whereas interaction with a pentapeptide inhibitor stabilises its open, 
extended form. Although the two structures of the enzyme show different movement, 
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both of them were proposed to be a monomeric protein composed of four distinct 
domains (Liu et al., 2002; Pinkas et al., 2007). The TG2 structure has been derived from 
that of FXIII and is composed of an N-terminal β-sandwich (residues 1-138), a large core 
domain (residues 139-471) and two β-barrels on its C-teminal site (residues 472-687) 
(Chen and Mehta, 1999; Lorand and Graham, 2003). Also the crystal structure of the red 
sea bream liver transglutaminase (fish derived TGase) has been shown to be similar to the 
structure of human FXIIIa, additionally indicating overall similarities between TG2 and 
FXIII (Noguchi et al., 2001). Although this four-sequential domain organisation, and the 
relative position of catalytic triad (Cys277, His335, and Asp358) residues is highly 
conserved among TG isoforms, (Griffin et al., 2002; Lorand and Graham, 2003), the charge 
distribution varies between different isoenzymes (Chen and Mehta, 1999). This may 
influence substrate specificity and further functions of each enzyme. The TG2 core 
domain contains the calcium binding site and the active transamidation regulatory site, 
while the last two domains have an inhibitory effect on the transamidating activity by 
impeding the substrate access to the active site (Casadio et al., 1999). The cysteine 
(Cys277) residue is essential for TG2 transamidation activity (Folk and Cole, 1966; Lee et 
al., 1993). However studies performed by Ismaa and co-workers (1997) have 
demonstrated that in addition to the catalytic domain also the flanking domains (N-
terminal β sandwich) can also influence the activity of the enzyme. Moreover another 
residue present in the core domain (tryptophan 241) was also implicated to be involved in 
TG cross-linking activity  (Murthy et al., 2002) while  recent studies has additionally 
demonstrated the presence of a few negatively charged amino acids localised in the TG2 
core domain which can influence TG2 activity by their ability to binding calcium (Király et 
al., 2009). Although the main function of TG2 core domain is its transamidation activity, 
further analysis revealed its engagement in the hydrolysis of ATP and GTP (Ismaa et al., 
1997). Ismaa and co-workers (2000) has localised the GTP binding site to a 15 amino acid 
segment of the core domain between 159 and 173 residues while further analysis 
revealed additional GTP binding sites present on a barrel 1 between 476-482 and 580-583 
amino acids (Liu et al., 2002; Begg et al., 2006).  
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Figure 1.3 A Proposed functional and structural domains organisation of tissue 
transglutaminase (Lesort et al., 2000); B as well as its three-dimensional (closed) structure 
designed and kindly provided by Dr Russell Collighan from Aston University. 
Ca
2+
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1.10.2 Regulation of activity, expression, and conformation of tissue transglutaminase 
 
Tissue transglutaminase is a bifunctional enzyme that in addition to its calcium- 
dependent cross-linking activity is capable of catalysing the magnesium dependent 
reaction by binding and hydrolysis of ATP and GTP (Lee et al., 1989). An understanding of 
these unique features of tissue transglutaminase has been the main task undertaken by 
many researchers over numerous years. Early in vitro studies on guinea pig liver 
transglutaminase have demonstrated that guanine nucleotides, especially GTP, can have 
an inhibitory effect on the calcium dependent activity of the enzyme (Achyuthan and 
Greenenberg, 1987).    
It is known that TG2 is located in many compartments of the human body, where it is 
engaged in physiological and pathological processes. Three-dimensional structure of TG2 
is allosterically regulated by binding calcium or nucleotides (GTP, ATP) (Begg et al., 
2006b). Being mainly a cytosolic protein, where the Ca2+ concentration is low, TG2 
transamidating activity remains latent (Monsonego et al., 1998, Liu et al., 2002). The 
binding of GTP locks TG2 in a closed conformation (Figure 1.4b) thus reducing its affinity 
for calcium ions and blocking its cross-linking functions (Achyuthan and Greenenberg, 
1987; Smethurst and Griffin, 1996; di Venere et al., 2000). In its latent conformation, a 
specific interaction between the catalytic core and barrel-1 and barrel-2 occurs which 
hinders accessibility of the TG2 active site to the substrate. The inhibitory effect of GTP is 
mediated by its binding to amino acids present on the barrel-1 domain (476-482 and 580-
583) and two residues present on the TG2 core domain (Ser171 and Lys173) and which 
stand out on a loop close to barrel 1 leading to its stabilisation and further masking TG2 
active site (Liu et al., 2002; Ismaa et al., 2000; Begg et al., 2006a). In addition, Begg and 
co-workers (2006b) have postulated that GTP when bound to the enzyme, destabilises 
Arg-579 and facilities the formation of the H bound between Tyr-516 located on the 
barrel-1 and Cys-277 present on the core domain thus favoring compact, inactive 
conformation of the enzyme. However the inhibition of cross-linking activity of the 
enzyme can be partially reversed by addition of calcium ions (Smethurst and Griffin, 
1996). 
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Figure 1.4 Structural conformation of tissue transglutaminase designed by Dr Russell 
Collighan from Aston University. The crystal structures of a calcium or an inhibitor-bound, 
and b GTP/GDP-bound TG2. The structures are shown as ribbons and present the N-
terminal β-sandwich domain (in green), the catalytic core (in light blue), the C-terminal β-
barrel1 and β-barrel2 (in red and blue) respectively (Pinkas et al., 2007).   
 
When calcium is bound to the enzyme it alters its conformation by displacing the β-barrel 
TG2 domains further apart from the catalytic core thus opening an access to the active 
transamidation site (Liu et al., 2002) (Figure 1.4 a).  
As described earlier, ATP has also been shown to bind to TG2 and undergo hydrolysis 
in a magnesium dependent manner (Lee et al., 1993). Studies carried out by Lai and co-
workers (1998) demonstrated that both Mg2+-GTP and Mg2+-ATP complexes are real 
substrates for TG2 hydrolysis and key regulators of the different enzymatic activities of 
TG2.  
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The binding of Mg2+-GTP by TG2 inhibits its protein cross-linking activity without 
affecting ATPase activity (Lai et al., 1998). In contrary, Mg2+-ATP induces conformational 
changes by preventing its ability to bind GTP, in addition having no influence on its 
protein transamidation activity (Lai et al., 1998). Inhibition of the GTPase activity by ATP, 
if GTP binding is not affected, could increase the TG2 Gh activity (Johnson and Terkeltaub 
2005).  
Under normal physiological conditions the intracellular level of calcium ions is 
insufficient to support transamidation by TG2. A membrane lipid 
sphingosylphosphocholine (Lyso-Sm) has been suggested to modulate TG2 TGase activity 
by enhancing it at low calcium concentration (10μM Ca2+) (Lai et al., 1997).  During 
interaction with TG2, Lyso-Sm induces changes in protein conformation that influence its 
affinity for calcium whilst not affecting substrate binding (Lai et al., 1997). Another 
molecule suggested to modify TG2 activity is nitric oxide, an inorganic free-radical 
molecule which targets TG2 via S-nitrosylation of protein thiol groups (TG2 has 18 free 
cysteine residues including the active site Cys 277) leading to reversible inhibition of its 
transamidation activity (Bernassola et al., 1999; Lai et. al., 2001) and increased TG2 
sensitivity to GTP. Recently, Telci et al. (2009) suggested that nitrosylation of TG2 
influences cellular deposition of the enzyme into the ECM thus regulating the function of 
the enzyme in the extracellular matrix. 
Additional studies on TG2 demonstrated its ability to act as a protein disulfide 
isomerise (PDI) by catalysing the formation of disulphide bonds (Hasegawa et al., 2003). 
This PDI activity of TG2 was shown to be independent from the presence of calcium ions 
and contrary to other TG2 activities remained unaffected by nucleotides including GTP 
(Hasegawa et al., 2003). Furthermore PDI activity was enhanced by the presence of 
glutathione disulfide, which suggests that TG2 may act as an isomerase in a cytosolic 
environment (Hasegawa et al., 2003). 
In addition, former studies identified TG2 from a human breast cancer cells as a 
serine/threonine kinase involved in the phosphorylation of the insulin-like growth factor 
(IGF)-binding protein 3 (IGFBP-3) (Mishra and Murthy, 2004). Recently, the biochemical 
activities of TG2 was shown to be regulated by protein kinase A which phosphorylate TG2 
thus enhancing its kinase activity as well as its transamidation activity (Mishra et al., 
2007).  
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1.10.3 Subcellular localisation of tissue transglutaminase  
 
Multiple factors can regulate the activity of tissue transglutaminase. TG2 is mainly a 
cytoplasmic protein but interaction with a variety of stimuli can lead TG2 to the nucleus, 
or to the extracellular matrix and cell surface (Lorand and Graham, 2003; Verderio and 
Griffin, 2005). A very little amount of enzyme can be found outside the cell however its 
presence can be detected in the cell membrane fractions (Barnes et al., 1985). Although 
TG2 does not contain a hydrophobic amino acid leader sequence it has been shown to 
dynamically translocate through the plasma membrane and into various subcellular 
compartments (Korner et al., 1989; Peng et al., 1999). Several factors have been 
suggested to be directly or indirectly involved in TG2 translocation (Gaudry et al., 1999a; 
Balklava et al., 2002; Akimov et al., 2000; Scarpellini et al., 2009), however the exact 
mechanism by which the enzyme is actually transported still remains unknown. It is 
known that when released from cells TG2 accumulates in the extracellular matrix where it 
interacts with fibronectin, having an influence on its stabilisation, as well as being 
involved in cell- matrix adhesion and many other processes, including cell migration and 
signal transduction (Gaudry et al., 1999; Balklava et al., 2002; Akimov et al., 2000; Akimov 
and Belkin, 2001; Belkin et al., 2001; Kabir-Salmani et al., 2005; Zemskov et al., 2006). The 
externalisation mechanism and physiological functions of TG2 in the ECM will be 
described in more detail further on in the thesis. Nevertheless, available evidence 
indicates the importance of the subcellular location of the enzyme for the regulation of its 
biochemical activities (Park et al., 2010). 
 
1.10.4 Tissue transglutaminase in the cytoplasm  
 
In the cytoplasmic environment TG2 activity is mainly regulated by low concentrations 
of calcium ions and high nucleotide concentrations, as described above. A study 
performed on a human endothelial cells revealed the activity of cytosolic TG2 remains 
latent under physiological concentration of ATP and GTP, and in the presence of 10µM 
calcium (Smethurst and Griffin, 1996). Depletion of GTP in situ (Zhang et al., 1998) and 
many other factors including UV irradiation, and oxidative stress (Shin et al., 2004; Yi et 
al., 2004; Ientile et al., 2007) enhances TG2 activity. In particular, the free radical species 
Chapter I: Introduction 
40 
 
(ROS) are shown to affect enzyme activity. When stress conditions are increased during 
exposure of the cell to UV light or heat the level of ROS increases. A study using Swiss 3T3 
fibroblasts and NIH3T3 cells indicated ROS involvement in stimulating TG2 activity in 
response to transforming growth factor-β (TGF-β) and arachidonic acids (Lee et al., 2003; 
Yi et al., 2004). 
 
1.10.5 Effects of tissue transglutaminase on the cell death 
 
Multiple factors can regulate the activity of tissue transglutaminase. Simultaneously 
the cross-linking activity of TG2 has been implicated in regulating numerous physiological 
processes including cell growth and differentiation, endocytosis and cell survival. 
However the most frequent role of cytosolic TG2 related to aberrant transamidation 
activity of enzyme has been associated with apoptosis, indicating that the extent activity 
of the enzyme may play crucial role in the dying cell.  
So far two major mechanisms of cell death have been described to take place under 
normal physiological conditions. Apoptosis is one of the two mechanisms which occurs via 
programmed cell death. It was characterised by changes in the nucleus and cytoplasm 
including chromatin cleavage and formation of vesicles which further undergo 
phagocytosis by neighbouring cells and macrophages. Apoptosis has been associated with 
embryonic morphogenesis, tissue remodeling and tumour growth (Green and Reed, 
1998). Initially, the involvement of TGase in programmed cell death was proposed by 
Fesus et al. (1987). Since then many studies have been undertaken on in vivo and in vitro 
models regarding TG2 engagement in apoptosis and revealed that when activated TG2 
catalyses the formation of insoluble apoptotic bodies (Fesus et al., 1989; Aeschlimann and 
Paulsson, 1994; Knight et al., 1993). The activation of TG2 is thought to stabilise the 
apoptotic cells before their clearance by phagocytytotic cells thus contributing to the 
prevention of inflammatory response. Studies in vivo using thymus and liver as model 
systems revealed that induction of apoptosis in TG2 knock-out mice is possible; 
nevertheless the clearance of apoptotic cells is delayed suggesting the importance of TG2 
for efficient phagocytosis (Szondy et al., 2003). The disturbance of apoptosis resulted 
from a deficiency in TGF-β activation and was associated with the inflammatory response  
(Szondy et al., 2003). Further investigation on the inflammatory response in TG2 knockout  
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mice revealed that TG2 facilitates phagocytosis not only in apoptotic cells but also in 
macrophages (Falasca et al., 2005). The lack of TG2 expression resulted in an impaired 
capacity of macrophages for engulfing but not for binding apoptotic cells (Falasca et al., 
2005). Thus all the evidence suggests involvement of TG2 in the clearance of apoptotic 
cells.  
Instead of playing an important role during apoptotic cell death TG2 can also affect the 
decision of the cell whether to undergo death or survive. As shown by Antonyak et al. 
(2002 and 2003) increased TG2 expression in NIH3T3 cells prevents apoptosis via a GTP-
binding mechanism associated with the cell survival. However when TG2 loses its GTP-
binding activity, the TG2 protective role can be converted into a cell death stimulating 
factor (Datta et al, 2007). Additional studies on TG2 in  cancerous cell lines has shown 
that its anti-apoptotic activity can result from activation of the NF- κB signaling pathway 
(Mann et al., 2006, Cao et al., 2008). In contrast a pro-apoptotic stimulus has been 
suggested for TG2 in NIH3T3 cells  treated with calphositin C. TG2 induces apoptosis by 
promoting oligomerization of a dual leucine zipper-bearing kinase (DLK) (Robitaille et al., 
2008). Moreover TG2 was shown to stimulate apoptotic cell death in a pancreatic cancer 
cell line Panc-28 cells (Fok and Mehta, 2007). Thus results indicate that these diverse 
downstream effects of the enzyme in dying cells depend on multiple parameters including 
cell type as well as apoptotic stimuli (Park et al., 2010). 
Necrosis is another mechanism of cell death that differs from apoptosis and occurs as a 
result of acute physical and chemical cell damage in an uncontrolled destructive manner.  
Necrotic cells are characterised by disruption of the membrane integrity, cell swelling, 
and active release of the intracellular macromolecules into the extracellular space leading 
to an inflammatory response. Necrosis can be closely associated with the elevating 
concentration of calcium ions which may lead to activation of calcium dependent 
enzymes (Fukuda et al., 1993). As reported by Zatloukal et al., (1992) enhanced activity of 
TG2 can lead to cell liver necrosis. Additional studies on mechanically injured fibroblasts, 
demonstrated that when TG2 is activated, it can cross-link proteins which results in the 
formation of protective SDS-insoluble shells thus preventing the leakage of harmful 
contents from death cells (Piredda et al., 1997; Nicholas et al., 2003). Nemes and co-
workers, (1997) showed that when the calcium concentration increases in response to 
calcium ionophore A-23187, the activity of the enzyme increases leading to cross-linking 
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of cytoskeletal proteins. Such cross-linked protein-rich cells are believed to facilitate a cell 
death and exclusion of death cells thus contribute to reduced inflammation and apparent 
tissue damage (Fesus and Szondy, 2005). However the lack of TG2, as demonstrated in 
MRL1pr/lpr mice was suggested to contribute to the development of autoimmune 
disorders (Piredda et al., 1997). Using a lung cancer–derived cell line, A549, Kawai and co-
workers (2008) showed that the transamidation activity of the enzyme is necessary for 
recovery of the membrane after mechanical wounding. Thus results may suggest that TG2 
activity can stabilise tissue post-trauma and further contribute to the maintenance of 
membrane integrity. 
  
1.10.6 Tissue transglutaminase on the plasma membrane 
 
Tissue transglutaminase when associated with the membrane acts as a G protein, 
being involved in the signal transmission from the outer to the inner cellular space. As 
shown by Nakaoka and co-workers (1994) TG2 from the rat liver membrane was engaged 
in signal transduction through the α1-adrenergic receptor whereas Nanda and co-workers 
(2001) reported the lack of signaling in TG2 knock-out mice. Absence of Gh coupling to α1-
adrenergic receptor, prevented α1-adrenergic receptor agonist from stimulating *α-
32P]GTP-photolabeling of a 74-KDa protein in liver membrane (Nanda et al., 2001). 
Agonist activation of TPα thromboxan A receptor stimulated TG2 as a G protein which 
was further demonstrated to trigger phospholipase C (PLC)-mediated inositol phosphate 
(IP) production (Vezza et al., 1999). However the interaction between Gh and PLC, 
seemed to have unclarified influence on the latter. On one hand Feng and co–workers 
(1996) suggested an inducible effect of Gh on PLC δ1, while Murthy et al. (1999) proposed 
TG2 to be a suppressor of PLC δ1 activity. In addition when bound to GTP, cytosolic 
Gh/transglutaminase was shown to release PLC δ1 from the inhibitory complex  (Murthy 
et al., 1999) which on the other hand was demonstrated to positively regulate the 
GTP:TG2 interaction (Baek et al., 2001). 
 
1.10.7 Tissue transglutaminase in the nucleus 
 
Another cell compartment in which detectable levels of TG2 was found is the nucleus. 
Studies on a human neuroblastoma SH-SY5Y cells revealed that 7% of the total TG2 was 
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present in the nucleus, from which 6% was associated with chromatin-associated proteins 
and the rest which is 1% was found in the nuclear matrix fraction (Lesort et al., 1998). 
Lesort and co-workers demonstrated that the nuclear activity of TG2 remains at a very 
low level however it can be elevated by maitotoxin mediated increase of intracellular 
level of calcium. It is yet unknown what is the translocation mechanism of TG2 to the 
nucleus. Passive transport of TG2 through the nuclear membrane is probably excluded 
due to the high molecular weight of the enzyme. Thus active transport of TG2 through the 
membrane was postulated (Peng et al., 1999). So far histones and retinoblastoma protein 
(Rb) have been identified as TG2 nuclear substrates (Ballestar et al., 1996; Oliviero, et al., 
1997). Additionally importin α-3 has been proposed to be a specific binding partner for 
TG2 that triggers its translocation to the nucleus (Peng et al., 1999). However importin α-
3 remains associated with TG2 only in the cytosol and dissociates from TG2 after crossing 
the nuclear membrane (Peng et al., 1999). Further studies showed glutamate stimulated 
translocation of the enzyme to the nucleus in differentiating astrocytes (Campisi et al., 
2003). In addition, treatment of pancreatic cancer cells Panc28 with calcium ionophore A-
23187 enhanced translocation of the TG2 in a complex with p56 in to the nucleus (Mann 
et al., 2006).  
 
1.10.8 Effect of tissue transglutamianse on cell growth and differentiation 
 
Tissue transglutaminase multiple functions have been implicated in many processes. 
Early studies indicated an involvement of TG2 cross-linking activity on cell differentiation 
and proliferation in various cell types (Birckbichler and Patterson, 1978). In fact authors 
demonstrated that high levels of enzyme activity inside the cell induced cell 
differentiation in comparison to cells with low levels of TGase activity. Further 
investigation using human WI-38 lung fibroblasts showed that cell treatment with the TG2 
inhibitor, cystamine stimulated their growth (Brickbichler et al., 1981). However, 
contradictory results were presented by Johnson and co-workers (1994) who reported 
that in comparable cells growth was due to over expression of TG2 indicating that the 
growth inhibition of TG2 might have resulted from non-specific effects of the inhibitor. 
Other discoveries revealed that TG2 can induce growth by indirect interaction with 
growth factors including transforming growth inhibitor facto TGFβ and hepatocyte growth 
factor (Kojima et al., 1993; Katoh et al., 1996). Additionally increase in expression of TG2 
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has been noticed during maturation of human monocytes to macrophages (Seiving et al., 
1991). Another study using neuroblastoma Neuro2a cells reported that increased 
expression of TG2 leads to NGF-induced neuronal differentiation of these cells (Condello 
et al., 2008). Moreover increases in TG2 expression was further correlated with 
chondrocyte differentiation although FXIIIA was also suggested to be involved since it is 
also a marker of chondrocyte differentiation in the growth plate (Aeschlimann et al., 
1993).  
Transamidation of proteins present in the extracellular matrix by TG2 was demonstrated 
to affect cell differentiation and function for example collagen cross-linked by the enzyme 
was shown to induce differentiation of osteoblasts (Chau et al., 2005). TG2 was suggested 
to be important in accelerating chondrocyte maturation to hyperthrophy in response to 
retinoic acid which is a well known inducer of TG2 expression (Johnson et. al., 2003). 
While other studies revealed that even nanomolar amounts of exogenous TG2 are 
sufficient to directly stimulate hyperthropic differentiation in chondrocytes (Johnson and 
Terkeltaub, 2005). Additionally when released from chondrocytes, TG2 was suggested to 
modulate differentiation of osteoblasts via extracellular TG2-induced PKA signaling 
(Nurminskaya and Kartinen, 2006). However, as stated by Johson et al., (2008) 
chondrocyte maturation was accelerated by TG2 and FXIIIA networking without 
requirement of TG-catalysed transamidation activity. 
 
1.10.9 Protein secretion pathways and externalisation of TG2 
 
Although TG2 has been mainly localised in an intracellular compartment playing 
intracellular functions, its presence has also been demonstrated on the cell surface as 
well as in the extracellular compartment (Gaudry et al., 1999a, b). Despite recent data 
indicating extracellular TG2, very little information has been provided regarding the 
mechanism of its secretion. 
During evolution, many mechanisms of protein translocation across eukaryotic 
membranes (nucleus, endoplasmic reticulum, mitochondria, peroxisomes, lysosomes etc.) 
have been developed and later on widely described (Görlich and Kutay, 1999; Shatz, 
1996; Agarraberes and Dice, 2001; Brocard et al., 2003).  Among proteins, there are 
messengers, characterised by N-terminal signals, hydrophobic sequences and amino acid 
regions that allow them to interact with translocation complexes located in the 
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intracellular space or on the plasma membrane (Zocchi and Rubartelli, 2001). These 
peptides lead secretory proteins through the classical, ER/Golgi dependent secretion 
pathway. Following synthesis in endoplasmic reticulum, proteins are transported further 
to the Golgi apparatus, from where they are carried by vesicles to their final destination 
(membrane localisation) (Mellman and Warren, 2000). Additionally, when translocation 
takes place across the intra and extracellular space of the ER, mitochondria and into 
lysosomes, targeted proteins needs to be in an unfolded conformation (Rapoport et al., 
1996; Shatz, 1996; Salvador et al., 2000). This conformation is not required for the 
proteins that are imported into peroxisomes as well as between the nucleus and cytosol 
(Brocard et al., 2003; Görlich and Kutay, 1999; Backhaus et al., 2004). However, in 
eukaryotic cells there are proteins, which are not subjected to the classical secretion 
pathway, but are still externalised from the inner to outer membrane space. Those 
proteins were identified to lack the N-terminal signal peptide, not to be glycosylated 
(even if they bear glycosylation motifs) thus do not pass into the ER, and become 
insensitive to the typical inhibitors (brefeldin A, monesin) of proteins that undergo 
classical secretion (Rubartelli et al., 1992; Tanudji et al., 2003).  
The secretion mechanism of proteins that lack signal peptides and are maintained in 
the cytosol before being released from cells, is known as unconventional/non-classical or 
leaderless protein secretion (Zocchi and Rubartelli, 2001). Proteins, that are translocated 
via this pathway include; pro-angiogenic growth factors such as FGF-1 and FGF-2 (Jackson 
et al., 1995; Engling et al., 2002;  Shäfer et al., 2004; Backhouse et al., 2003), 
inflammatory mediators such as 1β-interleukin (Rubartelli et al., 1990; Andrei et al., 
1999), lectins belonging to the  β-galactoside family (Cooper and Barondes, 1990; 
Lindstedt et al., 1993; Cho and Cummings, 1995; Lutomski et al., 1997). In addition the 
trafficking routes of viral proteins such as HIV-1 tat (Chang et al., 1997), herpes virus VP22 
(Elliot and O’Hare, 1997), foam virus beta protein (Lecellier et al., 2002), parasitic surface 
proteins (Denny et al., 2000) occur via unconventional secretion pathways as well.  
    Similarly, to other proteins that are secreted via non-classical pathways, TG2 and FXIIIA 
lack typical ER targeting signal sequences but still require the active conformation 
(Ichinose et al., 1990; Balklava et al., 2002). Many researchers have been interested in 
revealing the TG2 secretion pathway. So far, it is known that TG2 is released from both 
healthy and damaged cells but its externalisation increases during cell stress (Upchurch et 
al., 1991; Haroon et al., 1999; Johnson et al., 1999; Gaudry et al., 1999a, b; Gross et. al., 
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2003). Following mutagenesis studies of TG2, researchers suggested that as well as an 
active conformation, the presence of an intact N-terminal potential FN binding site is 
necessary for its secretion (Gaudry et al., 1999a). Mutagenesis studies on TG2 also 
revealed that when TG2 was in an inactive form (C277S) it was neither deposited into the 
ECM or secreted into medium (Balklava et  al., 2002). Similarly the presence of a non-
proline cis bond (Y274A) has also been shown to be important suggesting the 
involvement of TG2 activity and tertiary conformation in its externalisation mechanism 
(Balklava et al., 2002; Johnson and Terkeltaub 2005). Additionally, it was postulated that 
TG2-integrin interactions might have an influence on its externalisation (Akimov et al., 
2000). Recently Johnson et al (2008) has shown that interaction between FXIIIA and 
integrin α1β1 is required for TG2 secretion from chondrocytes by using α1β1 blocking 
antibody which inhibited TG2 externalisation to the cell surface induced by FXIIIA. In 
addition, studies on a lung cancer-derived cell line, A549 indicated TG2 to be released 
from damaged cells during a cell repair process and postulated its possible role in 
modulation of autoimmunity by preventing the release of the cell contents (Kawai et al., 
2008). Once externalised, TG2 can be internalised by endocytosis which requires the 
presence of LRP1 (a member of the LDL, low density lipoprotein receptor superfamily) 
and further degraded in lysosomes (Zemskov et al., 2007). 
 
1.11 Tissue transglutaminase in the extracellular environment 
 
1.11.1 Localisation of TG2 in the extracellular space 
 
The extracellular matrix is characterised by a high concentration of calcium ions and 
low concentration of TG2 inhibitory factors including GTP and zinc. Due to this fact, 
extracellular TG2 was believed to be in its active form (Park et al., 2010). However a 
statement presented by Go and Jones, (2008) that the oxidizing potential of the ECM is 
maintained at a stable level, may influence earlier presumptions. Recently, Pinkas et al., 
(2007) have demonstrated that most of the extracellular TG2 is locked in a closed 
conformation regardless of high concentrations of calcium ions. Additionally, studies 
using GTP-binding site mutant (K173L) in CH-8 cells showed a decrease in its secretion 
into the medium indicating that externalised TG2 is probably in an inactive, GTP-bound 
form (Johnson and Terkeltaub, 2005). In addition, interaction between TG2 and integrin 
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receptors present on the cell surface was demonstrated to be independent of its cross-
linking activity (Akimov et al., 2001a, b; Stephens et al., 2004). Meanwhile as shown by 
many researchers under physiological conditions, the cross-linking activity of extracellular 
TG2 is implicated in stabilising and remodeling of the ECM. Increased TG2 transamidation 
activity in the matrix was observed by Skill and co-workers (2004) in an opossum kidney 
proximal tubular epithelial cell line as a response to elevated level of glucose. In addition 
TG2 when treated with the TG inhibitor KCC009 was shown to reduce remodeling of 
fibronectin into the extracellular matrix in both in vitro and in vivo studies on 
glioblastoma cells (Yuan et al., 2007). Thus it still remains unclear when secreted into the 
extracellular environment whether TG2 is or is not required to function as an adaptor 
protein and/or cross-linking enzyme. 
Interactions of cells with the extracellular matrix is essential for many cellular 
processes including cell adhesion, migration, differentiation, growth, apoptosis and 
assembly of proteins into the ECM. TG2 has been implicated in stabilisation and 
reconstitution of the extracellular matrix. Its role in the stabilisation of the extracellular 
environment was first proposed by Battaglia and Shaprio in 1988. Since then TG2 has 
been shown to be  involved in binding and assembly of various proteins into the ECM 
including fibronectin (Tamaki and Aoki, 1981; Mosher et al., 1991), fibrin and fibrinogen 
(Cottrell et al., 1979; Guadiz et al., 1997) vitronectin (Sane et al., 1991) osteonectin 
(Aeschlimann et al., 1995) osteopontin (Prince et al., 1991; Sorenson et al., 1994) 
osteocalcin (Kaartinen et al., 1997) collagens (Mosher, 1984; Kleman et al., 1995; Esterre 
et al., 1998) laminin-nidogen complex (Aeschlimann et al., 1991) and elafin (Nara et al., 
1994). Moreover TG2 contributes to the organisation of the ECM by promoting tissue 
mineralization, stabilisation of dermo-epidermal junctions as well as modification and 
activation of different growth factors including transforming growth factor-β (TGF-β) in 
the ECM (Lorand and Graham, 2003).  
The activity of externalised TG2 into the ECM was found to be involved in connective 
and bone tissue remodeling (Aeschlimann et al., 1996). During endochondral bone 
formation which involves chondrocytes differentiation, proliferation, hyperthrophy and 
cartilage calcification, secretion of TG2 takes place. Initially at the proliferation stage TG2 
is present in the intracellular space from where during the chondrocyte differentiation 
process is externalised to the cell surface where it is implicated in cross-linking proteins 
prior to mineralization (Aeschlimann et al., 1993).  
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Another function that tissue transglutminase seems to have is to stabilise dermo-
epidermal junctions (DEJ). This specialized stable structure organised between the 
epidermis and the dermis is made up of molecules involved in specific protein-protein 
interactions from the hemidesmosomes at the basal surface of keratinocytes, the 
anchoring filaments connecting the hemidesmosomes to the basement membrane and 
the anchoring fibril linking the epithelium and the dermis (Lorand and Graham, 2003). The 
stability of skin by maintaining the integrity of dermo-epidermal junction is mainly 
achieved by anchoring fibrils. The major component of anchoring fibrils is collagen VII 
(Burgeson, 1993). Expression studies of transglutaminase activity in skin regenerating 
from cultured epithelial autographs proposed collagen VII to be a potential substrate for 
TG2 cross-linking activity as well revealing the importance of TG2 in the stability of 
dermo-epidermal junctions (Raghunath et al., 1996). Transglutaminase derived cross-link 
activity was also demonstrated to take place along the basement membrane where it was 
shown to interact with different substrates including laminin-nidogen complexes and 
osteonectin as well as in the elastic fibrillar apparatus (Aeschlimann and Paulsson, 1991; 
Aeschlimann et al., 1995; Brown-Augsburger et al., 1994; Trask et al., 2001). Elastic fibers 
consist of two different compartments: amorphous-appearing elastin and fibres 
(microfibrils). Microfibrils are found in many tissues as well as at dermo-epidermal 
junctions. The main components of microfibrils have been identified as fibrillin-1, fibrillin-
2 and micro-fibril-associated glycoprotein-1 (MAPG-1) (Brown-Augsburger et la., 1994). 
The fibrilins are characterised as the major components of microfibrilis that possess 
epidermal growth factor-like repeats in their domain structure (Brown-Augsburger et la., 
1994). Another protein known to be a microfibrilis component is MAPG-1, a small 
molecular weight protein associated with the extracellular matrix microfibrilis. Studies 
performed by Qian and Glanville (1997) and Brown-Augsburger and co-workers (1994) 
revealed that fibrillin-1 and MAPG-1 are both substrates for tissue transglutaminase 
transamidation activity. Available data demonstrated that tissue transglutaminase activity 
may be implicated in stabilising the anchoring fibrils and microfibrils to form dermo-
epidermal junctions.  
In vitro experiments suggest the involvement of TG2 in the activation of the latent 
form of transforming growth factor-β TGF-β (Lorand and Graham, 2003). Most of the 
time, TGF-β when secreted from cells remains in a biologically inactive form of a large 
latent complex consisting of mature TGF-β, the TGF-β propeptide called latency 
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associated peptide (LAP) and a latent TGF-β binding protein (LTBP). The dissociation of 
TGF-β from LAP peptide is required for its ability to bind receptors and further 
involvement in a wide range of cellular processes including cell proliferation, cell 
differentiation, cell migration, and the extracellular matrix deposition (Massague, 1990; 
Lyons et al., 1988; Nunes et al., 1997). It is not necessary in the case of LTBP; however it is 
involved in targeting TGF-β into the ECM (Taipale et al., 1994). Members of LTBP family 
are characterised by possessing epidermal growth factor-like repeats and eight cysteine 
repeats in their domain structure similar to microfibrilar proteins which may suggest the 
involvement of TG2 in regulation of the intracellular TGF-β. In vitro studies reveled that 
LTB-1 and large latent complex are substrates for transglutamianse and the covalent 
incorporation of LTB-1 into the extracellular matrix is transglutamianse dependent (Nunes 
et al., 1997). The immunochemical studies further confirmed by electron microscopy 
revealed that increased TG2 expression is correlated with an increased rate of LTB-1 
deposition into the ECM (Verderio et al., 1999). Additionally LTB-1 was co-localised 
together with TG2 and FN on the cell surface where TG2 activity is enhanced by the 
presence of calcium (Verderio et al., 1999). These results suggest that TG2 may contribute 
to the targeting of the latent TGF-β complex into the ECM by cross-linking the LTBP to 
matrix proteins. The engagement of TG2 in TGF-β1 activation was further demonstrated 
using TG2 -/- mice indicating that the lack of TG2 expression correlates to deficiency in 
TGF-β1 activation leading to impaired phagocytosis and prolonged inflammation (Szondy 
et al., 2003). These findings were further confirmed by Telci and co-workers (2009) who 
investigated the effect of nitrosylation on TG2 activity. TG2-induced fibroblasts treated 
with nitric oxide donor S-nitroso-N-acetylpenicillamine was shown to inhibit TG2 cross-
linking activity leading to decrease in expression and activity of TGF-β1 (Telci et al., 2009). 
   
1.11.2 Fibronectin in the extracellular environment 
 
In vitro studies demonstrated that fibronection is a well known substrate for TG2 and 
that binding between both of these molecules occurs with high affinity (Kd around 8-
10nM) and 2:1 stoichiometry (Lorand et al., 1988; LeMosy et al., 1992) independent of 
the GTPase and cross-linking activities of TG (Turner and Lorand, 1989). Fibronectin (FN) 
is a high molecular weight protein (around 440kDa) mainly present in blood, tissues as 
well as the ECM. Dependent on its localisation, FN can exist in two different forms: a 
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soluble protomeric form which can be found in blood plasma while an insoluble 
monomeric form is present in the extracellular environment of tissues (Magnusson and 
Mosher, 1998). Soluble FN is a dimeric glycoprotein composed of two similar chains 
linked by disulfide bonds. Each subunit of FN is made of a series of repeating amino acids 
sequences: Type I, II and III modules (figure 1.5). The structure of FN is composed of 12 
type I modules, 2 type II, 15 to 17 type III (depending on splicing) and a variable (V) 
sequence not homologous to other FN parts (Wierzbicka-Patynowski and Schwarzbauer, 
2003). These modules present on FN represent specific binding sites for various proteins 
as well as cell receptors. The 2 type III modules (undergo alternative splicing) are called 
ED-A (ED for extradomain) and ED-B. Plasma FN is characterised by lack of these ED 
domains; however cellular FN (synthesised locally in tissues) contains various amounts of 
either or both ED-A and ED-B (Magnusson and Mosher, 1998). Moreover, in plasma FN 
only one of the subunits contains the V region, while almost all cellular FN subunits 
contain this region (Schwarzbauer et al., 1989). The multiple domain structure of FN is 
important in maintaining the integrity of the matrix.  
Most adherent cell types synthesize FN and deposit it into the extracellular matrix. 
Assembly of FN into the ECM is a tightly regulated process that occurs in a multistep 
manner starting from initiation through elongation to stabilisation (Schwarzbauer and 
Sechler, 1999).  
Initially, soluble protomeric FN binds to specific sites present on the cell surface by 
means of its N-terminal 70 kDa region, in particular within modules I1-I5 (Sottile et al., 
1991). In addition FN interaction with adhesive receptors present on the cell surface, 
mainly through binding various integrin receptors (as shown in Figure 1.5) leads to its 
activation (Wierzbicka-Patynowski and Schwarzbauer, 2003). Especially α5β1 integrin was 
shown to be the major FN receptor which similar to a few other integrin receptors 
requires the Arg-Gly-Asp (RGD) cell –binding sequence within the III9 module along with 
the PHSRN synergy sequence located in III10 FN module (Hynes, 1992; Schwarzbauer and 
Sechler, 1999; Humphries et al., 2004). Other adhesive molecules that FN interacts with 
are fibrin, transmembrane HSPGs, and collagen. Moreover FN possesses a reactive 
glutamine residue close to the amino-terminal site by which it interacts with activated 
plasma transglutaminase FXIIIa. FXIIIa covalently cross-links FN into the fibrin clots leading 
to increased elasticity and thickness in the blood clot (Muszbek, 1999). In the next step 
cell associated FN is distributed over the cell surface and it is converted into cell-stabilised  
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multimers forming a fibrilllar newtork (Chen and Mosher, 1996; Magnusson and Mosher, 
1998). In the final stage, while assembly progresses, FN is regenerated and gradually 
converted into a detergent-insoluble form as it becomes further integrated in the 
organisation of the extracellular matrix (Wierzbicka-Patynowski and Schwarzbauer, 2003).  
 
1.11.3 TG2-Fibronectin interaction 
 
   Numerous recent studies point to the involvement of TG2 in interaction that take place 
between cells and the extracellular matrix (Akimov et al., 2000; Akimov et al., 2001; 
Lorand and Graham 2003). Although TG2 has no leader sequence and does not undergo 
any posttranslational modifications it can still be found on the cell surface as well as 
outside the cell where it interacts with many extracellular proteins (Upchurch et al, 1991; 
Aeschlimann and Paulsson, 1994; Verderio et al., 1999; Balklava et al., 2002; Zemskov et 
al., 2006).  
    A series of studies showed that TG2 can bind directly to the major extracellular protein 
FN with high affinity and this interaction does not require it’s cross-linking or GTPase 
activities (Lorand et al., 1988; LeMosey et al., 1992). The engagement of cell surface TG2 
in cell-matrix adhesion, cell migration, FN assembly and signalling strictly depends on its 
interaction with fibronectin (Akimov et al., 2000; Belkin et al., 2001; Akimov and Belkin, 
2001; Verderio et al., 2003). This interaction was shown to take place through the 42kDa 
region of fibronectin consisting of modules I6II1,2I7-9 which has a high affinity to TG2 
comparable to the whole FN molecule (Radek et al., 1993). Additionally this interaction 
was reported to be located apart from the integrin binding motifs on FN suggesting a 
supportive role for TG2 and integrins in mediating cell adhesion (Akimov et al., 2000; 
reviewed by Zemskov et al., 2006).  
Several contradicting reports appeared contributing to the localisation of the FN-
binding site on the TG2 sequence. The TG2-fibronectin interaction was suggested to be 
dependent on the intact NH2-terminal region of TG2 (Jeong et al., 1995; Gaudry et al., 
1999a). Further insight into the FN binding motifs present on guinea pig liver TG2 
indicated that the FN binding site is placed within a 28 kDa proteolytic fragment of the 
TG2 structure (Jeong et al., 1995). More recent site-directed mutagenesis studies based 
on using TG2/FXIIIA chimeric constructs containing swapped regions between TG2 and 
FXIIIA and TG2 deletion products demonstrated the presence of additional FN recognition 
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motif on the TG2 molecule (Hang et al., 2005). Moreover, more detailed investigation on 
a matter, including using synthetic peptides which encompass the first domain of TG2, 
revealed that peptide 88WTATVVDQQDCTLSLQLTT106 inhibited the TG2-FN interaction. The 
major FN binding site was mapped to the 88-106 amino acids of TG2 within the hairpin 
structure consisting of anti-parallel β strands 5 and 6 among which Asp94 and Asp97 were 
shown to be critical residues involved in TG2-FN interaction (Hang et al., 2005, Figure 7). 
 
1.12 Other molecular interaction of cell surface TG2 
 
In addition to the interaction with FN, recent studies revealed a close association of 
cell surface TG2 with several integrin receptors mainly via binding to the β1 and β3 
subunits present in different cell types (Gaudry et al., 1999 a, b; Akimov et al., 2000; 
Belkin et al, 2001; Akimov and Belkin, 2001; Tanaka et al., 2007).  
Integrins represents the major class of cell surface transmembrane adhesion receptors 
for ECM proteins as well as mediators in cell-matrix interaction. The interactions between 
cells and ECM proteins are important to stabilise tissue integrity as well as many other 
processes including cell proliferation, differentiation, migration, regulation of gene 
expression, formation of blood clotting, thrombosis and wound healing (Critchley et al., 
1999). These processes rely on the linkage of intracellular cytoskeleton via integrin 
cytoplasmic tails which allows transport of signals across the plasma membrane 
(Calderwood et al., 2000; Evans and Calderwood, 2007). Integrins are heterodimers 
containing α and β subunits; 8β subunits may interact with 18α subunits leading to the 
formation of 24 distinct integrins, expressed by all cell types excluding erythrocytes 
(Hynes, 2002). The association of the subunits plays important roles in binding of the 
ligands (Gailit and Ruoslahti, 1988).  
Integrins are not always active, very often they are expressed by cells in an inactive 
state in which they do not bind ligands and do not signal (Hynes, 2002). It has been shown 
that RGD peptides and small ligands can interact with not fully activated integrins while 
larger ligands including fibronectin, fibrinogen cannot (Coller 1986; Hynes, 2002). 
Activation is regulated by many inside-out signalling pathways inducing conformational 
changes within integrin subunits increasing their affinity for ligands (Sims et al., 1991; 
Calderwood 2004). It still remains unclear how this process proceed. However there is 
evidence suggesting that mainly talin (Ma et al., 2008) and in addition proteins belonging 
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to the kindlin family (Ma et al., 2008; Moser et al., 2008) are important for integrin 
activation. When bound to ligands, integrins form connections between the cytoskeleton 
and the ECM, cluster at focal contacts and then trigger signals through the outside-in 
signaling pathway (Harburger and Calderwood, 2009).  
In addition to integrins, other molecules were proposed to associate with TG2 at the 
cell surface and further modulate the biological functions of TG2 (reviewed by Verderio et 
al., 2009). HSPGs (heparan sulfate proteoglycans) are specialized glycoproteins made of a 
core protein, heparan sulfate (HS) glycosaminoglycan (GAG) chains and uronic acids 
(Bishop et al., 2007). Within the family, three distinct classes have been characterised: the 
membrane-spanning proteoglycans (syndecans, betaglycan and CD44v3), the 
glycphosphatidyl-inositiol (GPI)-linked proteoglycans (glypicans) and a varied group of 
secreted proteoglycans found in the ECM e.g. argin, collagen XVIII and perlecan (Bishop et 
al., 2007; Kirkpatrick and Selleck, 2007). The HS chains when assembled on core proteins 
by enzymes of the Golgi, undergo a series of reactions which cause their structural 
heterogenicity including differences in chain length and size, the spacing of tracts, and the 
extent of sulphation and epimerization within negatively charged groups (Bishop et al., 
2007). This structural variety in the HS chains allows HSPGs to bind a wide range of 
different proteins and affect many physiological processes (Kirkpatrick and Selleck, 2007).  
Signorini and co-workers (1988) when purified human erythrocyte TG2 on a Heparin-
Sepharose column, revealed that TG2 has a high affinity for heparin which is an analogue 
of heparan sulfate (HS). Additional studies on transglutaminase and heparin interaction 
demonstrated that binding to the heparin affects only slightly the catalytic activity of the 
enzyme but protects it from thermal unfolding as well as proteolytic degradation 
(Gambetti et al., 2005). Moreover by using surface plasmon resonance Scarpellini and co-
workers (2007, 2009) showed high affinity of recombinant human TG2 for heparin. These 
findings were further validated by solid phase binding assays  indicating that interaction 
between TG2, HS and heparin are of similar strength and additionally comparable to the 
strength of TG2-FN interactions (Scarpellini et al., 2009). In addition the ECM adhesive 
glycoproteins including vitronectin and fibronectin which were also shown to be TG2 
enzymatic substrates can bind to heparin indicating that heparin may be involved in TG2 
immobilization on these substrates (Sane et al., 1990; Verderio et al., 2009). 
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1.13 Cell surface and extracellular associated TG2 mediated cell adhesion  
 
Interactions of cells with the surrounding extracellular environment are essential for 
maintaining physiological cellular processes. These interactions have been shown to take 
place through a major classes of  adhesion receptors that are present on a variety of cell 
types including integrins, selectins, CAMs (cell adhesion molecules of immunoglobulin 
superfamily) and HSPGs (Zemskov et al., 2006). Membrane proteins (receptors) mediate 
cell-cell interactions as well as cell-matrix interactions with ECM glycoproteins such as 
fibronectin (FN), collagens, laminins as well as ECM proteoglycans (Zemskov et al., 2006).  
Initial studies suggesting the involvement of TG2 in promoting cell adhesion was 
published in 1986 by Slife and coauthors as well as by Tyrell and coworkers, who 
proposed that plasma membrane associated TG2 may form covalently cross-linked 
proteins matrices which can increase the adhesiveness of the cells. Since then evidence of 
cell surface TG2 promoting cell adhesion started to accumulate rapidly. Studies on Balb-C 
3T3 fibroblasts stably transfected with TG2 revealed alterations in cell morphology 
reflecting enhanced cell adhesion as well as their increased resistance to detachment 
with trypsin (Gentile et al., 1992). The cross-linking of fibronectin by cell associated TG2 
was shown to firmly anchor the endothelial cells into the basement membrane (Martinez 
et al., 1994). 
Additional investigations undertaken by Jones and coauthors (1997) on a human 
umbilical epithelial cell line ECV 304 demonstrated that reduced expression of TG2 by 
antisense technology resulted in diminished adhesion and spreading of endothelial cells 
and their sensitivity to detachment by proteolytic enzymes. 
So far TG2 transamidating activity has been implicated in the cell adhesion processes, 
however recent findings suggesting that TG2 can promote cell adhesion independent of 
its crosslinking activity (Gaudry et al., 1999b; Akimov et al., 2000; Takahashi et al., 2000), 
but is dependent on TG2 interactions with integrin receptors present on the cell surface. 
Following immunochemistry and electron microscopy studies using cells undergoing 
attachment and spreading, TG2 was found to localise in focal adhesion sites rich in β1 and 
β3 integrins where fibronectin fibril assembly progresses (Gaudry et al., 1999b; Akimov 
and Belkin 2001a,b). TG2 interaction with fibronectin is very important for its adhesion 
functions. Even more important is that the gelatin binding domain of FN does not 
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function as both an integrin and other receptors binding site (Zemskov et al., 2006). Thus, 
TG2 and integrins can play collaborative roles in the process of cell adhesion rather than 
compete between each other (Zemskov et al., 2006). Using different antibodies directed 
against TG2, different investigators managed to abolish the interaction between the 
enzyme and gelatin fragment of FN suggesting cell surface TG2 to be the principal 
adhesive receptor for this part of FN (Akimov et al., 2000; Belkin et al., 2001; Zemskov et 
al., 2006). Moreover this interaction was demonstrated to be involved in the formation of 
focal adhesions at the cell surface and further influencing intracellular signaling pathways 
by the activation of focal adhesion kinase FAK (Akimov et al., 2000). In addition FN bound 
extracellular TG2 was shown to be able to bind heparan sulfate chains present on the cell 
surface independently of the RGD-mediated fibronectin binding (Verderio et al., 2003). 
Therefore rescuing the inhibitory effect of cell adhesion induced by inhibitory RGD 
peptides on fibronectin alone (Verderio et al., 2003). This mechanism was shown to 
require activation of protein kinase (PKCα), further its interaction with integrin β1 leading 
to enhancement of actin stress fiber organization and FAK, ERK1/2 MAP kinases activation 
(Telci et al., 2008).  
TG2 released during cell damage or tissue injury was proposed to enhance or 
substitute for integrin mediated cell adhesion and intracellular signaling thus promoting 
cell survival (Telci et al., 2008; Collighan and Griffin, 2009). 
 
1.14 Tissue transglutaminase - a wound healing enzyme 
 
Injury that can cause internal and external tissue damage activates a complex, repair 
process, composed of a series of successive phases (inflammation, proliferation, 
formation and remodeling of extracellular matrix), which leads to reconstitution of 
wounded areas (Upchurch et al., 1991; Werner and Grose, 2003; Telci and Griffin, 2006). 
Wound healing is a carefully regulated process, based on complex interactions between 
the cells and mediators that are released from them during each of the healing phases. 
Those regulatory factors include various growth factors (PDGF, TGF-β, and VEGF), 
cytokines, chemokines and proteins delivered from disrupted blood vessels and 
degranulated platelets (Werner and Grose, 2003; Anitua et al., 2004, Telci and Griffin, 
2006,). Homeostasis, initiated at the beginning of injury, involves platelet aggregation and 
formation of a fibrin clot (Anitua et al., 2004). Further immune responses promote 
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capillary vasodilatation and phagocytosis that is carried out by neutrophils and 
macrophages (Gillitzer and Goebeler, 2001; Park and Barbul, 2004). Following the 
inflammatory phase, proliferation begins. At this stage, keratinocytes take part in 
recreation of the normal pattern of epithelial barrier and new capillaries are formed 
(angiogenesis) which helps to maintain the nutrition of the wounded area. Stimulated by 
regulatory factors, fibroblasts differentiate and migrate to the wound where they are 
engaged in granulation tissue formation and collagen production that is later on 
deposited into the wound area. Additionally, several matrix metalloproteases (MMPs) 
and tissue inhibitors of matrix metalloproteases (TIMPs) have been associated with 
matrix remodeling by creating a path for migrating cells into the wound area (McCawley 
and Matrisian, 2001). After pulling together the edges of the wound, the maturation 
phase takes place. Finally, granulation tissue is transformed into a mature scar whose 
architecture is re-modeled as random collagen fibrils are cross-linked. The remodeling 
continues for a prolonged period until deposition of collagen has increased the tensile 
strength of the scar (Werner and Grose, 2003; Verderio et al., 2004; Midwood et al., 
2004; Verderio et al., 2005; Telci and Griffin, 2006,).  
So far numerous studies reported the involvement of transglutaminases (with respect 
to their ability to mediate cross-linking reactions) in inflammation, general maintenance 
of tissue integrity and the wound healing process. Upon injury the formation of the blood 
clot takes place to fill in the wounded area. So far activated by thrombin the FXIIIa subunit 
was shown to catalyse fibrin transamidation which enhances the thickness of the clot 
(Muszbek et al., 1999). Nevertheless the evidence also suggests that abundant 
erythrocyte TG2 may also be involved in the blood clot formation and further in its 
stabilisation (Auld et al., 2001). During wounding cells present in disrupted area 
synthesise and release components which help to regulate the healing of injured tissue. 
One of these molecules are ECM proteins including FN to which TG2 has been shown to 
have a high affinity (Gaudry et al., 1999a). As demonstrated by Upchurch and co-workers 
(1987 and 1991) after mechanical or chemical injury TG2 becomes released from 
fibroblasts into the ECM around the wound where it associates with FN. The FN-TG2 
interaction has been shown to down-regulate TG2 transamidation activity (LeMosey et 
al., 1992) whereas the cross-linking function of the enzyme has been implicated in the 
stabilisation and/or remodeling of the ECM and further tissue repair (Figure 1.6) 
(Aeschlimann and Thomazy 2000). However as shown by numerous studies redistribution 
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of the enzyme in the ECM can take place as a result of its interaction with stress factors 
released during deterioration of organs such as liver, kidney or lung (Griffin et al., 1979, 
Johnson et al., 1999; Grenard et al., 2001b). The importance of TG2 activity in the 
different stages of healing process has been confirmed by the observation of impaired 
wound healing in TG2 -/- mice (Mearns et al., 2002). Initial studies undertaken by Griffin 
et al., (1979) suggest enhanced TG2 activity in herbicide-damaged lung in an experimental 
model of pulmonary fibrosis. Further examination on wounded rat dorsal skin reported 
increased activity of the enzyme in all skin layers during the healing process (Bowness et 
al., 1988).  
In addition, monitoring of the healing process on anesthetized rats using histological and 
immunohistoligical methods demonstrated elevated activity of TG2 in endothelial cells, 
macrophages and skeletal muscle cells at sites of neovascularization in the provisional 
fibrin matrix within all stages of the wounding process (Haroon et al., 1999). Moreover 
the expression of the enzyme has been shown to be regulated by cytokines including TGF-
β1, IL-6, and TNF-α present at the inflammatory stage of the healing process which may 
promote adhesion of white blood cells during inflammation (Haroon et al., 1999; Suto et 
al., 1993; Kim et al., 2002). Some investigators have connected TG2 with the 
inflammatory phase by its ability to enhance the activity of secretory phospholipase A2 
enzyme (sPLA2) (Cordella-Miele et al., 1990). As reported by different studies TG2 can 
modify of sPLA2 activity which when stimulated could increase release of arachidonic acid 
from the membrane leading to reduced biosynthesis of eicosanoids by cycloooxyganse 
(Verderio et al., 2004; Telci and Griffin, 2006). To reverse that effect, recombinant 
peptides capable of inhibiting TG2-catalysed post-translational activation ofs PLA2 were 
generated (Sohn et al., 2003). Moreover the increase in the TG2 expression has been 
linked with macrophages and promoting their role in phagocytosis (Szondy et al., 2003; 
Telci et al., 2006). It was demonstrated following examination of TG2-deficient moice 
which revealed a defect in the clearance of apoptotic cells by macrophages (Szondy et al., 
2003). Further investigation on inflammatory response in TG2 knockout mice confirmed 
the correlation between TG2 levels and macrophage mediated phagocytosis (Falasca et 
al., 2005). Additional evidence of tissue transglutaminase engagement in the wound 
healing process came from the analysis of biopsies from human patient’s burn skin 
autografts. In skin regenerating from keratinocyte autografts TG2-derived cross-links  
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Figure 1.6 Schematic modified from Verderio et al., 2005, showing wound healing 
phases with specification of actions that are undertaken by transglutaminases (TG1, 
TG2 and FXIIIA) during the healing process. A few hours after injury (12-24h), platelets 
aggregate to form a fibrin clot. Afterwards, inflammation begins (2-5 days), neutrophils 
and macrophages are directed into the wounded area where they release different 
factors that trigger matrix synthesis and, later on the fibroblast influx and replacement of 
the provisional matrix with granulation tissue (5 days-3 weeks). At the end of the wound 
process, which can last from the 3rd week as long as a few years, fibroblasts are 
transformed into myofibroblasts, and granulation tissue is replaced with a scar rich in 
collagen bundles.  
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were confirmed at the dermo-epidermal junctions, papillary dermis and surrounding 
capillaries (Raughunath et al., 1996). In a model of cell wounding, TG2 cross-linking 
activity was also shown to control the release of the intracellular contents of dying cells 
into the wound thus contributing to the maintenance of tissue integrity and reduced 
inflammatory response which results from the loss of cellular Ca2+ homeostasis (Nicholas 
et al., 2003). 
The involvement of TG2 in inflammatory phase of wound healing was also shown by 
various investigators in inflammatory diseases which correlated with abnormal activities 
of TG2 (Esposito and Caputo, 2005). 
 
1.15 Tissue transglutamianse and matrix associated pathologies 
 
1.15.1 Abnormal wound healing - fibrosis and scarring 
 
Successful wound healing results in reconstitution of the damaged area; however, 
some internal tissues and organs can encounter wound aberrations consequently leading 
to a variety of disorders. The difficulty occurs when injury becomes chronic resulting in 
over expression of the wound healing response that finally leads to scarring and fibrosis 
as well as cell deletion and damage of the tissue (Kim et al., 2002, Verderio et al., 2005). 
Numerous studies demonstrated the involvement of TG2 in maintaining the repair 
mechanism; however it has also been reported that TG2 may play pathological role when 
cell trauma or tissue insult occurs leading to increased inflammation, tissue fibrosis and 
scarring (Verderio et al., 2004). The first evidence of TG2 involvement in fibrotic disease 
came from Griffin et al., (1979) who observed alterations in TG2 activity in an 
experimental model of pulmonary fibrosis induced by paraquat (Griffin et al., 1979). 
Further investigations using animal models as well as human kidney biopsy material have 
shown correlation between elevated levels of TG2 expression and progressive renal 
scarring (Johnson et al., 1997; Johnson et al., 2003). Subsequently it was confirmed by 
Skill et al. (2004) who investigated the influence of increased levels of glucose on the 
tubular epithelial cells and its consequences on TG2 secretion into the ECM (Skill et al., 
2004). As further documented increased TG2 expression was shown to contribute to 
progression of interstitial fibrosis and scarring in diabetic nephropathy (Skill et al., 2004). 
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Additionally extracellular TG2 has also been reported to be involved in the severe chronic 
inflammatory states such as liver conditions (cirrhosis and fibrosis, alcoholic hepatopathy 
and hepatitis C) (Mirza et al., 1997; Grenard et al., 2001) and in renal and lung fibrosis 
(Griffin et al., 1979; Richards et al., 1991) as well as in heart where cardiac overexpression 
of TG2 leads to interstitial fibrosis in transgenic mice (Small et al., 1999). The major 
function of TG2 in many of these conditions has been linked to its ability to activate pro-
inflammatory cytokines such as TGF-β1 (which is a multi-step process ending with release 
of the active TGF-β1 subunit), leading to increased deposition of ECM (Verderio et al., 
1999; Griffin et al., 2002). The lack of TG2 expression in TG-deficient mice showed 
reduced activation of TGF-β1 resulting in decreased interstitial inflammation and 
protection against the development of renal fibrosis (Schweke et al., 2008). 
Impairment of homeostasis in ECM turnover is likely to be involved in the development 
of the atherosclerotic plaque (Ientile et al., 2007). One of the factors that has been found 
to stabilise the atherosclerotic plaque by preventing it from rupture is TG2 (Haroon et al., 
2001). Recent studies on the glaucomatous human trabecular meshwork suggested that 
elevated levels of TG2 and its tight TG2-FN interaction in the ECM may be associated with 
the pathologies of glaucoma (Tovar-Vidales et al., 2008). 
So far increased expression of TG2 has been highlighted by many researchers as one of 
the agents causing fibrosis and scarring. Therefore investigations have been undertaken 
to generate TG2 inhibitors. Two inhibitors including the membrane soluble irreversible 
inhibitor R283 or (1,3-dimethy2[(oxopropyl)thio]-imidazolium ) (Freund et al., 1994) and a 
membrane-impermeable irreversible inhibitor R281, or (N-benzyloxycarbonyl-L-
phenylalanyl-6-dimethylsulphonium-5-oxo-L-norleucin) (Griffin et al., 2008) have been 
shown to target extracellular TG2 transamidating activity and reduce interstitial scarring 
in a rat subtotal nephrectomy model of chronic renal fibrosis (Johnson et al., 2007; 
Collighan and Griffin, 2009). Thus the use of inhibitors looks like a very promising tool for 
the treatment of fibrotic conditions correlated with overexpression of TG2. 
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1.15.2 Cancer 
 
Numerous reports suggest the involvement of TG2 in the development of different 
cancer types. Alterations in the transamidation activity as well as GTP-binding properties  
of the enzyme could also affect tumour progression as well as the malignant phenotype. 
Early studies on the relationship between transglutaminase activity in malignant 
hepatoma, transformed human and hamster cells as well as mouse cells revealed a 
reduction in TG2 cross-linking activity in neoplastic cells in comparison to their normal 
counterparts (Birckbichler and Patterson, 1980). As further demonstrated by 
immunofluorescence the reduction of TG activity was correlated with the reduced 
amounts of TG2 antigen present in the particulate-fractions of transformed cells. 
Subsequently, induction of hepatocellular carcinomas in rats treated with 
diethylnitrosamine or 6-p-dimethylaminophenylazobenzothiazole lead to the reduction of 
enzyme activity and its redistribution to the particulate fraction of the cell (Barnes et al., 
1985). Following the subject, many other researchers observed the inverse correlation of 
TG2 activity and the susceptibility of a tumour to metastasis as well as redistribution of 
the enzyme to the particulate fractions (Hand et al., 1990; Knight et al., 1991; Beninati et 
al., 1993). In order to differentiate TG2 transamidation activity from its GTP-binding 
function, Mian et al. (1995) used transfected malignant hamster fibrosarcoma (MetB) 
cells with the wild type TG2 and (C277S) inactive mutant form. When synchronized into 
the S-phase of the cell cycle, both cells with overexpressed TG2 and inactive mutant in 
respect to the controls showed delayed progression from S-phase to G2/M phase (Mian et 
al., 1995) which remains in agreement with previous finding that reduced activity of the 
enzyme may favour tumour cell growth and invasion (Hand et al., 1990; Knight et al., 
1991).  
As a consequence of these findings, Jones et al., (2006) performed in vitro 
angiogenesis assays and further in vivo studies on two tumour models using exogenously 
applied TG2. Angiogenesis assays showed that application of active TG2 resulted in 
suppression of angiogenesis without causing cell death. Moreover in vivo experiments 
revealed that when injected into the CT26 colon carcinoma tumourus in mice, TG2 caused 
delays in tumour growth by inducing changes in the stability of the ECM while similar 
treatment on TG2 deficient mice resulted in increased tumour growth leading to 
increased death (Jones et al., 2006). Additionally recent investigations on tumour 
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suppressing proteins indicated TG2 to be a binding partner for GRP56 (down-regulated 
protein in metastatic malignant melanoma cells) and through this interaction to play a 
role in suppression of metastases and tumour growth (Xu et al., 2006). 
Multiple reports however documented overexpression of TG2 in several cancerous 
tissues including pancreatic ductal adenocarcinoma (PDAC) (Verma et al., 2006); breast 
carcinoma (Mehta et al., 2004; Mangala et al., 2007), malignant melanoma (Fok et al., 
2006) ovarian carcinoma (Satpathy et al., 2007; Hwang et al., 2009) and glioblastoma 
(Yuan et al., 2006). High expression of TG2 was shown to contribute to the development 
of chemoresistance as well as survival and metastasis of cancerous cells (Mehta et al., 
2004; Verma et al., 2006; Fok et al., 2006; Mangala et al., 2007; Hwang et al., 2008). For 
example in breast cancer cells TG2 was demonstrated to promote cell survival by 
activating integrin-mediated signaling pathways. Additionally in these cells, 
downregulation of endogenous TG2 by siRNA inhibited fibronectin mediated cell 
attachment and cell survival, while overexpression of the enzyme enhanced invasion of 
breast cancer cells and attachment to fibronectin (Herman et al., 2006; Mangala et al., 
2007). 
Moreover there are additional reports suggesting that TG2 when up-regulated in 
certain types of cancerous cells may play an anti-apoptotic function whereas siRNA down-
regulation of TG2 by treatment of these cells with inhibitors sensitizes them to apoptosis 
(Mehta, 1994; Antonyak et al., 2001; Herman et al., 2006; Kim et al., 2006; Mehta et al., 
2009). 
 
1.16 Tissue transglutaminase association with diseases 
 
Tissue transglutamianse is known to play pleiotropic functions in multiple cellular 
processes which help to maintain the homeostasis. However alterations in TG2 
expression have been suggested to contribute to the development of several pathologies 
including autoimmune celiac disease and variety of neurodegenerative diseases 
(Huntington, Alzheimer and Parkinson disease). 
 
 
 
 
Chapter I: Introduction 
64 
 
1.16.1 Tissue transglutaminase in celiac disease 
 
Numerous studies have been performed within the last few years on the engagement 
of TG2 activity in the pathogenesis of celiac disease. Celiac disease (CD) also termed celiac 
sprue and gluten-sensitive entheropathy is an inflammatory disorder characterised by 
damage of the intestinal epithelium resulting from abnormal intestinal immune response 
to dietary gluten proteins in the diet (Trier J.S. 1998; Jabri and Sollid 2009). In 1985, Bruce 
and co-workers described that tissue transglutamianse is expressed at low levels in a 
healthy small intestine, in contrary elevated levels of the enzyme were noticed in jejunal 
biopsies from the CD patients suggesting involvement of TG2 in the pathogenesis of the 
disease (Bruce et al., 1985).   Further investigations identified TG2 as the autoantigen of 
the endomysium specific autoantibodies that are characteristic for celiac disorder 
(Dieterich et al., 1997). As a result of these findings other researchers used IgA TG2 
antibodies as a tool to develop screening tests for the presence of celiac disease (Gillett 
and Freeman, 2000; Fabiani et al., 2001). 
In addition to the role of TG2 in the humoral response, the activity of the enzyme was 
also shown to be associated with generating gluten peptides that trigger a T-cell 
mediated reaction in the small intestine of CD individuals (Moelberg et al., 1998; van de 
Wal et al., 1998; Vader et al., 2002). Genetic predisposition to develop celiac disorder has 
been linked with MHC class II genes that encode HLA-DQ2 and HLA-DQ8 molecules 
(Lundin et al., 1994). HLA-DQ2 and HLA-DQ8 display a high affinity for negatively charged 
amino acids (van de Wal et al., 1996; Godkin et al., 1997). However native gluten 
possesses only a few negatively charged residues for binding to DQ2 and DQ8. Increase in 
the number of these negatively charged amino-acids is triggered by post-translational 
modifications. Conversion of glutamine residues in gluten derived peptides into glutamic 
acid has been shown to be catalysed by tissue transglutaminase (Moelberg et al., 1998; 
van der Wal et al., 1998). However TG2 deamidates only specific glutamine residues 
bearing Gln-X-Pro motifs (where X represents any amino acid residues) which are often 
present in gluten proteins (Vader et al., 2002; Jabri et al., 2009).The deamidation can take 
place in the acidic environment of the stomach or in the one that is deprived of amine 
donors. Therefore TG2 mediated reactions targeted against specific substrates stimulates  
T-cell epitopes by generating negatively charged peptides which binds the HLA- DQ2 and 
HLA-DQ8 molecules with high affinity (Vader et al., 2002; Dorum et al., 2009). 
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To sum up, tissue transglutaminase was characterised as the humoral auto-antigen in 
celiac disease but it still remains poorly understood whether the enzyme can function as T 
cell auto-antigen. However it was indicated by recent in vitro experiments performed by 
Ciccocioppo et al., (2010) on CD patients who revealed a role of TG2-specific T-cells 
mediated immune response in the pathogenesis of the disease (Ciccocioppo et al., 2010). 
 
1.16.2 Tissue transglutaminase in neurodegeneration 
 
Knowing that tissue transglutaminase is ubiquitously distributed throughout the 
human body, it is not surprising that its expression was also found in the brain (Kim et al., 
1999). Although the enzyme expression was detected in the central nervous system (CNS) 
mainly in neurons it has also been observed in glial cells (Kim et al., 1999; Lesort et al., 
1999). Within the central nervous system (CNS) TG2 has been postulated to play 
physiological and pathological functions. So far it has been shown to be involved in 
neuronal differentiation (Tucholski et al., 2001), neuronal apoptosis (Melino et al., 1994) 
and in maturation of the brain (Bailey and Johnson 2004). However TG2 has also been 
implicated in the development of the pathologies in the CNS. For example, mRNA, full 
length TG2 (Tolentino et al., 2002) and its short splice variants encoding a truncated form 
of enzyme missing the GTP-binding site (Citron et al., 2001) are elevated following the 
injury in the CNS. The increased level of TG2 and transcription of short splice variants 
facilitates uncontrolled cross-linking activity of the enzyme resulting in neuronal 
dysfunction and death (Citron et al., 2002). Given the findings, it has been hypothesized 
that TG2 may contribute to development of neurodengenerative diseases. 
Neurodegeneration is characterised by elevated levels of TG2 enzymatic activity include 
Huntington’s disease (Karpuj et al., 1999; Lesort et al., 1999), Alzheimer’s disease 
(Johnson et la., 1997; Citron et al., 2001; Kim et al., 1999), Parkinson’s disease (Citron et 
al., 2002) and progressive supranuclear palsy (Zemaitatis et al., 2003).  
The most common form of neurodegenerative disorder is Alzheimer’s disease (AD). It 
is caused by the formation of senile plaques and neurofibrillary tangles consisting of 
amyloid-β protein or neurotoxin protein aggregates consisting of hyperphosphorylated 
tau which accumulation leads to neuronal death (Wilhelmus et al., 2008). There is a 
strong evidence suggesting the TG2 plays role in the pathology of AD since the enzyme 
was found to co-localise with plaques (Zhang et al., 1998) and neurofibrillar tangles 
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(Citron et al., 2002) where additionally its elevated enzymatic activity was identified 
(Singer et al., 2002). Moreover β-amyloid which is present in fibrillar in plaques 
(Rasmussen et al., 1994) and the microtubule-binding protein tau that is a component of 
neurofibrillar tangles (Murthy et al., 1998) was demonstrated to act as substrates for TG2 
which was further shown to facilitate the formation of amyloid-β oligomers and insoluble 
tau aggregates or tau filamentous. Additionally TG2 was reported to mediate 
polyamination of tau protein leading to formation of non-degradable tau in neurons 
(Tucholski et al., 1999). The available data suggest that regulation of TG2 activity during 
aggregates formation may be used as a therapeutic target for Alzheimer’s diseases 
(Wilhelmus et al., 2008). 
Parkinson’s disease (PD) is a progressive movement disorder that is characterised by 
the loss of dopaminergic neurons in the substantia nigra. Pathologically this 
neurodegenration is manifested by the presence of intraneuronal inclusions known as 
Lewy bodies consisting of the α-synuclein protein (α-syn) (Spillantini et al., 1997). So far 
elevated expression of TG2 has been observed in substantia nigra of PD brain as well in 
Lewy bodies (Adringa et al., 2004; Junn et al., 2003). The first evidence of TG2 possible 
involvement in the aggregation of α-synuclein was documented by Jensen et al. (1995). 
Further investigations within that field using in vitro and cell models confirmed that TG2 
interacts with α-synuclein resulting in increased formation of intramolecular α-synuclein 
aggregates (Junn et al., 2003). However contradictory findings suggested that even 
though the enzyme catalyses cross-linking of intramolecular α-synuclein monomers it 
inhibits its fibrillization in vitro (Konno et al., 2005). The basis of these interactions 
remains poorly understood nevertheless recent studies indentified two lysine residues 
(Gln79 and Gln109) as the main α-synuclein substrate for the cross-linking activity of the 
enzyme (Schmid et al., 2009).  
An additional disorder linked with elevated levels of TG2 activity is Huntington’s 
disease (HD). Huntington’s disease is a progressive autosomal-dominant 
neurodegenerative disorder that is caused by polyglutamine tract expansion in the gene 
encoding for huntingtin protein (Lesort et al., 2000). Huntingtin is present in the 
aggregates that are specific for HD (Becher et al., 1998) and has been demonstrated to 
act as a substrate for TG2 crosslinking activity in vitro (Kahlem et al., 1996; Karpuj et al., 
1999). TG2 cross-links were detected in neurons in specific areas of Huntington’s brain 
where it co-localises with huntingtin protein in intracellular inclusions (Zainelli et al., 
Chapter I: Introduction 
67 
 
2003). Thus the enzyme was suggested to mediate the formation of huntingtin protein 
aggragates and in this manner to be involved in the pathogenesis of HD (Wilhelmus et al., 
2008). 
Based upon many available findings, elevated TG2 activity has been suggested to 
mediate the formation of neurotoxic aggregates in neurodegenerative disorders including 
Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease. Therefore inhibition 
of the enzymes transamidating activity might be a therapeutic strategy in prevention of 
development of these diseases (Wilhelmus et al., 2008). 
 
1.17 Aims 
 
Numerous studies have reported the versatility of TG2, revealing information about its 
involvement in physiological and pathological processes that take place in eukaryotic cells 
in vivo. Many of these pathologies are instigated by TG2 in the extracellular environment 
but the mechanism of secretion of the enzyme is still not known. Evidence indicates that 
the enzyme does not undergo a conventional ER/Golgi dependent secretion pathway. 
Data suggest that for TG2 to be secreted, an intact N-terminal FN binding site (for which it 
has high affinity) is required however in addition interaction of TG2 with its high affinity 
binding partners present both in the intracellular and extracellular space as well as with 
specific cell surface receptors may be involved in that process.  
 Although there are likely to be many factors involved in externalisation of TG2 its 
translocation to the cell surface and its conformational state when secreted still remain 
unknown.  
   Thus, the initial objective of this project was to develop suitable cell models to 
investigate the externalisation of TG2 and its translocation into the ECM. The second aim 
was focused on studying specific amino acid sequences or TG2 regions which can be 
engaged in this process. To further identify whether the enzyme interacts with any so far 
known proteins, mutagenesis studies based on generating TG2 point or single mutations 
as well as deletion products were undertaken. Knowing that GTP (one of the intracellular 
binding partner of the enzyme), FN (its extracellular partner) and cell surface receptors 
including heparan sulfate proteoglycans and integrins may play a role in its translocation 
to the ECM, the specific characterised or uncharacterised TG2 binding sites for each of its 
high affinity binding partners were targeted for mutagenesis.  
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     Therefore, depending on the results obtained in the initial investigations, the influence 
of mutations on the conformational state of the enzyme, its final localisation as well as its 
role in extracellular environment with a more in depth view on its involvement in 
mediating cell-adhesion will be further explored in this thesis.  
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MATERIALS 
 
2.1.1 General chemicals: 
 
All sterile solutions, reagents and tips were prepared by autoclaving at 121 °C; otherwise 
solutions were filtered through a 0.22 µm Whatman sterile filter. Most of the general 
chemicals were purchased from Sigma-Aldrich as stated below: 
 
Sigma – Aldrich Company Ltd, Dorset, UK: 
 
Serum free medium (DMEM), Magnesium chloride, sodium chloride, sulphuric acid, 
glycine, Tris base, Paraformaldehyde, Dimethyl Sulpoxide (DMSO), D-(+)-Glucose, 
Ethylenediaminetetraacetic acid (EDTA), Magnesium sulfate, Casein enzymatic hydrolase, 
and SigmaFast OPD, May Grunwald and Giemsa stains 
 
Additionally, other reagents and chemicals were supplied from:  
 
Bachem, Merseyside, UK: 
The synthetic peptide: H-Gly-Arg-Gly-Asp-Thr-Pro-OH (GRGDTP) and H-Gly-Arg-Ala-Asp-
Ser-Pro-OH (GRADSP) 
 
Peptide Synthetics, Fareham, UK: 
The synthetic peptides: H-Asn-Pro-Lys-Phe- Leu-Lys-Asn-Ala-Gly-Arg-Asp-Cys-Ser-Arg-Arg- 
Ser-Ser-OH (NPKFLKNAGRDCSRRSS), H-Asn-Pro-Lys-Phe- Leu-Lys-Asn-Ala-OH (NPKFLKNA), 
H-Gly-Arg-Asp-Cys-Ser-Arg-Arg-Ser-Ser-OH (GRDCSRRSS), H-Phe-Asn-Arg-Ala-Asp-Leu-Lys-
Pro-Arg-Cys-Gly-Ser-Ser-Asn-Lys-Sear-Arg-OH (FNRADLKPRCGSSNKSR), H-Ala-Glu-Glu-Leu-
Val-Leu-Glu-Arg-Cys-Asp-Leu-Glu-Leu-Glu-OH (AEELVLERCDLELE),  H-Glu-Glu-Cys-Arg-Leu-
Ala-Glu-Glu-Leu-Leu-Glu-Asp-Val-Leu-OH (EECRLAEELLEDVL) and H-Trp-Thr-Ala-Thr-Val-
Val-Asp-Gln-Gln-Asp-Cys-Thr-Leu-Ser-Leu-Gln-Leu-Thr-Thr-OH (WTATVVDQQDCTLSLQLTT) 
 
Sigma Genosys, UK: 
Oligonuclotide primers:  
Forward primers: 
5’GGACAGCCACCGTGGTAGCCCAGCAAGCCTGCACCCTCTCGC 3’ 
5’ GCTTTATCTACCAGGGCGAGGCCAAGTTCATCAAG 3’ 
5’ TACCAGGGCTCGGCCCTCTTCATCAAGAACATAC 3’ 
5’ GGGGAGCCCAAGCAGGCGGCCGCGCTGGTGGCTGAGGTGTC 3’ 
5’ CAACCCCAAGTTCCTGGCGAACGCCGGCGCTGACTGCTCCCG 3’ 
5’ GGACGGTACCATGACCAATGGCCGAGACCACCAC 3’ 
5’ GGACGGTACCATGGCCGAGGAGCTGGTCTTAGAG 3’ 
Reverse primers: 
5’ GCGAGAGGTGAAGGCTTGCTGGGCTACCACGGTGGCTGTCC 3’ 
5’ CTTGATGAACTTGGCCTCGCCCTGGTAGATAAAGC 3’ 
5’ GTATGTTCTTGATGAAGAGGGCCGAGCCCTGGTA 3’ 
5’ GACACCTCAGCCACCAGCGCGGCCGCCTGCTTGGGCTCCCC 3’ 
5’ CGGGAGCAGTCAGCGCCGGCGTTCGCCAGGAACTTGGGGTTG 3’ 
5’ GGACGCGGAAGCTTAGGCGGGGCCAATGATGAC 3’ 
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5’ GGACGCGGCCGCTCACCGGATCTTGATTTCTGG 3’ 
Sequencing primers: 
5’ GGTTCTTCCAGCGCCGCA 3’ 
5’ GGGTAAGCTTTCCGTATGTAGC 3’ 
5’ TAATACGACTCACTATAGGG 3’ 
5’ GGGTAAGCTTTCCGTATGTAGC 3’ 
 
Molecular Probes, Eugene (OR), USA: 
Biotin-X-cadaverine 
 
Melford, Suffolk, UK: 
Tris hydrochloride, Dithiothreitol (DTT), Carbenicilin disodium salt 
 
Merck Chemical Limited, Nottingham, UK: 
Albumin Bovine Serum, glacial acetic acid and Casein N,N-Dimethyl-Bovine 
 
Thermo Scientific, Northumberland,UK: 
EZ-link Sulf-NHS-LC-Biotin, High Capacity NeutrAvidin Agarose 
 
2.1.2 Bacterial lines and transformation reagents: 
 
Invitrogen, Ltd., Paisley, UK: 
DH5α strain of Escherichia coli 
 
Merck Chemical Limited, Nottingham, UK: 
NovaBlue Singles TM Competent cells, strain of Escherichia coli 
 
Oxoid Limited, Hampshire, UK: 
Yeast extract, Trypton T, and Agar bacteriological 
 
Sigma – Aldrich Company Ltd, Dorset, UK: 
Ampicilin 
 
2.1.3 Immunochemicals: 
 
Lab Vision Products, Thermo Fisher Scientific, UK: 
Transglutaminase II Ab-1 monoclonal antibody (CUB 7402) 
 
Sigma – Aldrich Company Ltd, Dorset, UK: 
Goat anti-mouse IgG-HRP conjugate, anti-mouse IgG α-tubulin 
 
2.1.4 Protein reagents: 
 
Sigma – Aldrich Company Ltd, Dorset, UK: 
Fibronectin from human plasma (FN), and extravidin- peroxidise 
70 kDa fibronectin from human plasma, 30kDa fibronectin from human plasma 
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Zedira GmBh, Darmstadt, Germany: 
Guinea pig liver tissue transglutaminase 
Human tissue transglutaminase recombinant in E.coli 
 
Domestic supplier: 
Marvel skimmed dried milk powder  
 
2.1.5 Electrophoresis and Western blotting reagents: 
 
Santa Cruz Biotechnology Inc., Calne, UK: 
RIPA cell lysis buffer 
 
Sigma – Aldrich Company Ltd, Dorset, UK: 
Acrylamide, Ammonium persulphate (AP), protease inhibitor cocktail for mammalian 
cells, Laemmli buffer (2x concentrated), GBX Developer/Replenisher, GBX 
fixer/Repelnisher, Kodak Biomax XAR detection Film 
 
Melford, Suffolk, UK: 
Tris-Glycine-SDS buffer, pH 8.5, sodium dodecyl sulphate (SDS) 
 
Bio-Rad Laboratories Ltd., Hetfordshire, UK: 
Gel loading tips 
 
Fisher Scientific UK Ltd., Leicestershire, UK: 
Western blotting filter papers 
 
GE Water & Process Technologies, UK: 
Nitrocellulose membrane 
 
Amersham Pharmacia Biotech. UK Ltd, Little Chalfont, UK: 
ECL development kit and the full range rainbow molecular marker 
 
2.1.6 Expression and cloning vectors: 
 
Invitrogen Ltd., Paisley, UK: 
pcDNA3.1/CT-GFP expression vector 
 
Merck Chemical Limited, Nottingham, UK: 
psTBlue-1 Perfectly blunt cloning kit 
 
2.1.7 Molecular biology kits, chemicals and reagents: 
 
UK New England Biolabs, Knowl Piece, UK: 
DNA marker - 2-log DNA ladder (0.1-10kb), restriction enzymes - Not I, Kpn I, Ear I, Eag I, 
Bst XI, T4 DNA ligase 
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Fermentas, York, UK: 
Restriction enzyme – PpiI 
 
Promega, Southampton, UK: 
Pfu DNA Polymerise, plasmid DNA purification kits: Pure Yield Plasmid Miniprep system, 
Wizard plus SV Minipreps DNA Purification system, Wizard SV gel and PCR Clean-up 
system,  
 
Qiagen, Crawley, UK: 
Plasmid DNA purification kit: Endotoxin free plasmid maxi  
 
Merck Chemical Limited, Nottingham, UK: 
KOD HOT Start DNA Polymerase 
 
Stratagene, Cheshire, UK: 
Quick change II site directed mutagenesis kit 
 
Melford, Suffolk, UK: 
Molecular grade water, agarose, Low melting temperature agarose, Tris-Acetate-EDTA 
buffer pH 8.0, Ispropyl-β-D-1-thio-galactopyranoside IPTG, 5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside X-gal 
 
2.1.8 Cell  transfection reagents: 
 
Sigma – Aldrich Company Ltd, Dorset, UK: 
HEPES buffered saline, Calcium chloride solution 
 
Lonza Wokingham LTD., Berkshire, UK: 
Nukleofactor kit R 
 
2.1.9 Everyday use consumables: 
 
Appleton Woods Ltd., Birmingham, UK: 
Tissue culture plates (TCP) (6- and 96-well plates), Petri dishes, wide range of flasks (T25, 
T75, T100), 2 ml microcentrifuge tubes, 15ml and 50ml sterile centrifuge tubes, 5ml, 
10ml, 25ml sterile pipettes,  10µl, 100µl and 1ml pipette tips 
 
2.1.10 Other consumables: 
 
Sterilin Ltd., Bargoed, UK: 
Microtiter 96-well plates 
 
NuncTM, Thermo Fisher Scientific, Roskilde, Denmark: 
Cryotube vials, high binding 96-well plates 
 
Laboratory supplier: 
the irreversible peptidic inhibitor R281 
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2.1.11 Equipment: 
 
Laboratory instruments listed below were purchased from the following distributors: 
 
Appleton Woods Ltd., Birmingham, UK 
Spectrafuge 24D, Mini gyro-rocker (Stuart), Orbital shaker 
 
Beckam Coulter Ltd., High Wycombe, UK: 
Avanti J-E centrifuge, Allegra X-15R centrifuge, MicrofugeR 22R centrifuge 
 
Sanyo Ltd., Watford, UK 
Orbi-safe shaker, Sanyo Tissue culture CO2 incubator 
 
Bio-Rad Laboratories Ltd., Watford, UK: 
DNA electrophoresis system - Protean III minigel system, power supply – Power Pac basic 
 
Bibby Scientific Limited, Stone, UK: 
Jenway Spectrophotometer Genowa 
 
Amaxa, GmbX, Germany: 
Nukleofaktor system 
 
Amersham Biosciences, Sweden: 
Heparin Sepharose, HiTrapTM Heparin HP (1ml, 5ml) 
 
Sigma – Aldrich Company Ltd, Dorset, UK: 
GTP-Agarose column (2ml) 
 
Cleaver Scientific, Rugby, UK: 
Agarose electrophoresis equipment (tanks and power supply) 
 
Biotek, Potton, UK: 
Absorbance microplate reader ELx808TM 
 
Amersham Biosciences, Sweden: 
ÄKTA purifier, FPLC system 
 
 
Fluorescent microscope, Ziess Axiovert 200 
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METHODS 
 
2.2 Methods 
 
2.2.1 Generation of the wild type TG2 
  
2.2.1.1 Expression and purification of wtTG2 
 
 
The cDNA encoding human endothelial TG2 was cloned into the pcDNA3.1/Myc-
HisA/Neo vector and then into the HindIII and PmeI restriction sites of the pGene/V5-His 
vector for mifepristone inducible expression in mammalian cells (Hang et al., 2005). These 
clones were kindly provided by Dr A.M. Belkin (University Maryland, USA). Obtained 
plasmids were transformed into NovaBlue Singles Competent cells (E.coli) (Novagen), and 
plated directly on ampicillin containing agar plates for selection and incubated overnight 
at 37 °C. Single colonies were grown in LB medium (1.0% Tryptone, 0.5% Yeast Extract, 
1.0% NaCl, pH 7.0 plus ampicillin 100μg/ml) for 18 hours at 37 °C. After centrifugation 
plasmid DNA was purified using Wizard Plus SV Miniprep (Promega) according to the 
manufacture’s protocol. The purity of plasmids was confirmed by using 0.8% (w/v) 
agarose gel electrophoresis in TAE buffer (Tris-acetate-EDTA, pH 8.3).  
 
2.2.1.2 DNA analysis on agarose gel electrophoresis  
 
Agarose gels were composed of agarose (w/v depending on gel percentage) by melting 
it in 1xTris-acetate-EDTA buffer, pH 8.3 (TAE, 40mM Tris, 0.114% glacial acetic acid(v/v) 
and 1mM EDTA) in a microwave oven. After cooling the solution to 55-60 °C, ethidium 
bromide (10mg/ml) was added to a final concentration of 0.5μg/ml, the gel was poured 
on a casting plate in a Bio-Rad DNA electrophoresis tray and allowed to solidify for about 
1hour at RT or +4 °C (low melting point agarose gel). Earlier prepared DNA samples were 
diluted 1/10 with 10x DNA loading buffer (100mM EDTA, 1% SDS(w/v), 0.25% 
bromophenol blue(w/v) and 0.25% xylene cyanol(w/v)) and loaded into wells. As a marker 
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a 1-10kb DNA ladder (Biolabs) was used. Electrophoresis was performed at 10v/cm until 
the bromphenol blue was near the end of the gel. 
 
2.2.1.3 Primer design and DNA amplification  
 
Table I 
A list of primers for TG2 amplification 
TG2 FP 5’ GGTACCATGGCCGAGGAGCTGGTC 3’ 
TG2 RP 5’ GCGGCCGCTTAGGCGGGGCCAATGATGAC 3’ 
 
The purified inserts were amplified with primers (forward and reverse primers 
especially designed for TG2  using PrimerSelect software, Lasergene), which introduced a 
KpnI site before the TG2  initiation codons and a NotI site after the stop codons (Table I). 
PCR reactions were assembled with the following components: 
 
Table II 
A list of components used for TG2 amplification 
Component  Final concentration 
Pfu DNA Polymerase 10x 
buffer with MgSO4 
5μl 1x 
2mM dNTPs mix 5μl 200μM each 
Forward primer (TG2) 0.5μl TG2 0.372μg/0.5μl 
Reverse primer (TG2) 0.5μl TG2 0.449μg/0.5μl 
DNA template 1μl 0.5μg/50µl, 1000x 
Pfu DNA Polymerase 1μl 1.25u/50µl 
Nuclease free water 37μl  
 
The reactions were carried out in the presence of Pfu DNA Polymerase (Promega) and 
cycled in a Primus thermal cycler using the following conditions (Table III): 
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Table III 
PCR reaction conditions 
Step Temperature Time Number of Cycles 
Denaturation 95 °C 2 minutes 1 cycle 
Denaturation 
Annealing 
Extension 
95°C 
42-65°C 
72-74°C 
1 minute 
1 minute 
5 minutes 
 
25-35 cycles 
Final extension 74°C 5 minutes 1 cycle 
Soak 4°C Indefinite 1 cycle 
 
2.2.1.4  Subcloning of amplified cDNAs 
 
The PCR products were separated on 0.8% agarose gels and purified using Wizard SV 
gel plus a PCR clean up system and then cloned into psTBlue-1 vector using the Perfectly 
Blunt Cloning kit from Novagen. The cultures from E.coli, transformed with the  ligation 
products, were grown overnight at 37 °C, on agar plates with 100µg/ml ampicillin (Sigma-
Aldrich) and 50ug/ml carbenicillin (Melford laboratories), which were additionally 
supplemented with 35ul of 50mg/ml X-gal (Melford laboratories) and 20ul of 100mM 
IPTG (Melford laboratories) to allow blue/white screening. The blue colonies, assumed to 
contain religated vector, were not taken for further examination. The white colonies, 
were spread again onto ampicillin agar plates and grown overnight at 37 °C. The size of 
the cDNA was rapidly estimated following the cracking procedure described in “Promega- 
protocols guide book”. Briefly, each picked colony was added into an eppendorf tube that 
contained 50µl of 10mM EDTA pH 8.0, then suspended in 50ul 2xcracking buffer (0.2M 
NaOH, 0.5% SDS, 20% sucrose) and incubated at 70 °C for 5 min. After cooling to RT, 1.5μl 
of 4M KCL plus 0.5μl of 0.4% bromophenol blue was transferred into each tube  which 
were placed on ice for 5 min. Obtained suspensions were centrifuged at 13 000rpm for 3 
min at 4 °C and loaded on 0.8% agarose gels. After performing electrophoresis, samples 
which contained cDNA constructs that were significantly bigger from the rest were 
chosen for miniprep purification following the instructions of Wizard Plus SV Miniprep 
DNA Purification system (Promega). To separate inserts from the vectors, first they were 
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digested with KpnI and NotI restriction enzymes and run for 1 hour on 1.5% low melting 
point agarose gels with a constant power of 100V. Cleaved inserts were cut from the gel, 
once more purified using Promega clean up system and subcloned into the pcDNA3.1/CT-
GFP expression vector. To isolate endotoxin-free DNAs for transfection, obtained 
plasmids were purified using Endotoxin free plasmid maxi kit (Qiagen, UK) according to 
the manufacturer’s protocol. Plasmid DNA quality was estimated by agarose gel 
electrophoresis and the concentration was calculated by the absorbance at 260nm, by 
the ratio of A260 nm to A280 nm absorbance values.  
 
2.2.2 Mutagenesis studies 
 
2.2.2.1 Primer design and DNA amplification 
 
2.2.2.1 A TG2 point mutations 
 
Endotoxin free plasmid DNA containing wild type TG2 was used as a DNA template to 
generate a set of different TG2 mutants. The Quick change site-directed mutagenesis kit 
(Stratagene) was used to create single point mutations (GTP 1 and GTP2 mutants) and 
multiple point mutations (HS1, HS2 and FN1 mutants) as shown in Table IV. All the 
reactions were performed according to the manufacturer’s protocol.  
 
Table IV 
A list of TG2 point mutants 
 
Construct TG2 Point Mutations  
FN1 
GTP1 
GTP2 
HS1 
HS2 
(D94A, D97A) 
(S171E) 
(K173L) 
(K600A, R601A, K602A) 
(K205A, R209A) 
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This method requires designing two oligonucleotide primers, each complementary to the 
opposite strands of the vector containing the insert of interest and containing the 
required mutation(s) (Table V). Specific oligonucleotide primers are extended during 
temperature cycling by Pfu DNA Polymerase which leads to generation of the mutated 
plasmids.  
 
Table V 
A list of primers and their sequences 
Construct Primer Sequence 
 
FN1 
GTP1  
GTP2 
HS1 
HS2 
 
FN1 
GTP1 
GTP2 
HS1 
HS2 
Forward primers 
5’ GGACAGCCACCGTGGTAGCCCAGCAAGCCTGCACCCTCTCGC 3’ 
5’ GCTTTATCTACCAGGGCGAGGCCAAGTTCATCAAG 3’ 
5’ TACCAGGGCTCGGCCCTCTTCATCAAGAACATAC 3’ 
5’ GGGGAGCCCAAGCAGGCGGCCGCGCTGGTGGCTGAGGTGTC 3’ 
5’ CAACCCCAAGTTCCTGGCGAACGCCGGCGCTGACTGCTCCCG 3’ 
Reverse primers 
5’ GCGAGAGGTGAAGGCTTGCTGGGCTACCACGGTGGCTGTCC 3’ 
5’ CTTGATGAACTTGGCCTCGCCCTGGTAGATAAAGC 3’ 
5’ GTATGTTCTTGATGAAGAGGGCCGAGCCCTGGTA 3’ 
5’ GACACCTCAGCCACCAGCGCGGCCGCCTGCTTGGGCTCCCC 3’ 
5’ CGGGAGCAGTCAGCGCCGGCGTTCGCCAGGAACTTGGGGTTG 3’ 
 
As shown in Table VI, the obtained plasmids were digested with specifically chosen 
restriction enzymes (since the mutation creates new or removes existing restriction sites) 
and run on a 0.8% agarose gel with constant voltage 100V to verify whether the obtained 
constructs contained the desired mutation.  
 
 
 
 
 
Chapter II: Materials and Methods 
 
 
80 
 
 
Table VI 
A list of restriction enzymes used to digest desired TG2 mutation 
Construct  Restriction enzyme  
FN1 
GTP1 
GTP2 
HS1 
HS2 
 BstXI 
PpiI 
EarI 
NotI 
EagI 
 
 
To further confirm the correct sequences of the TG2 mutants each plasmid DNA was 
sequenced. Again for that purpose a set of primers (either forward and reverse or only 
reverse in case of the HS1 mutant) were designed using PrimerSelect software, 
Lasergene). 
 
Table VII 
A list of sequencing primers 
Construct Primer sequence 
 
FN1 
GTP1 
GTP2 
HS2 
 
FN1 
GTP1 
GTP2 
HS2 
HS1 
                                    Forward primers 
                 
                     
                     
 
                                    Reverse primers 
 
 
 
 
 
 
5’ GGGTAAGCTTTCCGTATGTAGC 3’ 
 
5’ GACCTGTGCCGGGAGAAGC 3’ 
5’ GGTTCTTCCAGCGCCGCA 3’ 
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To isolate endotoxin-free DNAs for transfection, obtained plasmids were purified using 
Endotoxin free plasmid maxi kit (Qiagen, UK) according to the manufacturer’s protocol. 
Plasmid DNA quality was estimated by agarose gel electrophoresis and the concentration 
was calculated by the absorbance at 260nm, by the ratio of A260 nm to A280 nm . 
 
2.2.2.1 B TG2 deletion products  
 
A set of TG2 deletion mutants (deletion of the first 15 amino acids of the N-terminal 
site and deletion of the whole C-terminal domain of the wild type TG2) was generated 
based on the TG2 insert expressed in the pcDNA3.1/CT-GFP vector.  
 
Table VIII 
A list of TG2 deletions 
Construct  TG2 deletion products 
N- 
C- 
TG2 (del 1-15 amino acids) 
TG2 (del 594-687 amino acids) 
 
Both deletion mutants were created by PCR amplification using the set of 
oligonucleotide primers as shown in Table IX which introduces mutations between KpnI 
and NotI restriction sites on the DNA template.  
 
Table IX 
A list of primers and their sequences 
Primer Sequence 
Forward primers 
N- 
C- 
Reverse primers 
N- 
C- 
 
5’ GGACGGTACCATGACCAATGGCCGAGACCACCAC 3’ 
5’ GGACGGTACCATGGCCGAGGAGCTGGTCTTAGAG 3’ 
 
5’ GGACGCGGAAGCTTAGGCGGGGCCAATGATGAC 3’ 
            5’ GGACGCGGCCGCTCACCGGATCTTGATTTCTGG 3’ 
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PCR reactions were assembled with the following components: 
 
Table X 
A list of components used for PCR reaction 
Component Volume  Final concentration 
KOD Hot Start DNA Polymerase 10x 
buffer 
5µl  1x 
2mM dNTPs mix 5µl  200μM each 
25mM MgSO4 3µl  1.5mM MgSO4 
Forward primer 0.5µl  N- (0.52μg/0.5μl) 
C- (0.53μg/0.5μl) 
Reverse primer 0.5µl  N- (0.5μg/0.5μl) 
C- (0.48μg/0.5μl) 
DNA template (TG2) 1µl  0.5μg/50μl, 1000x 
KOD Hot Start DNA Polymerase (1U/μl) 
Nuclease free water 
1µl 
34µl 
 0.02U/50μl 
 
The reactions were carried out in the presence of KOD Hot Start DNA Polymerase 
(Novagen) and cycled in a Primus thermal cycler using the following conditions: 
 
Table XI 
Condition of PCR reaction 
Step Temperature Time Number of cycles 
Denaturation 95 °C 2 minutes 1 cycle 
Denaturation 
Annealing 
Extension 
95°C 
60°C 
72-74°C 
0.5 minute 
0.5 minute 
2 minutes 
 
30 cycles 
Final extension 74°C 5 minutes 1 cycle 
 
Obtained PCR products and an empty expression vector pcDNA3.1/CT-GFP were 
digested with KpnI and NotI restriction enzymes. To eliminate any remaining buffers all 
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constructs were purified using Wizard SV gel plus a PCR clean up system and visualised on 
a 0.8% agarose gel with a constant power of 100V. Purified inserts were then subcloned 
into the pcDNA3.1/CT-GFP expression vector. To isolate endotoxin-free DNAs for 
transfection, obtained plasmids were purified using Endotoxin free plasmid maxi kit 
(Qiagen, UK) according to the manufacturer’s protocol. Plasmid DNAs quality was 
estimated by agarose gel electrophoresis and the concentration was calculated by the 
absorbance at 260nm, by the ratio of A260 nm to A280 nm absorbance values.  
Again the identity and proper arrangement of the TG2 deletion mutants was analysed 
by DNA sequencing by means of specially designed sequencing primers as shown in Table 
XII. 
 
Table XII 
A list of sequencing primers for sequencing of TG2 deletion mutants 
Construct                                  Sequencing primers     
Forward primers 
N- 
C- 
Reverse primers 
N- 
C- 
 
                                     
 
 
  
 
2.2.3  Cell culture 
 
2.2.3.1 Cell lines 
 
Cell lines used in this project including human kidney epithelial cells HEK 293/T17 and 
mouse embryo fibroblasts NIH3T3 were obtained from American Type Culture Collection 
(ATCC, USA).  HEK293 is a cell line that is generated by the transformation of normal 
human kidney embryonic cells with andenovirus type 5 DNA (Graham et al., 1977). The 
type of kidney cell that the HEK293 cells are derived from is unknown. It has been 
speculated that the cells may be neuronal in origin. However it is more plausible that cells 
5’ TAATACGACTCACTATAGGG 3’ 
5’ GGGTAAGCTTTCCGTATGTAGC 3’ 
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derived from an embryonic kidney would rather be epithelial, endothelial or fibroblasts. 
Nevertheless the reason for using those cells results from their ability to efficiently 
express wide range of recombinant proteins that are subcloned into the expression 
vector, which carries SV40 as origin of replication to allow its amplification in the host cell 
(van Craenenbroeck et al., 2000; Durocher et al., 2002). Additionally human dermal 
osteoblasts (HOB) were kindly provided by Dr S. Anderson  (University of Nottingham, 
UK). This cell line was obtained from femoral heads of trabecular bone and spontaneously 
immortalised.  
Each cell type was cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 
10% (v/v) heat inactivated foetal calf serum (FCS), 2 mM L-glutamine, nonessential amino 
acids, 100 U/ml of penicillin and 100µg/ml of streptomycin followed by incubation in a 
humidified atmosphere at 37ºC, 5%(v/v) CO2, 95%(v/v) air to maintain their optimal 
growth conditions. 
The human kidney epithelial cells HEK293/T17 expressing wt TG2 as well as TGase 
mutants were grown in a supplemented growth medium (DMEM) excluding any 
penicillin/streptomycin supplement since the presence of antibiotic in the  growing 
medium could affect the efficiency of transfection.  
The NIH3T3 fibroblasts expressing wt TG2 as well as TGase mutants were supplemented 
with antibiotics in complete DMEM. 
 
2.2.3.2 Cell passaging and counting 
 
Cells were passaged at approximately 90% confluence. The cell monolayer was rinsed 
with PBS pH 7.4 and treated with 0.25% (w/v) trypsin, 2mM EDTA solution in PBS, pH 7.4 
at 37 °C prior to detachment of the cells. To neutralize the trypsin, cells were collected in 
the growth medium and centrifuged at 250xg for 5 minutes and then reseeded in the 
tissue culture flask until they reached the required confluence. To determine the 
concentration of cells in a suspension a hemacytometer was used. Approximately 10ul of 
cell suspension was added into each hemacytometer chamber and then cells were 
counted 4 times using phase/contrast microscopy. The cell number was calculated as 
follows: ‘established number of cells x dilution factor/mm2 of counted area x chamber 
depth’. 
Chapter II: Materials and Methods 
 
 
85 
 
2.2.3.3 Cryopreservation of cells 
 
Cells were trypsinised, and treated as described before (2.2.3.2). Centrifuged again to 
discard remaining medium and resuspended in a cryopreservative solution containing 
heat inactivated FCS containing 10 % (v/v) DMSO.  Cells were then transferred into 
cryogenic vials and frozen in – 70°C overnight before long-term storage in liquid nitrogen. 
 
2.2.3.4 Thawing frozen cells 
 
Cryogenic vials containing frozen cells were removed from liquid nitrogen and thawed 
in a water bath at 37 °C. The cell suspension was placed into a falcon tube and mixed very 
gently with 5ml of supplemented growth medium. The whole suspension was then 
centrifuged at 250xg to eliminate any traces of DMSO. The remaining pellet was 
resuspended in the growth medium and transferred into the T25 tissue culture flask 
which was placed in the incubator at 37 °C. 
 
2.2.3.5 Transient transfection of cells with the wild type TG2 and TG2 constructs 
 
The human kidney epithelial cells were used for experimental procedures between 5 
to 30 passages. After reaching 80%-90% confluence, cells were passaged using 
supplemented growth medium without antibiotic and required amount of cells was 
calculated in a hemacytometer (2.2.3.2). For transient transfection, 6.5 x 105 cells were 
seeded into each well of a 6-well tissue culture plate (TCP).  To optimize the experimental 
conditions, first HEK 293/T17 cells were transfected with 2µg of empty expression vector 
(pcDNA3.1/CT-GFP) using 250mM CaCl2 as a tranfection reagent. Then cells were 
transfected with 2µg of wild type and mutant (FN1, GTP1, GTP2, HS1, HS2, N-, C-) TGase 
cDNA, respectively. Transfection was performed following the manufacturer’s protocol. 
After 24 and 48 hours incubation at 37°C the efficiency of transfection was estimated 
using fluorescence microscopy.  
Similarly the NIH3T3 fibroblasts were used for experimental procedures between 5 to 
30 passages. After reaching 80%-90% confluence, cells were passaged using 
supplemented growth medium with antibiotic and the required amount of cells was 
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calculated in a haemocytometer (2.2.3.2). To transiently transfect these cells, a kit from 
Lonza (Amaxa cell line nukleofaktor kit R) was used following the manufacturer’s 
instructions. To verify the efficiency of transfection, 1 x 106 cells were transfected with 
4µg of empty expression vector (pcDNA3.1/CT-GFP). For transfection of wild type and 
mutant (FN1, GTP1, GTP2, HS1, HS2, N-, C-) TGase cDNA, 4ug of DNA was used. After 24 
and 48 hours incubation at 37°C the strength of signal was estimated using fluorescence 
microscopy.  
 
2.2.3.6 Preparation of total cell lysate 
 
    After 48 hours incubation at 37°C, the adherent cells were washed twice with ice cold 
PBS, pH 7.4 and resuspended in 60 µl of ice-cold buffer made after mixing 1ml of RIPA 
lysis buffer (Santa Cruz Biotechnology) plus 10μl protease inhibitor cocktail (Sigma) and 
20µg/ml PMSF. After 20 minutes incubation on ice the cells lysate was scraped from the 
bottom of wells. Cell extracts were clarified by centrifugation at 300g for 5 minutes at 
4°C. Clear supernatants were collected into eppendorf tubes and stored at - 70°C for 
further analysis by electrophoresis. 
 
2.2.3.7 Determination of protein’s concentration 
 
    The protein content in cells lysates was determined by the Lowry method (Lowry et al., 
1951) using a commercially available kit from Bio-Rad, following the manufacturer’s 
instructions. Briefly, 5µl of BSA solution ranging from 0.1-1.5 mg/ml was used as a 
standard and added into the 96 wells plate in triplicate. A further 1µl of cells lysate 
dissolved in 4µl of dH2O was added into the microtitre plate in triplicate respectively. 25 
µl of Reagent A and 200 µl of reagent B were then added into each well and incubated at 
room temperature for 15 minutes. Absorbance values were read at 750nm using an 
Absorbance microplate reader ELx808TM to produce the calibration graph. 
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2.2.4 Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE 
electrophoresis) 
 
2.2.4.1 Sample preparation 
 
The protein extracts (total cell lysates) collected from untransfected as well as tranfected 
cells were resolved by SDS-PAGE electrophoresis using a Protean III minigel system. All 
cell lysates were equally (1:1 ratio) dissolved in 2x Laemmli buffer (125mM Tris-CL, pH 
6.8, 20% (v/v) glycerol, 4% (w/v) SDS, 10% (v/v) 2-β-mercaphtoethanol and 0.004% 
bromophenol blue) and denatured in boiling water for 5 min. After cooling, a maximum of 
50ug of protein was loaded on the gel. To visualize protein separation during 
electrophoresis a full range of rainbow molecular markers were used (Amersham 
Biosciences). 
 
2.2.4.2 SDS-PAGE electrophoresis 
 
     Separation of protein extracts by SDS-PAGE electrophoresis was based on the 
modification of the method described by Laemmli et al., 1970 using a Protean III minigel 
system (BioRad, UK). Both, resolving and stacking gels were made in the Protean III 
minigel system from 3% (w/v) polyacrylamide, and Tris-Cl/SDS buffer solution. The 
running gel was composed of 0.75M Tris, 0.2% (w/v) SDS pH 8.8 while the stacking gel 
was made of 0.25M Tris, 0.2% (w/v) SDS pH 6.8. Gel polymerization was initiated using 
10% (w/v) Ammonium persulphate and the required volume of N,N,N´,N´-
Tetramethylethylenediamine (TEMED). The exact recipe for preparing resolving and 
stacking gels is shown in Tables XIII, and XIV. 
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Table XIII 
A list of Resolving gel components 
Stock solution  Final concentration 
 
 
30% (w/v)  acrylamide/bis-acrylamide 
 
Tris-SDS pH 8.8 
 
dH2O 
 
10% (w/v) Ammonium persulphate 
 
TEMED 
8% 10% 
 
4 ml 
 
3.75 ml 
 
7.25 ml 
 
50 µl 
 
10 µl 
 
5 ml 
 
3.75 ml 
 
6.25 ml 
 
50 µl 
 
10 µl 
 
 
 
Table XIV 
A list of Stacking gel components 
Stock solution Final concentration 
 
30% (w/v)  acrylamide/bis-acrylamide 
 
Tris-SDS pH 6.8 
 
dH2O 
 
10% (w/v) Ammonium persulphate 
 
TEMED 
 
650 µl 
 
1.25 ml 
 
3.05 ml 
 
25 µl 
 
5 µl 
 
 
     The resolving gel was pipetted into the sandwich and then covered by water saturated 
butan-2-ol to flatten the gel’s surface and prevent air bubbles from getting inside the gel. 
The prepared gel was left for 1 hour at room temperature to polymerize.  Afterwards, the 
butan 2-ol was removed and washed with distilled water and the wet surface of the gel 
was dried using a filter paper. Meanwhile the 0.75mm stacking gel was prepared and 
poured on the top of the resolving gel and allowed to polymerize (Laemmli et al., 1970). A 
10-well or 15-well comb was placed into the stacking gel. The gel was allowed to 
polymerize at room temperature for another 45 minutes. Then the combs were removed 
Chapter II: Materials and Methods 
 
 
89 
 
and gel placed in a Protean III mini gel tank which contained Tris-glycine electrode 
running buffer, pH 8.5 (25mM Tris-Base, 192mM glycine and 0.1% (w/v) SDS). 
Electrophoresis was performed at the constant voltage of 100V through the stacking gel 
and 120V through the resolving gel. When the bromophenol blue dye reached the bottom 
of the gels, the gels were taken out from the chambers and processed further. 
 
2.2.5 Western blotting of separated by electrophoresis proteins 
 
Gels containing separated proteins were transferred to a nitrocellulose membrane by 
a Bio-Rad wet blot system following the protocol of Towbin et al., 1979. The fiber pads, 
filter paper and nitrocellulose membrane were pre soaked in an ice cold transfer buffer 
(48 mM Tris-Cl, 39 mM glycine, 0.0375% (w/v) SDS and 20% (v/v) methanol). The protein 
gels were removed from the chambers and soaked in a transfer buffer. Afterwards the 
sandwich was formed; first one fibre pad was placed on the black side of the gel holder 
cassette, then on its top a filter paper was laid onto it. Another layer was made by the 
protein gel which was covered by a nitrocellulose membrane. Next a filter paper was 
placed on the top of the nitrocellulose membrane and covered with a second fibre pad. 
When the sandwich was formed, the gel holder cassette was finally closed and the 
blotting cassette inserted into the blotting apparatus filled and with ice cold transfer 
buffer. The cassette was inserted in a blotting apparatus so that the membrane faced the 
anode electrode.  The transfer was carried out for 90 minutes at 150mA and the blotted 
membrane was washed once with PBS, pH 7.4 then further processed to blocking 
procedure. 
 
 
2.2.5.1 Detection of TG2 antigen by Western blotting  
 
     The blotted membranes were rinsed in deionised water and shaken 1.5 hour with 
gentle agitation in blocking solution (5% dried milk dissolved in TBS-0.05%Tween 20(v/v), 
pH 7.4) to eliminate any no specific binding which could occur during the transfer. The 
blots were incubated overnight at 4 °C with the required antibody diluted in blocking 
solution. Following probing with primary antibody, the blots were washed three times 
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with TBS-0.05%Tween (v/v), pH 7.4 and additionally with blocking solution. After washing 
the membranes were incubated 2 hours at room temperature with Horseradish 
peroxidase conjugated antibody diluted 1:2000 in blocking solution. Afterwards, the 
secondary antibody was decanted; the membranes were washed once again, rinsed and 
soaked with PBS pH 7.4. TG2 bands were detected using the Amersham ECL 
Chemiluminescence system kit (Amersham Biosciences) following the manufacture’s 
instruction to allow visualisation of the proteins on the developed X-ray film (Kodak 
Biomax XAR film, Sigma). Detection was carried out in a dark room, for 5minutes to 1 
hour depending on the intensity of the signal. The film was developed using GBX 
developer/replenisher (Sigma-Aldrich, UK), rinsed with water and then fixed in GBX 
fixer/replenisher (Sigma-Aldrich, UK). 
     To control the equal loading of proteins, obtained blots were first stripped and then 
reprobed with a monoclonal antibody directed against tubulin (internal marker for equal 
loading). Following the 30 minutes stripping in the stripping buffer (100mM 2-
mercaptoethanol, 2% SDS and 62.5mM Tris-HCl, pH 6.7), the membranes were twice 
washed with TBS-0.05%Tween(v/v), pH 7.4 and blocked at RT for 1 hour in blocking buffer 
(3% dried milk dissolved in TBS-0.05%Tween 20(v/v), pH 7.4). The chemiluminescence 
signal was detected on X-ray film after reprobing the membranes with control mouse 
monoclonal anti-tubulin antibody (Sigma-Aldrich, UK) diluted 1:1000 in a blocking buffer, 
followed by peroxidase conjugate monoclonal anti-mouse IgG (Sigma-Aldrich, UK). 
      To quantitate the obtained results the densitometry analysis was performed using 
ImageJ software. The net values obtained from TG2 bands were normalised against 
values from the corresponding tubulin bands.  
 
 2.2.6 Characterisation of the mutants  
 
2.2.6.1 Affinity chromatography 
 
2.2.6.1 A   Preparation of cleared cell lysates for the affinity chromatography 
 
 
     HEK cells were transiently transfected with wild type TG2, and TG2 mutants as 
described in section (2.2.3.5). After 48 hours incubation at 37°C cells were washed twice 
with ice cold PBS, pH 7.4 and lysed by addition of non-denaturating buffer composed of 
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(20mM Tris-Cl pH 7.4, 10mM EGTA, 2mM EDTA, 1mM NaF and 1mM Na3VO4). Lysed cells 
were clarified by centrifugation for 5 minutes at 300g at 4°C. Cleared supernatants were 
collected into eppendorf tubes and stored at – 70 °C until required. 
 
2.2.6.1 B Heparin Sepharose affinity column 
 
     The resulting supernatants obtained from HEK293/T17 cells transfected with wtTG2, 
and TG2 mutants, as described before (section 2.2.3.5) were pelleted to discard cellular 
debris and membranes and applied to a 5ml bed volume Heparin Sepharose column 
(Amersham Biosciences, Sweden) equilibrated in 50mM Tris-Cl, 1mM EDTA, 1mMDTT pH 
7.5 buffer. Each sample was applied manually to the column in equilibration buffer at an 
approximate flow rate at 1ml/min at room temperature. After washing the column with 
15ml of equilibration buffer bound proteins were eluted with 1M NaCl in 50mM Tris-Cl, 
1mM EDTA, and 1mM DTT, pH 7.5. Both flow-through and eluted volumes were 
fractionated into 300μl aliquots of each well of a microtiter plate and assayed for TG2 
activity. The resulting fractions were verified by SDS-PAGE electrophoresis and Western 
blotting using anti-TG2 monoclonal antibody for detection of TG2 bands. 
 
2.2.6.2 Solid phase binding assay (ELISA) 
 
The assay is a modification of the original method established by Achyuthan et al. (1995). 
The solid phase binding assay used to measure the binding affinity of TGase for 
fibronection was performed on 96 well TCP plates (Corning Costar, UK) coated with 
5μg/ml of plasma fibronectin (Sigma-Aldrich, UK) diluted in a 50mM Tris-Cl, pH 7.4. The 
coating procedure was carried out at 4°C whereas most steps were performed at room 
temperature. To eliminate any possibility of non specific binding the wells were blocked 
for 30 min with 5% (w/v) fat-free milk in PBS, pH 7.4. After washing twice with PBS-Tween 
and once with PBS pH 7.4, cell homogenates (50μl per well) were added to the coated 
TCP wells and incubated for 1 hour at 37ᵒC. After washing as before, 50μl of the anti-TG2 
antibody (CUB7402) diluted 1:1000 in a blocking solution was added to the wells and left 
for 2 hours and washed again. Followed by 2 hours incubation with 50µl of goat anti-
mouse IgG HRP conjugate antibody similarly diluted in a blocking buffer bound 
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horseradish peroxidase activity was measured by addition of Sigma Fast OPD substrate 
and the colorimetric reaction was stopped with 2.5M H2SO4 and further assayed 
spectrophotometrically at 490nm using an Absorbance microplate reader (Biotek 
ELx808TM). 
 
2.2.7 TG2 activity assays  
 
2.2.7.1 Biotin X-cadaverine incorporation into N,N’-dimethylcasein 
 
     This assay is based on measuring TG2-activity by a modification of the technique 
originally described by Slaughter and co-workers (Slaughter et al., 1992). Briefly, each well 
of a 96-well plate was coated with 100µl of 10mg/ml N,N’-dimethylcasein in 50mM Tris-
Cl, pH 8.0, and incubated overnight at 4°C. After one wash with TBS-0.05%Tween 20(v/v), 
pH 7.6 and TBS, pH 7.6, 50µl of column flow-through as well as each eluted fraction 
collected from the Heparin Sepharose column, was added into the coated wells of the 96-
well plate. Additionally 50µl of 50mM Tris-Cl pH 8.0, 0.25mM biotin X-cadaverine, 
10mMDTT, 20mMCaCl2 was added into each well. The reaction was allowed to proceed 
for 1 hour at 37°C. The plate was then washed once with TBS-0.05%Tween 20(v/v), pH 7.6 
and TBS, pH 7.6 before being blocked with 100µl of 3% (w/v) BSA in TBS, pH 7.6) for 30 
minutes at 37°C. After another wash, biotin X-cadaverine incorporation into N,N’-
dimethylcasein was detected by incubation for 1 hour at 37°C with 100µl extravidin-
peroxidase (Sigma-Aldrich, UK) diluted 1:2000 in 3% (w/v) BSA in TBS, pH 7.6. After 
another set of washes, TG2 activity was measured using Sigma Fast OPD, tablets dissolved 
in 20ml of distilled H20. The colour was developed by adding 2.5M H2SO4 and the 
absorbance at 490nm measured using a micoplate reader ELx808
TM.  
 
2.2.7.2 Measurememnt of TG2 activity by Biotin X- cadaverine incorporation into 
fibronectin 
 
This TG2-activity assay is based on a measuring the incorporation of biotin X-cadaverine 
into fibronectin as described by Jones and his collaborators (Jones et. al., 1997). Briefly, 
wells of a 96-well TCP plate were coated with 5 µg/ml of human plasma fibronectin and 
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incubated overnight at 4°C. After 30 min blocking with 3% BSA (w/v) in Tris-Cl, pH 7.4, the 
total volume of 100 µl of each TG2 construct resuspended in the Tris-based buffer 
containing 5mM CaCl2, 10mM DTT, 0.132mM biotin x-cadaverine was added to the plate 
and TG2 immobilisation was allowed to proceed for 2 hours at 37°C. To monitor the 
reaction, two different controls containing guinea pig liver TG2 used at 10ng/well were 
used in the assay. To confirm the influence of calcium on the activity of the enzyme, 5mM 
CaCl2 was replaced with 5mM EDTA. In order to stop the reaction, the wells were washed 
three times with 2mM EDTA in PBS pH 7.4. 0.1% (w/v) sodium deoxycholate in PBS pH 7.4 
containing 2mM EDTA was then added to the plates which were then gently agitated for 
10 minutes at room temperature. Following three washes with 50mM Tris-Cl, pH 7.4 the 
incorporated biotin X-cadaverine was detected by incubation for 1 hour at 37°C with 
100µl extravidin-peroxidase (Sigma-Aldrich, UK) diluted 1:5000 in 3% (w/v) BSA in TBS, pH 
7.4.After another set of washes, the TG2 activity was analysed using Sigma Fast OPD, 
tablets dissolved in 20ml of distilled H20. The colour development was stopped by 
addition of 2.5M H2SO4 and the absorbance was measured at 490nm using a microplate 
reader ELx808TM.  
 
2.2.8 Peptide synthesis 
 
2.2.8.1 Peptides synthesis and characterisation 
 
The possible heparin sulfate and FN binding site peptides corresponding to human TG2 
were synthesised by Peptide Synthetics, UK. The purity (>95%) and composition of the 
peptides were confirmed by high performance liquid chromatography. The peptides 
included possible heparin binding site: NPKFLKNAGRDCSRRSS (P1); NPKFLKNA (P2); 
GRDCSRRSS (P3) and scrambled peptide FNRADLKPRCGSSNKSR (P1s). The possible FN 
binding site on the N-terminal end of TG2:  AEELVLERCDLELE (P4) and scrambled peptide 
EECRLAEELLEDVL (P4s). Additionally as a positive control for P4 peptide 
WTATVVDQQDCTLSLQLTT (P5) peptide was synthesized as stated above and used as 
described by Hang et.al, (2005). 
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2.2.9 Cell adhesion assay: 
 
2.2.9.1 Fibronectin (FN) coating 
 
The tissue culture plates (TCP) were coated with 50µl of 5µg/ml fibronectin (FN) diluted in 
50mM Tris-Cl, pH 7.4. Coated plates were then incubated overnight at 4°C. 
 
2.2.9.2 Immobilisation of TG2 on FN matrices 
 
The stock of purified guinea pig liver TG2 (Zedira, Germany) was prepared at 
concentrations of 1mg/ml. Following one wash with 50mM Tris-Cl, pH 7.4 the enzyme 
was immobilised on the FN coated plates. The 20µg/ml of guinea pig liver TG2 was 
prepared by diluting it in PBS containing 2mM EDTA, pH 7.4, to suppress the Ca2+-
dependent cross-linking activity of TG2. The immobilisation of TG2 proceeded for 1hour 
at 37°C. 
 
2.2.9.3 RGD-mediated cell adhesion 
 
Exponentially growing cells in a supplemented growth medium (DMEM), were 
trypsinised. After centrifugation at 300g for 5 minutes, the supernatant was discarded 
and the obtained pellet was suspended in a serum free medium in order to remove any 
remaining serum proteins. Following two washes, 2.5x105 cells/ml cell suspensions were 
incubated for 20-25 minutes at 37°C in a 5% CO2, 95% (v/v) air atmosphere, with two 
synthetic peptides, named as follow: GRGDTP and GRADSP (Bachem, UK). The 
concentration of peptides was prepared at:  50µg/ml (~75µM), 100µg/ml (~150µM), 
150µg/ml (~225µM), 200µg/ml (~300µm) and 250µg/ml (~375µm). Meanwhile the FN 
coated plate, with and without immobilized guinea pig TG2, was washed once with Tris-
Cl, pH 7.4 and serum free medium. A further 100µl of cells were seeded into each well of 
the TCP plate and allowed to attach in the presence of peptides during incubation at 37°C. 
The cell adhesion assay was limited to 20-50 minutes to minimize the secretion of any 
endogenous proteins.   
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2.2.9.4 Cell fixation and permeabilisation  
 
Following cell attachment, medium was removed from the TCP wells and plates were 
washed once with PBS, pH 7.4. The remaining cells were fixed by using 100ul/well of 3.7% 
(w/v) paraformaldehyde prepared in PBS, pH 7.4 for 15 minutes at room temperature. To 
remove the fixative, wells of the plate were washed twice with PBS, pH 7.4 and then 
incubated with 100µl of 0.1% (v/v) Triton in PBS, pH 7.4 for 15 minutes at room 
temperature. The wells were then washed once with PBS, pH 7.4. 
 
2.2.9.5 May - Grunwald -Giemsa staining 
 
To assign the amount of attached cells, a two-step staining method was used. Briefly, this 
method is based on using two different dyes, one May Grunwald dye (Sigma-Aldrich, UK) 
stains cytoplasm while the other one Giemsa (Sigm-Aldrich, UK) stains nucleus. Following 
fixation and permeabilisation, 100µl of May - Grunwald stain was added into each well of 
TCP plate and left for 15 minutes at room temperature. When the cytoplasm was stained, 
the dye was removed and the plate was once washed with PBS, pH 7.4. Then the TCP 
wells were incubated with 100µl of 5% (v/v) in dH2O Giemsa stain for 20 minutes at room 
temperature. Afterwards the stain was removed and the plate was washed once with 
dH2O and left to dry.  
 
2.2.9.6 Quantitative determination of adherent cells 
 
To quantify the amount of attached versus spread cells on a fibronectin coated tissue 
culture plate, the sum of three images of non overlapping fields from the centre of the 
well was calculated. Each image of cells was captured by a digital camera (Nikon) at 20x 
magnification and further analysed using Scion Image program written at the National 
Institutes of Health. The amount of cells from the centre of the well per image was 
assessed through threshold and particle analysis settings. Spread cells were characterised 
by a round and flattened shape, which results from the rearrangement in the actin 
skeleton. Spread cells were distinguished from attached (non-spread) cells by their two-
colour staining (pink cytoplasm, purple nucleus). They were quantified by density slicing, 
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particle analysis settings and highlighted by adopting the right Lut intensity. In contrary 
the amount of attached cells was determined by summing up three images from three 
non overlapping fields. As a control, cells not-treated with any peptide were used. 
Similarly, the average mean of those attached cells was calculated using non overlapping 
images from three different wells and used as the 100% attached cells. The mean number 
of attached cells (cell attachment) was determined as the percentage of cell attachment 
on FN. The mean percentage of spread cells (cell spreading) on FN was examined 
separately and expressed as 100%. The mean percentage of cell attachment and cell 
spreading on a FN coated plate containing immobilised guinea pig liver TG2  was then 
normalised against and compared to the mean percentage of cell attachment and 
spreading on a control FN coated plated.  
 
2.2.10 Localisation of mutants and wild type TG2 at the cell surface and their deposition 
into the ECM  
 
2.2.10.1  Biotinylation of cell surface proteins 
 
After 48 hours post-transfection of HEK293/T17 and NIH3T3 cells, cell monolayers were 
rinsed three times with ice-cold PBS pH 8.0 and labelled 20 minutes on ice with 0.8mM 
sulfo-NHS-LC-biotin (Sigma-Aldrich, UK) dissolved in PBS pH 8.0. To stop the reaction cells 
were washed with 50mM Tris-HCl, pH8.0 and then lysed for 30 minutes on ice with 1% 
SDS (w/v) in PBS pH 8.0.  Following protein determination lysates were denaturated in 
boiling water and clarified by 20 min centrifugation at 14 000xg at room temperature. 
Afterwards cleared supernatants containing 200μg protein aliquots were incubated 
overnight at 4°C with NeutrAvidin-Agarose resins (Thermo-Fisher Scientific, UK). The next 
day proteins bound to NeutrAvidin-agarose were washed three times with PBS pH 8.0 and 
further dissolved in 2x Laemmli loading buffer (Sigma-Aldrich, UK). Following 
denaturation proteins were separated by 8% (w/v) gel electrophoresis and analyzed by 
Western blot analysis by using anti-TG2 monoclonal antibody. 
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2.2.10.2 Changes in ECM-deposited TG2 by Western blotting analysis 
 
To determine the distribution of wild type TG2 and TGase mutants (FN, GTP1, GTP2, HS1, 
HS2, N-, C-) in the extracellular matrix (ECM), NIH 3T3 cells were transiently transfected as 
described in section (2.2.3.6) using 6 well plates. For extracellular matrix deposition by 
NIH 3T3 cells transfected with wild type TG2 as well as TGase constructs, the incubation 
time for cell growth was prolonged for 72 hours. Additionally to slow down the speed of 
cell proliferation after 24 hours post-tranfection, 10% (v/v) foetal bovine serum present in 
a supplemented culture medium was replaced with 1% (v/v) foetal bovine serum. After 72 
hours incubation at 37°C in a 5% CO2, 95% (v/v) air atmosphere, culture medium was 
removed and attached cells were washed three times with ice cold PBS, pH 7.4. In order 
to detach cells, the bottom of each well was covered with 2mMEDTA in PBS, pH 7.4 and 
the incubation was allowed to proceed for 30 minutes at 37°C. Detached cells were 
collected into eppendorf tubes leaving ECM laid down by transfected cells on the bottom 
of the wells. Following two washes with 2mMEDTA in PBS, pH 7.4, any remaining soluble 
fractions present on the ECM, were dissolved using 0.1% (w/v) deoxycholate in PBS, pH 
7.4 for 5 minutes at room temperature.  The wells of the plate were washed with 0.1% 
(w/v) deoxycholate in PBS pH 7.4 followed by PBS, pH 7.4. Afterwards insoluble ECM 
fractions were dissolved in 2x Laemmli loading buffer (125mM Tris-Cl, pH 6.8, 20% (v/v) 
glycerol, 4% (v/v) SDS, 10% (v/v) 2-β-mercaphtoethanol and 0.004% bromophenol blue), 
collected into eppendorf tubes and denatured in boiling water for 5 min. The samples 
containing the ECM insoluble proteins were then resolved by SDS-Page electrophoresis 
and transferred onto the nitrocellulose membrane by Western blotting (section 2.2.5). 
Following overnight incubation at 4°C with TG2 monoclonal antibody (CUB 7402) diluted 
1:1000 in a blocking solution the  membrane was treated with peroxidase conjugate 
monoclonal anti-mouse IgG antibody and the presence of extracellular matrix bound TG2 
detected by enhanced chemiluminescence system as described in section (2.2.5.1).  
 
2.2.11 Statistical analysis 
 
Results shown are the mean +/- SD. The statistically significant differences between 
obtained data sets in cell adhesion assays were determined by Mann-Whitney test at 95% 
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level of significance. When p< 0.05, the differences between data points were considered 
to be statistically significant and presented with the *, and ◊ symbols. The statistically 
significant absorbance and net area values were analysed by Student’s t test and 
presented as significant when the p < 0.05 (*, ◦, ◊), and p<0.001 (•) using the Excel 
statistical analysis programme.  
 
  
 
 
 
 
 
Chapter III: Mutagenesis studies and 
characterisation of the mutants 
 
 
 
 
 
 
 
 
 
 
 
Chapter III: Mutagenesis studies and characterisation of the mutants 
100 
 
3.1 INTRODUCTION 
 
To date, tissue transglutaminase (TG2) is the most studied and the best characterised 
enzyme within the whole transglutaminase family. The enzyme is expressed by a variety 
of cells and tissues and plays a crucial role in a variety of intra as well as extracellular 
biological phenomena that take place in mammalian organisms. Apart from its 
transglutaminase activity, TG2 also has GTPase, ATPase, protein disulphide isomerase and 
serine/threonine kinase activities (Griffin et al., 2002; Lee et al., 1989; Hasegawa et al., 
2003; Mishra and Murthy, 2004) although not all of these have been fully characterised. 
In relation to subcellular localisation, TG2 is found mainly in the cytosol and also in the 
nucleus and mitochondria. Additionally, a moderate but significant amount of the enzyme 
is associated with the cell surface from where it is deposited into the extracellular matrix. 
Being mainly a cytosolic protein, where the Ca2+ concentration is low and GTP 
concentration high, TG2 transamidating activity remains latent (Monsonego et al., 1998; 
Liu et al., 2002). Analysis of the structure of TG2 shows that it consists of 4 domains 
(Lesort et al., 2000). Domain 2 contains the active site which consists of the catalytic triad 
Cys277, His335 and Asp358. The active site is inaccessible to substrate in the GTP-bound 
conformation by the juxtaposition of domains 3 and 4. In the presence of calcium, 
conformational changes within TG2 cause domains 3 and 4 to fold away from domain 2, 
exposing the active site (Griffin et al., 2002; Bergamini, 2007). When GTP is bound, TG2 is 
locked in a closed conformation, reducing its affinity for calcium ions and blocking its 
cross-linking activity (Achyutan and Greenenberg, 1987; Smethurst and Griffin, 1996; di 
Venere et al., 2000). There have been many attempts to localise the GTP binding site of 
TG2. Initial studies by Takeuchi et al., (1992) proposed the existence of three possible 
GTP-nucleotide binding sites located at amino acid residues 46-69, 345-367, and 520-544 
of guinea pig liver transglutaminase. Further investigations using rabbit liver 
transglutaminase demonstrated much higher affinity of a 36 kDa fragment for [alpha-32P] 
GTP compared to the 80 kDa fragment, suggesting the importance of the N-terminal 
domain of TG2 in nucleotide binding (Singh et al., 1995). Also the N-terminus of 
recombinant human TG2, in particular amino acid residues 1-185 were later reported to 
be important for GTP hydrolysis (Lai et al., 1996). Molecular modeling studies based on a 
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sequence homology with FXIIIA revealed, however, that neither the N-terminal nor C-
terminal domains of TG2 contain nucleotide hydrolysis sites, but are rather localised 
within the catalytic core domain (amino acid reissued 139-185) distinct from the catalytic 
triad (Ismaa et al., 1997). Despite those suggestions, one of the C-terminal domains, 
barrel 1 with 517-523 residues was found to be further implicated in stabilisation of GTP 
binding (Monsonego et al., 1997). These findings were later confirmed by Ismaa et al., 
(2000) using TG2/FXIIIA chimeras and TG2 single point mutants all localised within the 
catalytic core and further mapped to amino residues 159-173, with peptide 
159YVLTQQGFIYQGSVK173 reported to be important for GTP binding to TG2. In addition, x-
ray crystallography of human TG2 revealed that the GTP-binding site is placed in a 
hydrophobic pocket between domain 2 and domain 3, and is composed of mostly domain 
3 amino acid residues 476-482, 580-583 as well as Phe174 which is located on domain 2 
(Liu et al., 2002). Other studies have shown that TG2 is the only exception within the 
transglutaminase family that can bind guanine nucleotides to control its cross-linking 
activity (Liu et. al., 2002, Figure 4). This is in agreement with additional investigators who 
confirmed the involvement of GTP in regulating the activity of the enzyme inside the cell 
(Begg et al., 2006a).  
Multiple factors can regulate the activity of tissue transglutaminase leading it to the 
extracellular matrix and cell surface (Lorand and Graham, 2003; Verderio and Griffin, 
2005). Several factors have been suggested to be directly or indirectly involved in TG2 
translocation (Gaudry et al., 1999; Balklava et al., 2002; Akimov et al., 2000; Scarpellini et 
al., 2009). However, the exact mechanism by which the enzyme is actually secreted 
remains unclear. So far, the diversity of proteins translocation mechanisms across plasma 
membranes have been investigated and reported (Zocchi and Rubartelli, 2001; Nickel et 
al., 2005; Nickel, 2007). However, there are limited data regarding the mechanism of TG2 
externalisation, the subsequent fate of its externalisation as well as possible involvement 
of any of TG2 high affinity binding partners in that process.  
It is known that released TG2 accumulates in the extracellular matrix where it interacts 
with fibronectin (Gaudry et al., 1999a). Following immunofluorescence experiments on 
WI-38 human lung fibroblasts, TG2 was shown to co-localise with FN in the pericellular 
matrix. This binding was found to be inhibited after cell treatment with anti-fibronectin 
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antibodies (Upchurch et al., 1987).  As suggested by Lorand et al., (1988) FN might work 
as a specific carrier for TG2, possibly also playing a role in preventing unnecessary cross-
linking of plasma membrane proteins by the enzyme.  Moreover, TG2 was found to bind 
plasma FN independently of the presence of calcium indicating the involvement of a 
domain other than the catalytic core in its complexation with FN (Turner and Lorand, 
1989).  Affinity binding experiments based on using three different proteolytic fragments 
of FN (21 kDa, 30 kDa, and 42kDa) revealed the 42 kDa fragment to contain the TG2 
binding site (Radek et al., 1993). The interaction of FN with erythrocyte and liver TG2 was 
also examined by electron microscopy and identified the binding site for TG2 within 5-10 
nm of the N-terminal site of FN (LeMosey et al., 1992). The TG2-fibronectin interaction 
was further suggested to be dependent on the intact NH2-terminal region of TG2 (Jeong 
et al., 1995; Gaudry et al., 1999a). Deeper insight into the FN binding motifs indicated 
that the FN binding site is contained within a 28 kDa proteolytic fragment of TG2, with the 
first 7 amino acids considered to be of great importance for this interaction (Jeong et al., 
1995). In addition, as shown by Gaudry et al., (1999a) the first 7 amino acids are also 
important for the localisation of the enzyme at the cell surface of transiently-transfected 
COS-27 cells which takes place in association with FN. More recently, site-directed 
mutagenesis studies based on using TG2/FXIIIA chimeric constructs and TG2 deletion 
products demonstrated the presence of an additional FN recognition motif on a TG2 
molecule (Hang et al., 2005). This novel FN binding site was localised to amino acid 
residues 88-106, which is mainly hairpin structure consisting of anti-parallel β strands 5 
and 6 among which Asp94 and Asp97 were shown to be critical for TG2-FN interaction 
(Hang et al., 2005).  
The interaction of TG2 with fibronectin was suggested to play an important role in the 
localisation of the enzyme at the cell surface and also be involved in its translocation. In 
addition, it was also postulated to be very important for its adhesive functions (Akimov et 
al., 2000; Belkin et al., 2001; Zemskov et al., 2006). Additionally, integrins were suggested 
to play a collaborative role to TG2 in the process of cell adhesion rather than compete 
with enzyme (reviewed by Zemskov et al., 2006). Furthermore a TG2-integrin interaction 
was postulated to have an influence on externalisation of the enzyme (Akimov et al., 
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2000; Johnson et al., 2008). As stated by Akimov et al., (2000) the C-terminal domain of 
the enzyme was suggested to bear the integrin binding motifs. 
     In addition to integrins, other molecules were proposed to associate with TG2 at the 
cell surface and further be involved in its translocation across the cell membrane 
(Verderio et al., 2009). Heparan sulfate proteoglycans (HSPGs) are known to function as 
cell surface co-receptors for ECM and growth factors and can display ligands which attract 
their high affinity partners. These interactions are mainly mediated through their 
glycosaminoglycan chains (Bernfield et al., 1999). Over the past years, the influence of 
both glycosaminoglycans heparan sulfate (HS) and heparin on cell behaviour has been 
demonstrated (reviewed by Bernfield et al., 1999). Additionally heparin has been 
considered to be synonymous with HS since both molecules contain negatively charged 
linear polysaccharides. Furthermore they undergo similar biosynthetic routes which 
however results in their sequence diversity (reviewed by Esko and Lindahl, 2001). 
Additionally when it comes to the localisation, heparin can be found in vivo in the 
granules of mast cells while HS is present mainly on the cell surface where it covalently 
binds different core proteins which form HSPGs (Bernfield et al., 1999). Even thought they 
have been shown to differ in the degree of sulfation, higher sulfation of liver HS (Lyon et 
al., 1994) the isolation of HS resembling heparin from ologodendrocye type-2 progenitor 
cells indicates that those two molecules might be related in this respect (Stringer et al., 
1999; Powell et al., 2004).  
     The heparin-TG2 interaction has been suggested to be high affinity; however the 
localisation of heparan sulfate binding motifs on TG2 still remains unexplored. The known 
heparin-binding sites of other proteins seem to share certain common features that have 
been used to identify the heparin-binding sites of uncharacterised proteins. For instance, 
many linear HSPG-binding motifs are composed of a particular organisation of basic 
amino acid residues, such as XBBXBX or XBBBXXBX, where B is a basic amino acid whose 
side chain is exposed on the protein surface and X is a neutral or hydrophobic amino acid 
whose side chain is directed towards the protein interior (Cardin and Weintraub, 1989). 
Other motifs are composed of a 3D organisation of basic amino acid residues that are not 
necessarily adjacent to each other in the primary sequence. Consequently, a combination 
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of both sequence and structure analysis is required for the identification of novel HSPG 
binding motifs.  
     In order to understand whether any TG2 high affinity binding partners influence TG2 
localisation at the cell surface or into the extracellular matrix, mutagenesis studies were 
undertaken. The main regions of TG2 targeted for mutagenesis included the suggested FN 
binding sites, the GTP binding site, as well as proposed integrin binding motifs. 
Additionally it was of most importance to identify the HSPG-binding site on TG2 using a 
combination of molecular modelling and site-directed mutagenesis.  
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3.2 METHODS 
 
3.2.1 Analysis of transfection efficiency by fluorescence microscopy  
 
     To determine the transfection efficiency, HEK 293/T17 and NIH 3T3 cells were 
transiently transfected with 2μg/ml and 4μg/ml of empty vector pcDNA3.1/CT-GFP, 
respectively. 48 hours after transfection, images were obtained using a Zeiss Axiovert 
200M fluorescence microscope equipped with laser adjusted at 507 nm. Transfection 
efficiency was evaluated using the Scion image analysis program (www.scioncorp.com) 
which was developed at the National Institute of Health (Washington DC, USA). 
 
3.2. 2 Insertion of wt TG2 cDNA into pcDNA3.1/CT-GFP vector 
 
     Plasmid vector pGene/V5-His, containing the TG2 cDNA (kind gift from Alexey Belkin, 
University of Maryland, US), was used as the source of TG2 cDNA. The TG2 coding region 
was amplified by PCR (Materials and Methods 2.2.1.3) using primers 
5’GGTACCATGGCCGAGGAGCTGGTC3’ and 5’GCGGCCGCTTAGGCGGGGCCAATGATGAC3’ 
which were designed with KpnI and NotI restriction sites to facilitate directional cloning 
into plasmid pcDNA3.1/CT-GFP. The PCR product was cloned using Perfectly Blunt Cloning 
kit (Novagen) according to the manufacturer’s protocol. Plasmid pSTBlue1 containing the 
cloned PCR product was digested (see 2.2.1.4) with KpnI and NotI enzymes to liberate the 
TG2 cDNA, which was purified and subcloned into KpnI and NotI digested plasmid 
pcDNA3.1/CT-GFP. Recombinant clones were identified on the basis of their increased 
size, confirmed by digestion with KpnI and NotI, and their inserts nucleotide sequenced. 
pcDNA3.1/CT-GFP:TG2 plasmid DNA was then purified with Endotoxin free plasmid maxi 
kit (Qiagen, UK) to isolate DNA suitable for transfection. 
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3.2.3 Generation of TG2 mutants 
 
QuickChange site directed mutagenesis kit (Stratagene, UK) was used to create point 
mutations in TG2.  Briefly, complementary sense and antisense oligoneuclotide primers 
were designed for each mutation. Using plasmid pcDNA3.1/CT-GFP: TG2 as template, PCR 
was performed according to the manufacturer’s protocol to generate mutant plasmid 
DNA. The methylation dependent endonuclease DpnI was used to selectively digest 
parent plasmid DNA and mutated plasmid DNA transformed into XL1 supercompetent 
cells. Plasmid DNA was purified from colonies and analysed by restriction digestion 
analysis where appropriate (Materials and Methods 2.2.2.1 A). Additionally, nucleotide 
sequencing analysis was performed on all mutated sequences of the enzyme.  
 
3.2.4 Generation of TG2 deletion products 
 
     Both TG2 deletion mutants (∆1-15TG2 and ∆594-687) were generated by PCR 
amplification using appropriate primers (N-terminal mutant - 5’ GGACGGTACCATGA 
CCAATGGCCGAGACCACCAC 3’ and 5’ GGACGCGGAAGCTTAGGCGGGG CCAATGATGAC 3’; 
C-terminal mutant - 5’ GGACGGTACCATGGCCGAGGAGCTGGTCTTAGAG 3’ and 5’ GGACGC 
GGCCGCTCACCGGATCTTGATTTCTGG 3’. As detailed in Materials and Methods (2.2.2.1 B) 
when amplified, obtained plasmids DNA were transformed into the DHα5 competent cells 
(Invitrogen, UK) and further purified, and digested with NotI and KpnI enzymes in order to 
confirm desired deletion. Additionally each single deletion mutant was sent for 
sequencing to verify its DNA sequence. 
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3.2.5 Characterisation of the mutants 
 
3.2.5.1 Analysis of wild type TG2 and TG2 mutant’s expression 
 
     To verify the expression level of recombinant TG2, plasmid DNA was transiently 
transfected into the human embryonic kidney cells (HEK 293/T17) as well as mouse NIH 
3T3 fibroblasts. Cell extracts (lysed as in Materials and Methods 2.2.3.6) were analysed by 
SDS-PAGE electrophoresis and verified for the presence of TG2 antigen by Western 
blotting as described in Materials and Methods (2.2.5).  
 
3.2.5.2  Solid phase fibronectin binding assay (ELISA) 
 
     For the determination of TG2 binding to immobilised fibronectin, a modification of the 
method of Achyuthan et al. (1995) was used as described in Methods section (2.2.6.2). 
Bound TG2 protein was expressed as absorbance at 490 nm per mg of total protein 
measured by Lowry method (Lowry et al., 1951).  
 
 
3.2.5.3 Guanosine 5’-triphosphate-Agarose (GTP-Agarose) affinity chromatography 
 
     All chromatographic steps were performed using an Äkta Purifier (GE Healthcare) Cell 
lysates (150 µl) were mixed with 450µl of 50mM Tris-Cl, 1mM EDTA, 1mM DTT, 10mM 
MgCl2,, pH 7.5 and the mixture was then applied to a 2ml bed volume GTP-Agarose 
column (Sigma-Aldrich, UK) equilibrated in 50mM Tris-Cl, 1mM EDTA, 1mM DTT, 2mM 
MgCl2, pH 7.5 at a flow rate of 1 ml/min at room temperature. After washing with 20ml of  
50mM Tris-Cl, 1mM EDTA, 1mM DTT, 10mM MgCl2,, pH 7.5, bound protein was eluted 
from the column with the same buffer containing 5mM GTP, collecting 0.3ml fractions 
into a microtitre plate using a Frac-950 fraction collector (GE Healthcare). Fractions were 
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analysed by SDS-PAGE and Western blotting using CUB 7402 as detailed in Materials and 
Methods (2.2.4 and 2.2.5). 
 
3.2.5.4  Heparin Sepharose affinity chromatography 
 
 
      All chromatographic steps were performed using an Äkta Purifier (GE Healthcare) Cell 
lysates (150 µl) were mixed with 450 µl of 50mM Tris-Cl, 1mM EDTA, 1mM DTT, pH 7.5 
and applied to a 5ml bed volume Heparin Sepharose column (HiTrapTM Heparin HP, 
Amersham Biosciences, Sweden) equilibrated in 50mM Tris-Cl, 1mM EDTA, 1mMDTT pH 
7.5 buffer at a flow rate of 1 ml/min at room temperature. The column was then washed 
with 25ml of the same buffer before elution with a linear gradient of 0-1M NaCl in 50mM 
Tris-Cl, 1mM EDTA, and 1mM DTT, pH 7.5, collecting 0.3 ml fractions into a microtitre 
plate using a Frac-950 fraction collector (GE Healthcare). Fractions were analysed for TG2 
activity (as described in Materials and Methods Section 2.2.7.1) and also by SDS-PAGE and 
Western blotting using CUB 7402. 
 
3.2.6 Influence of GTP and TG2 inhibitor on TG2-Heparin interaction 
 
 Cell lysates were incubated for 1 hour at room temperature in 50mM Tris-Cl, 1mM 
EDTA, 1mM DTT, 0.5mM GTP, 2mM MgCl2 pH 7.5 to ensure that all TG2 was present in 
the GTP-bound closed conformation. Alternatively, cell lysates were incubated with 
0.5mM TG2 inhibitor in 50mM Tris-Cl, 1mM EDTA, 1mMDTT pH 7.5 buffer for 30 minutes 
on ice to ensure that all TG2 was converted to the inactive inhibitor-reacted open form. 
Cell lysates were then subjected to heparin affinity chromatography as described in 
3.3.14. 
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3.2.7 Measurement of TG2 activity 
 
3.2.7.1   Biotin X-cadaverine incorporation into N,N’-dimethylcasein 
 
                  The transamidating activity of the enzyme was verified by Biotin X-cadaverine 
incorporation into N,N’-dimethylcasein as described in Methods section (2.2.7.1). 
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3.3 RESULTS 
3.3.1 Mutagenesis studies 
 
     TG2 cDNA was amplified by PCR using primers which contained flanking KpnI and NotI 
sites to facilitate directional cloning, and was cloned into pSTBlue-1 vector (Merck 
Chemical Limited, UK). After confirmation of successful cloning, the TG2 cDNA was 
excised from pSTBlue-1 by KpnI and NotI digestion and subcloned between the KpnI and 
NotI sites of pcDNA3.1/CT-GFP vector (Fig 3.3.1). An additional advantage of using the 
pcDNA3.1/CT-GFP vector is that GFP expression will allow simple detection of transfected 
cells by fluorescent microscopy. 
 
3.3.2 Subcloning of TG2 cDNA into pSTBlue-1 and pcDNA3.1/CT-GFP 
 
Plasmid DNA was digested with KpnI and NotI to ensure that the TG2 insert was the 
correct size. As can be seen in Fig 3.3.2A, digestion of plasmid pSTBlue-1:TG2 liberated a 
fragment of 2.3 kb in agreement with that calculated from the nucleotide sequence. The 
2.3 kb insert was further subcloned into pcDNA3.1/CT-GFP (Fig 3.3.2 B). 
 
3.3.3 Expression of wild type TG2 in human embryonic HEK293/T17 cells 
 
To examine the expression level of TG2 from pcDNA3.1/CT-GFP: TG2, plasmid DNA 
was transiently transfected into the human embryonic kidney cells (HEK293T). These cells 
were chosen because they express negligible levels of endogenous TG2. To obtain a high 
efficiency of transfection, the plasmid DNA was purified using endotoxin free GenElute 
Endotoxin-Free Maxiprep kit according to the manufacturer’s protocol. 
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Figure 3.3.1 Schematic showing the map of pcDNA3.1/CT-GFP expression vector 
(Invitrogen, UK). 
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A 
                     
 
B  
 
 
 
Figure 3.3.2 A, B Electrophoretic analysis of psTBlue-1:TG2 and pcDNA3.1/CT-GFP:TG2 
digested with NotI and KpnI . A The upper band represents psTBlue-1 vector (3.95kbp) 
while the lower band corresponds to inserts size (around 2.3kbp) B The upper band 
represents pcDNA3.1 vector (6.1kbp) and lower correspond to inserts size (around 
2.3kbp). 
 
      psTBlue-1:TG2    psTBlue-1 
            digested          digested 
 
      
10kbp 
5kbp 
2kbp 
1kbp 
3kbp 
10kbp 
6kbp 
3kbp 
2kbp 
1kbp 
      pcDNA3.1:TG2    pcDNA3.1 
            digested          digested 
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The plasmid quality was verified on agarose gel, and the concentration was calculated 
using Genowa spectrophotometer. HEK cells were transiently transfected by a calcium 
phosphate-based method on cells grown to 80-90% confluence. The use of GFP as a 
marker of transfection allowed direct observation of transfection efficiency which was 
estimated at around 60-70% after 48 hours post-transfection (Fig. 3.3.3B). After transient 
transfection of HEK293/T17 cells with 2 μg/ml of plasmid DNA encoding wt TG2 and 48 
hours incubation at 37°C the expression of the protein was assessed using SDS-PAGE 
followed by Western blot analysis (Materials and Methods 2.2.4 and 2.2.5). As shown in 
Fig. 3.3.3C, the wild type TG2 showed band of the expected molecular weight (78kDa) 
when compared to negative controls including empty vector transfected and 
untransfected cells.  
 
3.3.4 Expression of wild type TG2 in NIH3T3 mouse fibroblasts 
 
     Similarly to HEK293/T17 cells, NIH3T3 cells were characterised by undetectable levels 
of endogenous TG2 expression, thus being a good model for investigating the expression 
of the enzyme. NIH3T3 cells were transiently transfected by electroporation using 
Nucleofector® (Lonza) kit R as described in Materials and Methods (2.2.3.5). To optimize 
the transfection efficiency, cells were initially transfected with pcDNA3.1/GFP only using a 
range of amounts of plasmid DNA (2-5μg) and transfected cells counted by fluorescent 
microscopy (results not shown). As shown in Fig. 3.3.4B, optimum transfection efficiency 
was achieved using 4μg of plasmid after 48 hours post-transfection. Using these 
conditions, TG2 plasmids were transfected into NIH3T3 cells. After 48 hours incubation at 
37°C, protein expression was analysed by SDS-PAGE and TG2 antigen determined by 
Western blot analysis using monoclonal anti-TG2 antibody (CUB 7402) as described in 
Materials and Methods section (2.2.4 and 2.2.5). All transfected plasmids resulted in an 
expressed TG2 band at the expected size. Cells transfected with empty vector and 
untransfected cell controls showed no detectable TG2 (Fig. 3.3.4C) 
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Figure 3.3.3  
 
Figure 3.3.3 A, B  Fluorescent microscopy analysis of expression efficiency of HEK 
293/T17 cells after transient transfection with pcDNA3.1/GFP vector. Transiently 
transfected cells were analysed by fluorescent microscopy using Zeiss Axiovert 200M 
microscope equipped with laser adjusts at 507 nm.  A Untransfected cells showed no 
signal strength while B transfected with empty vector cells showed around 60% 
transfection efficiency 
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Figure 3.3.3 C 
 
Figure 3.3.3 C Western blotting to show expression level of wild type TG2 in 
HEK293/T17 cells 48-hours post-transfection.  HEK293/T17 cells were transiently 
transfected with 2μg of plasmid DNA encoding wild type TG2.  Transient transfection was 
allowed to proceed for 48 hours. Afterwards cells were lysed and the protein content was 
determined by Lowry method (Lowry et.al., 1951). As a result 50μg of the protein extracts 
(whole cell lysates) collected from both untransfected, empty vector transfected, and 
wild-type transfected cells were analysed by SDS-PAGE as described in Materials and 
Method section (2.2.4). The presence of TG2 antigen was detected using anti-TG2 
(CUB7402) antibody followed by peroxidase-conjugated secondary antibody as described 
in Materials and Methods (2.2.5). 
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Figure 3.3.4 
 
Figure 3.3.4 A, B Analysis of transfection efficiency of NIH3T3 cells transfected with 
pcDNA3.1/CT-GFP by fluorescent microscopy. A Untransfected cells revealed no signal in 
comparison to B transfected cells where transfection efficiency was estimated at around 
50%. 
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C 
 
 
 
 
Figure 3.3.4 
 
Figure 3.3.4 C Western blotting showing the expression of wild type TG2 in NIH3T3 cells 
48 hours post-transfection.  NIH3T3 cells were transiently transfected with 4μg of 
plasmid DNA encoding wild type TG2 using Nucleofector kit R (Lonza). 48 hours after 
transfection, cells were lysed and the protein content was determined by Lowry method 
(Lowry et.al., 1951). 50μg of the protein extracts (whole cell lysates) collected from 
untransfected cells, pcDNA3.1/CT-GFP transfected control and pcDNA3.1/CT-GFP: TG2 
transfected cells were resolved by SDS-PAGE as described in Materials and Methods 
section (2.2.4). The presence of TG2 antigen was detected by Western blotting using anti-
TG2 (CUB7402) antibody followed by goat anti-mouse IgG HRP-conjugated secondary 
antibody as described in Materials and Methods (2.2.5). The membrane was stripped and 
further reprobed with anti-mouse α-tubulin antibody to normalise protein loading. 
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3.3.5 Identification of the sites on TG2 responsible for binding high affinity partners  
 
     In order to find out whether any of the TG2 binding partners affected its intra or 
extracellular localisation, the goal was to generate mutants which were show abolished 
or at least reduced binding strength to specific TG2 partners. As shown in Fig. 3.3.5I and 
Fig. 3.3.5II, targeted TG2 amino acid sequences included: Asp94 and Asp97 (residues 
claimed by Hang et al., 2005 to be crucial for TG2-FN interaction), N-terminal β-sandwich 
TG2 domain (which was indicated by Gaudry et al., (1999) to as well play an important 
role in TG2-FN interaction), possible heparan sulfate binding site residues (assuming that 
TG2 can interact with HSPGs receptors when released from cells to the cell surface as 
stated by Verderio et al., 2009) as well as Ser171 and Lys173, the main residues responsible 
for TG2-GTP interaction when present in an intracellular environment (Ismaa et al., 2000). 
Additionally a TG2 region that was suggested to be involved in TG2-integrin interaction 
(Akimov et al., 2000) and might contain the possible heparan sulfate binding motifs, the 
C-terminal domain, was targeted for deletion.  
 
3.3.6 Identification of putative heparin-binding motifs in TG2 
 
   Examination of the primary amino acid sequence of TG2 for the linear consensus GAG 
binding motifs XBBXBX and XBBBXXBX, where B is a basic amino acid whose side chain is 
exposed on the protein surface and X is a neutral or hydrophobic amino acid whose side 
chain is directed towards the protein interior (Cardin & Weintraub, 1989), reveals one 
such sequence 261LRRWKN266 close to the active site of TG2. This sequence has already 
been suggested as a possible HSPG binding site for TG2 (Verderio et al. 2009). However, 
examination of the crystal structure of TG2 (1KV3) shows that 261LRRWKN266 is part of an 
alpha helix, whereas the XBBXBX consensus must be in a β-sheet in order for the basic 
residues to face the same direction. A common structural theme of linear GAG binding 
motifs is that there are two basic residues approximately 20Å apart to accommodate a 
pentasaccharide, facing in opposite directions on an alpha helix (Margalit et al., 1993). 
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Figure 3.3.5I 
 
 
Figure 3.3.5I Schematic showing organisation of structural domains of tissue 
transglutaminase with indication of amino acid sequences or regions that were targeted 
for mutagenesis to generate different TG2 mutants. Illustrated mutations include: 
deletion of the first 15 amino acids from the first NH2-terminal domain of TG2 (Δ1-
15TG2), FN1 mutant (D94A, D97A), GTP1 mutant (S171E), GTP2 mutant (K173L), HS2 
(K205A, R209A) and HS1 (K600A, R601A, K602A) mutants and deletion of the last C-
terminal domain of TG2 (Δ594-687TG2). 
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Figure 3.3.5II A 
 
 
Figure 3.3.5II Illustration of all the TG2 mutants generated for the purpose of 
investigation the interaction of the enzyme with his high affinity binding partners 
including fibronectin, HSPGs, integrins as well as GTP. A FN1 mutant (D94A, D97A), B 
deletion of the first 15 amino acids from the first NH2-terminal domain of TG2 (Δ1-15TG2) 
C HS1 (K600A, R601A, K602A) and HS2 (K205A, R209A) mutants D GTP1 (S171E) and GTP2 
(K173L) mutants E deletion of the last C-terminal domain of TG2 (Δ594-687TG2). 
 
D97A 
D94A 
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Figure 3.3.5II B, C 
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Figure 3.3.5II D, E 
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Since 261LRRWKN266 is too short to satisfy this requirement either, it is unlikely to be able 
to bind GAGs and so was not investigated. It has been suggested that the three 
dimensional arrangement of basic amino acid residues is more important than linear 
clustering, such that many GAG binding motifs can also be comprised of sequence-distant 
basic amino acid residues (Hileman et al., 1998).  Examination of the crystal structure of 
TG2 revealed two likely candidate motifs, 590KIRILGEPKQKRK602 (HS1) which is located at 
the tip of C-terminal beta barrel 2 and another comprised of 
202KFLKNAGRDCSRRSSPVYVGR222, with K387 (HS2), forming a shallow pocket lined with 
basic residues (Fig. 3.3.6A). 
 
3.3.7 Generation of TG2 point mutants  
 
    Plasmid pcDNA3.1/CT-GFP: TG2 vector was used as a template to generate the TG2 
mutants. All the point mutations were generated using Quickchange mutagenesis kit 
(Stratagene) as described in section (2.2.2). Primers were designed to also include silent 
mutations to either introduce or delete a restriction site, allowing simple assessment of 
successful mutagenesis by restriction analysis. The resulting plasmids were digested with 
the appropriate restriction enzymes and compared to the wild type. Possible heparan 
sulfate binding site mutant HS1 showed two linear bands (~ 8.9kbp, ~ 6.8kbp) in 
comparison to the wild type digested with the same (NotI) enzyme (Fig., 3.3.7A). In 
addition HS2 mutant showed three different bands (~ 4.2kbp, ~ 2.1kbp, ~ 1.9kbp) when 
digested with EagI enzyme in comparison to the control showing four linear bands on the 
gel. FN1 mutant when digested with BstXI enzyme showed two linear bands as well (~ 
8.3kbp, ~ 4.9kbp) when compared to the wild type. After digestion of plasmid DNA 
carrying GTP1 mutation with PpiI, four different linear bands (~ 2.9kbp, ~ 2.7kbp, ~ 
1.3kbp, and 870bp) were seen on an agarose gel which differed when compared to 
plasmid carrying wt TG2 digested with the same restriction enzyme. Similarly, GTP2 
mutant showed 10 linear bands on agarose gel (~ 2.8kbp, ~ 1.8kbp, ~ 1.5kbp, ~ 680bp, ~ 
550bp, ~ 450bp, ~ 530bp, ~ 210bp, ~ 75bp, ~ 34bp) in comparison to 8 bands which 
appeared on a gel after digesting the wild type control with EarI (Fig 3.3.7B).  
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Figure 3.3.6 A, B Illustration of 3D structure analysis of possible heparan sulfate binding 
site motifs present on TG2 molecule.  
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Figure 3.3.7 A Electrophoretic analysis of restriction digested wt TG2, HS1 mutant 
(K600A, R601A, K602A), FN mutant (D94A, D97A) and HS2 mutant (K205A, R209A) 
plasmids. Each of the mutants was generated using Quick change site directed 
mutagenesis kit from Stratagene by means of specially designed primers (section 2.2.2.1 
A) using pcDNA3.1/CT-GFP: TG2 vector as a DNA template. Obtained plasmids DNA were 
run on 0.8% agarose gel using DNA log ladder (1-10kbp) (Lane 1 and Lane 7).  
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Figure 3.3.7 B Electrophoretic analysis of restriction digested wt TG2, GTP1 mutant 
(S171E) and GTP2 mutant (K173L). Each of the mutants was generated using Quick 
change site directed mutagenesis kit from Stratagene by means of specially designed 
primers (section 2.2.2.1 A) using pcDNA3.1/CT-GFP: TG2 vector as a DNA template. 
Obtained plasmids DNA were run on 0.8% agarose gel using DNA log ladder (1-10kbp) or 
DNA log ladder (0.1bp-1.5kbp).  
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All mutant plasmids were subjected to nucleotide sequencing to confirm mutations and 
integrity of the TG2 sequence. 
 
3.3.8 Generation of TG2 deletion mutants 
 
     Both deletion mutants including deletion of the first 15 amino acids from the NH2-β 
sandwich TG2 domain (Δ1-15TG2) and deletion of the last domain of the enzyme (Δ594-
687TG2) were generated by PCR amplification using pcDNA3.1/CT-GFP: TG2 as template 
and oligonucleotide primers with flanking KpnI and NotI restriction sites to allow 
directional cloning of products into pcDNA3.1/CT-GFP. Resulting plasmids were purified 
and digested with NotI and KpnI enzymes and compared to the wild type (Fig. 3.3.8).As 
expected there was a noticeable difference in the size of the bands corresponding to the 
TG2 insert when compared to the wild type. For Δ1-15 TG2 this was 2.2kbp and for Δ394-
687 it was 2kbp. Plasmid DNA was verified by nucleotide sequence analysis.  
 
3.3.9 Expression of wild type TG2 and TG2 mutants in HEK293/T17 cells 
 
      Mutant TG2 enzymes for binding of fibronectin FN1 (D94A, D97A) and N-terminal 
deletion (Δ1-15TG2), HSPG binding mutants HS1  (K600A, R601A, K602A) and HS2 (K205A, 
R209A), GTP binding mutants GTP1 (S171E) and GTP2 (K173L) as well as C-terminal 
deletion (Δ594-687TG2) were transfected into HEK293T cells to assess expression levels. 
All mutants showed bands of the expected molecular weight (Fig. 3.3.9A) however 
differed in expression levels (Fig. 3.3.9B). GTP-defective binding site mutant (GTP1) and 
N-terminal deletion were shown to be expressed less in comparison to the wild type 
protein, while HSPGs mutants as well as FN1, GTP2 and C-terminal deletion mutant were 
expressed at a much higher or similar level by cells, respectively.  
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Figure 3.3.8 Electrophoretic analysis of NotI and KpnI digested wt TG2 and TG2 deletion 
products (Δ1-15 TG2 and Δ594-687 TG2) . Each of these mutants was generated by PCR 
by means of specially designed primers (section 2.2.2.1 B) using pcDNA3.1/CT-GFP: TG2 
as template. Inserts were subcloned into pcDNA3.1/CT-GFP and resulting plasmid were 
digested with KpnI and NotI and run on 0.8% agarose gel using DNA log ladder (1-10kbp).  
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3.3.10 Expression of wild type TG2 and TG2 mutants in NIH3T3 cells 
 
     Mutant plasmids were transfected into NIH3T3 cells to assess the expression level. 48 
hours after transfection, cells were lysed and 50 μg of protein from each cell extract were 
analysed by SDS-PAGE and Western blotting. All mutants showed expressed TG2 proteins 
of the expected molecular weight (Fig. 3.3.10A) with untransfected and empty vector 
controls showing no bands. Some of the mutants showed additional bands at 50kDA, 
possibly due to proteolytic degradation. Differences in expression level were revealed 
after densitometry analysis (Fig. 3.3.10B). GTP1 mutant (S171E), and TG2 deletion mutant 
(∆ 1-15 TG2) were shown to be expressed less in comparison to wild type TG2, whereas 
HS1 (K600A, R601A, K602A), HS2 (K205A, R209A), FN1 (D94A, D97A), GTP2 (K173L) 
mutants and C-terminal deletion (Δ594-687) were expressed at a higher or similar level.  
 
3.3.11 GTP-agarose affinity chromatography of GTP1 and GTP2 mutants 
 
     The TG2 constructs containing GTP-defective binding site mutants were transiently 
transfected into the HEK293/T17 cells as detailed in Materials and Methods (2.2.3.5). In 
order to assess impairment in GTP binding by these mutants (Ismaa et al., 2000), cell 
extracts were subjected to GTP-agarose affinity chromatography (Methods 3.2.5.3). As a 
positive control, cell lysate containing the wild type protein was also analysed. Fractions 
collected from the column were subjected to SDS-PAGE and Western blotted with anti-
TG2 antibody (CUB7402) for the presence of TG2 antigen. As shown in Fig. 3.3.11, both 
GTP1 and GTP2 mutants were found in a flow-through after failing to bind to the GTP-
agarose whereas wt TG2 bound to the column and was only eluted in the presence of 
competing GTP (5mM).  
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Figure 3.3.9 Expression level of wt TG2 and TG2 mutants in HEK293/T17 cells. A 
HEK293/T17 cells were transiently transfected with 2μg of plasmid DNA encoding the wild 
type enzyme and TG2 mutants and incubated for 48 hours at 37°C.  Transfected cells 
were lysed, protein content was determined using Lowry method (section 2.2.3.7) and 
50μg of protein was resolved by SDS-PAGE and the presence of TG2 antigen determined 
by Western blotting as described in Materials and Methods (2.2.5). B Relative expression 
levels of TG2 proteins normalised to tubulin after densitometric analysis using ImageJ 
software. 
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Figure 3.3.10 Expression level of wt TG2 and TG2 mutants in NIH3T3 cells. A NIH3T3 cells 
were transiently transfected with 4μg of plasmid DNA encoding the wild type enzyme and 
TG2 mutants and incubated for 48 hours at 37°C.  Transfected cells were lysed, protein 
content was determined using Lowry method (section 2.2.3.7) and 50μg of protein was 
resolved by SDS-PAGE and the presence of TG2 antigen determined by Western blotting 
as described in Materials and Methods (2.2.5). B Relative expression levels of TG2 
proteins normalised to tubulin after densitometric analysis using ImageJ software.  
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Figure 3.3.11 Western blot analysis of GTP-agarose affinity chromatography fractions 
for GTP1, GTP2 and TG2. HEK293/T17 cells were transiently transfected using 2μg of each 
plasmid DNA. After 48 hours, transfected cells were lysed using a non-denaturating 
method as described in Materials and Methods (2.2.6.1 A). The resulting cell extracts 
were mixed with 50mM Tris-Cl, 1mM EDTA, 1mM DTT, 10mM MgCl2, pH 7.5 and then to 
the column equilibrated in the same buffer. After washing with buffer, proteins were 
eluted with the same buffer containing 5mM GTP. The flow-through (1-8), wash (9-12) 
and eluted fractions (13-25) were analysed by SDS-PAGE electrophoresis followed by 
Western blotting as described under Materials and Methods (2.2.4 and 2.2.5). 
GTP1  1  2  3  4  5  6  7   8   9  10 11 12  13 14 15 16 17 18 19 20 21  22  23 24 25 
Flow-through Wash Eluted fractions 
GTP2  1  2  3   4   5  6  7   8   9  10 11 12  13 14 15 16 17 18 19 20 21  22  23 24 25 
TG2  1  2  3   4  5  6  7   8   9  10 11 12  13 14 15 16 17 18 19 20 21  22  23 24 25 
Chapter III: Mutagenesis studies and characterisation of the mutants 
133 
 
3.3.12 The NH2-β sandwich of the TG2 first domain is crucial for binding to fibronectin 
  
The TG2-FN interaction has been stated to be important in regulating many processes 
that take place in mammals. TG2 binds FN via its 28kDa proteolytic fragment which 
contains the first and a big part of the second TG2 domain (Jeong et al., 1995). Moreover 
the N-terminal domain and residues Asp94 and Asp97 were suggested to be crucial (Gaudry 
et al., 1999; Hang et al., 2005). Early studies revealed that a mutant deficient in the first 
seven N-terminal amino acid residues abolished binding to fibronectin. However, this 
mutant was also shown to be unstable (Jeong et al., 1995). Therefore to verify whether 
the first domain plays an important role in TG2-FN interaction, we produced a TG2 
deletion mutant deficient in the first 15 amino acids (Δ 1-15TG2), which has been 
demonstrated to be expressed and stable (Hang et al., 2005). In addition, knowing that 
Asp94 and Asp97 are also essential for FN binding, we have mutated them by substituting 
alanine in a place of aspartic acid to generate the FN1 mutant (D94A, D97A). The NΔ1-15 
and FN1 mutants were assessed for their ability to bind to fibronectin in a solid phase 
binding assay utilising purified FN as stated in Methods (2.2.6.2) and then normalised to 
the relative expression level of mutant TG2 in the cell lysates as described under 
Materials and Methods (2.2.5.1). Both of the mutants showed a significant loss of binding 
ability to the FN when compared to the wild type (Fig. 3.3.12). However the binding 
strength differed depending on the mutation. The D94A, D97A mutant described 
previously (Hang et al., 2005) demonstrated approximately 45% binding compared to wild 
type TG2, whereas the Δ1-15 deletion mutant had approximately 30% binding compared 
to wild type.      
 
3.3.13 The high affinity heparin binding site of TG2 is located in the catalytic core 
domain 
  It is known that TG2 binds to heparin (an analogue of heparan sulfate) with high affinity, 
a property that has been exploited for its purification (Signorini et al., 1988).  
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A 
B                 
                        
Figure 3.3.12 Binding of mutant FN1 (D94A and D97A) and N-terminal deletion mutant 
(Δ 1-15 TG2) to fibronectin. A Fibronectin binding was assayed by ELISA using microtitre 
plates coated with 5μg/ml fibronectin. 50-60 μg of proteins from cell extracts were added 
to each well and bound TG2 was determined using monoclonal anti-TG2 antibody 
(CUB7402) followed by HRP-conjugated secondary antibody (2.2.5). The reaction was 
determined spectrophotometrically at 490nm wavelength. B The expression of total TG2 
in cell lysates was evaluated by Western blotting and compared to the equal loading 
marker α-tubulin by densitometry analysis. The binding strength to FN of wild type and 
mutant TG2 was then normalised to the relative expression levels of wild type and 
mutant TG2 in the cell lysates, respectively after densitometric analysis of blots. 
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To study the interaction between TG2 and HSPGs and to test whether any of the 
identified possible heparan sulfate binding sites shows impairment in the binding affinity 
to the heparan sulfate, the wild type as well as mutants HS1 (K600A, R601A, K602A) and 
HS2 (K205A, R209A)  were tested for their ability to bind to a heparin Sepharose column. 
All constructs were transfected into HEK293/T17 cells and when ready were lysed using a 
non-denaturating lysis buffer to avoid denaturation (Materials and Methods 2.2.6.1 A).  
The binding strength of TG2 and mutants HS1 and HS2 to heparin Sepharose was 
determined by elution with an increasing salt gradient (Figure 3.3.13 A). All fractions 
(flow-through, wash and elution) that were collected from the column were verified for 
the presence of TG2 antigen by immunoblotting with anti-TG2 antibody as detailed in 
Materials and Methods (2.2.4 and 2.2.5). As shown in Fig.  3.3.13 B, TG2 was eluted at 
two distinct salt concentrations 100 mM and 330 mM, suggesting that two different 
populations of enzyme were present. To exclude the possibility that the observed low 
affinity binding was due to denatured TG2, the transglutaminase activity of eluted 
fractions was determined and this showed that specific activity did not differ between the 
high and low affinity binding fractions (Fig. 3.3.13 C).  
     Mutant HS1 bound heparin identically to TG2, with low and high affinity, whereas HS2 
lost the capability to bind with high affinity to heparin (Fig. 3.3.13 B). However, HS2 
retained its low affinity binding to heparin (60mM), suggesting that residues K205 and 
R209 contributed to high affinity binding to heparin. Since both mutants HS1 and HS2 
resulted in the same net charge reduction, this alteration in HS2 binding was not simply 
due to electrostatic interaction.  
     HS1 mutant showed high affinity binding to heparin so it was not necessary to 
determine its activity. As shown in Fig. 3.3.13 D, HS2 fractions eluted with low salt 
concentration showed activity suggesting that the loss of binding was not due to 
denaturation or a gross alteration in structure. Also, activity was also noticed in flow-
through fractions indicating that some of the mutant remained unbound. 
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A 
 
 
 
 
Figure. 3.3.13 A Graph showing TG2-Heparin interaction. Green line is % of elution buffer 
(1M NaCl in 50mMTris-Cl, 1mMEDTA, 1mMDTT, pH 7.5), brown line is % conductivity, 
blue line is absorbance at 280nm. 
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B  
 
 
 
 
 
 
 
 
Figure 3.3.13 B Analysis of possible heparan sulfate binding site mutants, HS1 (K600A, 
R6001A, K602A) and HS2 (K205A, R209A) binding ability to heparin. Cell extracts 
obtained after non-denaturating lysis of transiently transfected HEK293/T17 cells, were 
diluted with 50mM Tris-Cl, 1mM EDTA, 1mM DTT, pH 7.5 (Methods 3.2.5.4) and applied 
to the heparin Sepharose column. Proteins were eluted with a linear gradient of 0-1M 
NaCl in 50mM Tris-Cl, 1mM EDTA, 1mM DTT, pH 7.5. Both flow-through and eluted 
fractions (1-25 as shown in a results) were analysed by SDS-PAGE and Western blotting 
using anti-TG2 monoclonal antibody (CUB 7402) for the presence of TG2 antigen. 
TG2  1  2  3  4   5   6  7  8   9  10 11 12 13 14 15 16 17 18 19 20 21 22 23 2425   
 
HS2  1  2  3  4   5   6  7  8   9  10 11 1213 14 15 16 17 18 19 20 21 22 23 24 25   
Flow-Through Eluted fractions with     salt concentration Salt 
HS1  1  2  3  4   5   6  7  8   9  10 11 12 13 14 15 16 17 18 19 20 21 22 23 2425   
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Figure 3.3.13 C, D Measurement of transglutaminase activity in eluted fractions from 
the heparin Sepharose column. Fractions were mixed with 0.25mM Biotin X-cadaverine, 
10mMDTT, 20mMCaCl2 in 50mM Tris-Cl pH 8.0 and then incubated on a N,N’-
dimethylcasein coated TCP plate. After washing with TBS-0.05%Tween 20(v/v), pH 7.6 and 
TBS, pH 7.6, plates were blocked with 3% (w/v) BSA in TBS, pH 7.6 and then Biotin X-
cadaverine incorporation was measured with extravidin-peroxidase and analysed 
spectrophotometrically at 490nm (Materials and Methods 2.2.7.1). 
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3.3.14 High affinity heparin binding is dependent on TG2 conformation 
Since TG2 can adopt two extremes of conformation in the presence or absence of GTP, 
the effect of GTP binding on the association of TG2 with heparin was investigated (Fig. 
3.3.14B). In order to do so, cell extracts obtained from transfected cells were pre-
incubated either with 0.5mM TG2 inhibitor and then loaded on the heparin Sepharose 
column and compared to the wild type enzyme. Purified fractions were later collected 
and the amount of bound TG2 was estimated by Western blot analysis as described in 
Materials and Method (2.2.4 and 2.2.5). Eluted wt TG2 was again showed to bind to the 
column with two different affinities (Fig. 3.3.14 A). In the presence of GTP, which results 
in a compact globular conformation, all of the TG2 bound with high affinity to heparin 
(Fig. 3.3.14 B), whereas after reaction with the irreversible peptidic inhibitor R281 (Griffin 
et al., 2009), which restricts the conformation to an extended form, the TG2 bound to 
heparin with an intermediate affinity (Fig. 3.3.14 C). Since the GTP-bound globular form of 
TG2 bound to heparin with high affinity whilst the extended R281-bound form still 
retained an affinity higher than that of HS2, this suggests that the loss of high affinity 
binding of HS2 is not solely due to an altered conformation. Therefore, residues K205 and 
R209 in TG2 are very likely to be directly involved in high affinity heparin binding. As 
shown in Fig. 3.3.14 D, E, F, the activity of TG2 (and similarly HS2) is inhibited by GTP. 
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Figure 3.3.14 Effect of TG conformation on binding to heparin Sepharose. A Cell extracts 
(~ 150µl) from HEK293/T17 cells transfected with wtTG2 were loaded onto a 5ml heparin 
Sepharose column, equilibrated in 50mM Tris-Cl, 1mM EDTA, 1mM DTT pH 7.5 buffer at 
room temperature. B Cell extracts were pre-incubated with 50mM Tris-Cl, 1mM EDTA, 
1mM DTT, 0.5mMGTP, 2mM MgCl2 pH 7.5 or C with 50mM Tris-Cl, 1mM EDTA, 1mM DTT, 
0.5mM TG2 inhibitor R281, pH 7.5. Both flow-through and resulting fractions (1-25 as 
shown in a results) were assayed for TG2 activity and analysed by SDS-PAGE and Western 
blotting using anti-TG2 monoclonal antibody (CUB 7402) for the presence of TG2 antigen 
as stated in Materials and Methods (2.2.4 and 2.2.5). 
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Figure 3.3.14  D, E, F  Measurement of TG2 activity in fractions eluted from the heparin 
Sepharose column. Collected fractions were mixed with 50mM Tris-Cl pH 8.0, 0.25mM 
Biotin X-cadaverine, 10mMDTT, 20mMCaCl2 and then incubated on a fibronectin coated 
plate as described in Experimental procedure (Materials and Methods 2.2.7.1). After 
washing with TBS-0.05% (v/v) Tween 20, pH 7.6 and TBS, pH 7.6, plates were blocked with 
3% (w/v) BSA in TBS, pH 7.6 and then biotin X-cadaverine incorporation was measured 
with extravidin-peroxidase  and analysed spectrophotometrically at 490nm. 
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3.3.15 Affinity to heparin differs depending on TG2 mutation 
 
     It was also decided to investigate how other TG2 mutant enzymes, including TG2 active 
site mutant (C277S), FN1 (D94A, D97A), N- and C- terminal deletion mutants (∆1-15 TG2, 
∆594-687 TG2, respectively) affected binding to heparin. The active site mutant (C277S) is 
known to lack TG2 transamidating activity as well as force the enzyme into its extended 
conformation (Lee et al., 1993; Begg et al., 2006b). As stated before, the irreversible 
peptidic inhibitor R281 (Griffin et al., 2009) also stabilizes the enzyme in an extended 
form.   As shown in Fig. 3.3.15 B, C277S mutant bound to heparin with low affinity in a 
similar manner to TG2 treated with R281 inhibitor (Fig. 3.3.14 C) suggesting that the TG2-
heparin interaction is dependent on the enzyme conformation. Additionally, N-terminal 
mutant Δ1-15 was shown to bind to the heparin with low affinity (Fig. 3.3.15 D), similarly 
to C277S. The FN1 mutant, however, bound to heparin in a manner comparable to the wt 
enzyme. The C-terminal deletion mutant was eluted in a continuous pattern indicating 
some heparin binding was still present but much weaker than that of the wild type 
enzyme (Fig. 3.3.15 C and E). 
 
3.3.16 Binding of GTP mutants to heparin 
 
     To investigate how GTP binding to the enzyme affects its interaction with heparin, two 
GTP-defective binding site mutants GTP1 (S171E) and GTP2 (K173L) were applied on the 
Heparin column. It is known that when GTP binds to the enzyme it blocks it from binding 
Ca2+ and alters the enzyme conformation into the closed form. The mutant S171E was 
reported (Begg et al., 2006a) to be locked into the open conformation whilst the influence 
of mutation K173L on TG2 conformation is unknown. To test interaction between TG2 
construct and Heparin, cell extracts obtained after transfection of HEK293/T17 cells were 
applied on the Heparin column as detailed in Materials and Method (2.2.6.1.B).  
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Figure 3.3.15 Analysis of wt TG2 and TG2 mutants FN1 (D94A, D97A), N - terminal 
deletion (∆1-15TG2) and C – terminal deletion (∆594-687TG2) binding ability to heparin. 
Transiently transfected HEK 293/T17 cells were lysed in a non-denaturating lysis buffer 
and dissolved in an equilibrating buffer (Materials and Methods 2.2.6.1.A) before being 
applied on the Heparin Sepharose column. Desired proteins were eluted with 1mM NaCl 
in 50mM Tris-Cl, 1mM EDTA, and 1mM DTT, pH 7.5. Both flow-through and resulting 
fractions (1-25 as shown in a results) were verified by SDS-PAGE electrophoresis and 
western blotting using anti-TG2 monoclonal antibody (CUB 7402) for the presence of TG2 
antigen.  
 
 
 
 
 
 
 
 
Chapter III: Mutagenesis studies and characterisation of the mutants 
146 
 
A 
 
B 
 
C 
 
D 
 
E 
 
 
TG2  1  2  3  4   5   6  7   8  9  10  11  12 13 14 15161718 1920 2122 23 24 25   
  
 
Flow-Through Salt Eluted fractions with      salt concentration 
 C277S  1  2  3  4   5   6  7  8   9  10 11 12 13 14 15161718 19 20 21 22 23 2425   
FN1  1  2  3  4   5   6  7  8   9  10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25   
  N   1  2  3  4   5   6  7  8   9  10  11 12  13 14 15 16 17 18 19 20 21 22 23 2425   
C   1  2  3  4   5   6  7  8   9  10  11  12 13 14 15 16 17 18 19 20 21 22 23 2425   
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Further purified fractions (1-25 fractions) were resolved by SDS-PAGE electrophoresis and 
the presence of TG2 antigen was determined using anti-TG2 antibody (CUB7402) by 
Western blotting (2.2.4 and 2.2.5). As shown in Fig. 3.3.16 A, the wild type enzyme 
revealed the same binding pattern as previously described (Fig. 3.3.15A).Similarly GTP2 
mutant was eluted with lower and higher salt concentration suggesting that it binds 
Heparin with two different affinities (Fig. 3.3.16 C). GTP1 mutant (S171E) binds to the 
column with low and high affinity, but when eluted retains continuous pattern indicating 
the weaker affinity to Heparin in comparison to the wild type TG2 (Fig. 3.3.16 B). However 
this binding pattern show differences when compared to the active site mutant which 
similarly to GTP1 alters TG2 conformation into an open form.  
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Figure 3.3.16 A, B, C   Analysis of wt TG2 and GTP-binding defective site mutants, GTP1 
(S171E) and GTP2 (K173L) binding ability to heparin. Transiently transfected HEK 
293/T17 cells were lysed in a non-denaturating lysis buffer and dissolved in the 
equilibrating buffer (Methods 3.2.5.4) before being applied on the Heparin Sepharose 
column. Desired proteins were eluted with 1mM NaCl in 50mM Tris-Cl, 1mM EDTA, and 
1mM DTT, pH 7.5. Both flow-through and resulting fractions (1-25 as shown in a results) 
were verified by SDS-PAGE electrophoresis and Western blotting using anti-TG2 
monoclonal antibody (CUB 7402) for the presence of TG2 antigen. 
 
 
 
Flow-Through Salt Eluted fractions with      salt concentration 
TG2  1  2  3  4   5   6  7  8  9 10  11  12  13 14 15 16 17 18 19 20 21 22 23 24 25   
GTP1  1  2  3  4   5   6  7  8  9 10  11  12  13 14 15 16 17 18 19 20 21 22 23 24 25   
  GTP2  1  2  3  4   5   6  7  8  9 10  11  12  13 14 15 16 17 18 19 20 21 22 23 24 25   
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3.4 DISCUSSION 
The importance of maintaining homeostasis in mammalian organisms is crucial for 
their proper functioning. There is strong evidence suggesting that one of the enzymes 
that belong to the transglutaminase family (TG2) is essential for efficient homeostasis 
during wound repair processes (Telci and Griffin, 2006; Verderio et al., 2005). Although 
TG2 has been characterised as a wound healing mediator and its engagement in the 
healing process and many other processes including cell-cell and cell-matrix interactions 
was widely described, its secretion mechanism remains unknown. Available evidence 
suggests that TG2 secretion increases when cells and tissues are exposed to stress and 
proceeds through an unconventional pathway (Upchurch et al., 1991; Haroon et al., 1999; 
Johnson et al., 1999; Gaudry et al., 1999; Balklava et al., 2002; reviewed by Zemskov et 
al., 2006). Nevertheless, the exact fate of TG2 after secretion, involvement of its high 
affinity binding partners and effect of its conformational state when secreted is still not 
fully understood.   
It is known that TG2 is widely distributed in a variety of mammalian cells as well as 
tissues that differ in its expression levels (Thomazy and Fesus, 1989; Zemskov et al., 
2006). There are cells that show high expression of TG2 (endothelial cells and 
macrophages), which sometimes remains on a constitutive level (endothelium) or is up- 
regulated by specific stimuli such as inflammatory cytokines (INF-γ in rat intestinal cells 
and IL-6 in human Hepatoblastoma cells) as well as steroids, vitamin D, and growth 
factors including TGF-β1 by possibly TGF-β1/BMP4 response element in TG2 gene (Ritter 
and Davbies, 1998; Kim et al., 2002; Verderio et al., 2005;Zemskov et al., 2006, ). To 
determine the expression levels of TG2 and the mutants and their effects on cellular 
localisation, two different cell lines were used as a model. Human kidney embryonic 
(HEK293/T17) were chosen as the initial cell model. The motivation for this approach 
stems from the fact that these cells are known to contain undetectable levels of TG2 
therefore being a sensitive model for detection of transfected protein and are easily 
transfected. However in order to extend these investigations, a cell model using mouse 
fibroblast line (NIH3T3 cells) was applied. The reason for using this particular cell line 
arises from the fact that similarly to HEK293/T17 cells, these cells are characterised by 
negligible amounts of endogenous TG2. 
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 To be able to understand how TG2 is externalised from different cells, and which 
factors lead to its localisation at the plasma membrane, a series of TG2 mutants were 
prepared. TG2 lacks a typical signal peptide thus being secreted through non-classical 
pathway. So far it is known that TG2 when externalised accumulates into the ECM where 
it interacts with FN. However, there is still some uncertainty about which amino acid 
sequence(s) is/are involved in that interaction. Hang et al., (2005) suggest that the first 
domain of the enzyme, in particular the sequence (WTATVVDQQDCTLSLQLTT) is directly 
involved in FN binding. It has also been suggested that the N-terminus is required for FN 
binding (Gaudry et al., 1999a).  Therefore these residues were targeted for mutagenesis.  
Additionally it was of interest to investigate how GTP can affect TG2 localisation and 
conformation. Thus two main GTP- binding amino acids, S171 and K173, were substituted 
(Ismaa et al., 2000). Also, the influence of interaction of TG2 with either integrins or 
HSPGs present at the cell surface is unknown. Consequently possible integrin and HSPG 
binding sites on TG2 were targeted for mutagenesis. The entire set of mutants was 
initially transient transfected into HEK293T/T17 cells (human embryonic cells) to establish 
an experimental system that allows the exploration of the trafficking route as well as the 
final localisation of the enzyme. 
 For transfection of HEK 293/T17 the calcium phosphate method was used, whereas 
for transfection of NIH3T3 cells the Nukleofactor kit R system was applied. Both of these 
methods proved to be efficient enough without exposing the cells to any significant 
toxicity.  Measurement of TG2 protein in the transfected cells showed that both wild type 
and mutant TG2 proteins were efficiently expressed. However densitometric analysis of 
the expression levels showed differences between the different mutants within the same 
cell line, and also between the two cell lines. It is possible that the mutations affected 
protein expression or stability, especially in the case of the N-terminal deletion mutant 
which when transfected caused minor changes in the morphology of both cell types 
affecting their expression and appeared to be degraded. 
Characterisation of the phenotypes of all the mutants was performed to ensure that 
the mutations had the desired effect. In agreement with previous findings (Hang et al., 
2005; Gaudry et al., 1999), we have confirmed that both D94 and D97 and an intact N-
terminus are important for TG2 binding to FN. However, we have shown that the N-
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terminal 15 amino acids of the enzyme play even more important role in binding (Fig 
3.3.12). This suggests that both of these distinct sites are important for TG2 to be able to 
fully interact with its high binding partner FN. Analysis of the two GTP-binding mutants 
GTP1 (S171E) and GTP2 (K173L) (Ismaa et al., 2000) confirmed that they lost the ability to 
bind GTP. After analysis of the TG2 crystal structures and electrostatic surface charges of 
the wild type protein and based on the available literature two distinct sites (the core 
domain and C-terminal domain) were chosen for mutagenesis. Thus we generated site-
directed mutations in human TG2 of Lys-600, Arg-601 and Lys-602 to Ala (HS1) and Lys-
205 and Arg-209 to Ala (HS2) and analyse their capability to bind to heparin. The HS2 
mutant was shown to bind to the column with very low affinity compared to either the 
HS1 mutant or the wild type protein.  It was also confirmed that the HS2 mutant was still 
catalytically active, indicating that its loss of heparin binding was not due to either 
misfolding or protein denaturation. This result shows that the region around K205 and 
R209 comprise the major heparan sulfate binding site of TG2.  
One of the goals of our investigation was to explore whether conformational changes 
of TG2 can influence its interaction with heparin. In order to do that, the wild type TG2 
was pre-incubated with GTP, which as shown earlier (Smethurst and Griffin, 1996; di 
Venere et al., 2000) enforces the closed conformation. In addition, TG2 was also reacted 
with the irreversible TG2 inhibitor R281 (Griffin et al., 2009) which enforces the open 
conformational state. Incubation with GTP reinforced high affinity binding to heparin 
whereas incubation with R281 inhibitor abolished strong interaction between TG2 and 
heparin, with only low affinity binding observed. Since TG activity assays were used to 
confirm that bound enzyme retained activity, this suggested that the TG2-heparin 
interaction is conformation dependent, with the closed conformation (GTP-bound) 
showing the strongest interaction.  
With the binding and conformational requirements for the TG2-heparin interaction 
established, it was important to assess the behaviour of the other TG2 mutants. It is 
known that the TG2 active site mutant (C277S) not only abolishes activity but also 
stabilises TG2 in an extended conformation (Lee et. al., 1993, Begg et. al., 2006b). 
Therefore it was of interest to determine how this mutant bound to heparin. As expected, 
C277S did not show high affinity binding to heparin, instead binding with an affinity 
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similar to that of R281 inhibitor-reacted TG2 (also open conformation). N-terminal 
deletion mutant (Δ1-15TG2) bound to heparin with low affinity, indicating that this 
particular deletion may also have altered conformation. The FN1 (D94A and D97A) 
mutant was observed to bind to heparin in a comparable manner to the wild type. 
Deletion of the last TG2 domain (Δ594-687) resulted in intermediate binding strength to 
heparin, which suggests that this mutation may result in a conformation somewhere 
between the open and closed states.  
                     The GTP2 (K173L) GTP-binding mutant bound to heparin similarly to the wild type. 
However, GTP1 mutant (S171E), which is known to be in an open conformation (Begg et 
al., 2006a), had intermediate affinity to heparin. This suggests that other local effects may 
be important as well as gross conformation. As shown by Begg et al., (2006 a, b), either 
mutation of GTP-binding or Cys277 residues can influence the conformation of the 
enzyme. S171E, when mutated loses its ability to bind GTP due to a conformational effect 
on the positioning of residues Lys173 and Phe174, which, similarly to Ser171, are located on 
the same β-strand (Begg et al., 2006a). Likewise, C277S showed reduced affinity for GTP, 
by affecting Tyr516 (the residue of β-barrel 1, domain that contains the main GTP binding 
site) H bond interaction and greatly decreasing the compact form of the enzyme (Begg et 
al., 2006b). Therefore any disruptions in that interaction could induce the protein 
transition into the open form in a different manner than the one induced by the GTP1 
mutant which might have caused differences in the binding pattern to heparin.  
 
  
 
 
 
 
 
 
Chapter IV: Involvement of TG2 mutants in 
the localisation of enzyme to the cell 
surface and its deposition into the ECM 
 
 
 
 
 
 
 
 
 
 
Chapter IV: Involvement of TG2 mutants in the localisation of enzyme to the cell surface and its 
deposition into the ECM 
154 
 
4.1 INTRODUCTION 
 
In mammals nine different transglutaminases have been described at the genomic 
level (Grenard et al., 2001). Although TGase isoenzymes are characterised by the 
structural homology conserved within four distinct domains when first crystallized they 
were trapped in a conformational state that obscured the active site (Grenard et al., 
2001; Yee et al., 1994; Ahvazi et al., 2004, Liu et al., 2002). TG2 however has now been 
fully characterised in two distinct (compact and extended) conformations (Liu et al, 2002; 
Pinkas et al., 2007). These conformational changes of the enzyme often dependent on its 
intra or extracellular localisation which may be important for its interactions with its 
binding partners present within the cell compartments or at the cell surface and ECM. 
When intracellular, TG2 binds GTP which locks it in a compact conformation. In the 
extracellular environment where the calcium concentration is high TG2 has been believed 
to be in an open active state. However this may not be the case, because of variations in 
the extracellular redox potential (Go and Jones 2008). In addition as shown by Verderio et 
al., (2003) TG2 added exogenously to the standard culture required the presence of DTT 
for its activation. Further studies also indicated independently that despite the relatively 
high concentration of calcium in the ECM, TG2 still could be in its closed, GTP-bound form 
(Pinkas et al., 2007; Johnson and Terkeltaub 2005). 
Predominantly TG2 has been considered to be an intracellular protein, however 
further studies revealed that it can be also found on the plasma membrane and in the 
ECM (Gaudry et al., 1999a, b; Akimov and Belkin 2001a, b). Despite available data 
indicating externalisation of TG2 to be independent of the classical, reticulum/Golgi 
pathway, the mechanism of its secretion still remains unclear. TG2 does not have a signal 
peptide thus it is very unlikely for it to undergo ER/Golgi dependent N-glycosylation 
despite bearing glycosylation sites (Folk and Finlayson 1977, Gentile et al., 1991). 
Therefore TG2 must be translocated through the membrane via a non-classical pathway 
(Gaudry et al., 1999a, b; Akimov and Belkin 2001 a, b; Verderio et al., 2009; Collighan and 
Griffin, 2009). Recent studies suggest that TG2 is mainly released from damaged cells, and 
contributes to the repair of the damaged cell membrane by cross-linking the proteins 
Chapter IV: Involvement of TG2 mutants in the localisation of enzyme to the cell surface and its 
deposition into the ECM 
155 
 
involved in membrane fusion (Kawai et al., 2008). When externalised, TG2 does not 
simply leak out the cell which was demonstrated using different TG2 mutants (Cys-277S 
and Tyr-274) that impair distribution of the enzyme into the ECM (Balklava et al, 2002).  
Once exported, TG2 was shown to associate with the plasma membrane and to co-
localise with ECM proteins which may play an important role in the externalisation of the 
enzyme. Initial studies showed that for the enzyme to be secreted it requires an intact N-
terminal binding site which also appears to be one of the FN binding site motifs on the 
TG2 molecule (Gaudry et al., 1999 a, b). Whereas further investigation also indicated the 
involvement of β1 integrin in this process for which TG2 has a high affinity (Akimov et al., 
2000). Although the integrin binding sites has never been localised within the TG2 domain 
structure, at first it was suggested to be present at the C-termini (Akimov et al., 2000) and 
further at the N-terminal site of the enzyme (Hang et al., 2005). In addition the presence 
of the non-proline cis bond on Tyr-274 was shown to be important for both the activity of 
the enzyme and its secretion, while the presence of the active Cys-277 site was 
demonstrated to play a role in the localisation of the enzyme into the matrix (Balklava et 
al., 2002; Johnson and Terkeltaub 2005). These data strongly suggest that TG2 
externalisation is mediated via conformational changes which may be moderated by Tyr-
274 and Cys-277 residues (Johnson and Terkeltaub, 2005; Collighan and Griffin, 2009).  
When released from cells, TG2 has been shown to be localised in the ECM where it 
actively contributes to reconstitution and/or stabilisation of ECM structures. The 
extracellular matrix is a very complex mesh, which surrounds and supports cells by 
providing them with a scaffold for adhesion, growth, migration, differentiation and many 
other aspects that are critical for cell functions. The most prominent components of the 
ECM are collagen and elastin which provide strength and flexibility to the matrix, 
fibronectin which plays mainly an adhesive or integral function within the matrix, 
numerous proteoglycans and heparan sulfates which are important for stabilising its 
structure. Additionally ECM consists of different bound molecules including growth 
factors and cytokines, metalloproteinases (MMPs), and enzymes of which TG2 is one of 
special interest. Initial studies by Upchurch et al., (1991) on TG2 localisation within the 
ECM revealed that TG2 can be found in the ECM within the wound area where it 
extensively cross-links the surrounding environment. Its cross-linking activity has been 
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further implicated in the matrix resistance to proteolytic degradation (Johnson et al., 
1999). There are many extracellular proteins that TG2 has affinity for; however one of 
them has been shown to be particularly attractive for the enzyme. The tight interaction 
within TG2 and FN has been reported by many (Gaudry et al., 1999a, b; Hang et al., 2005) 
who have made attempts to characterise the FN binding site on TG2. This site has been 
mapped within the N-terminal TG2 domain, with peptide 88WTATVVDQQDCTLSLQLTT106 
reported to directly mimic this strong TG2-FN interaction (Hang et al., 2005). The close 
association between cell surface TG2 and FN has been shown to be important for the 
assembly of FN into the ECM, which however cannot take place without the presence of 
α5β1 integrin (Akimov et al., 2001a, and b). The assembly of FN must be properly 
controlled and the activity of the enzyme was shown to be unnecessary for this process. 
However once externalised TG2 was suggested to be associated with the assembly of 
fibronectin fibrils (Akimov et al., 2001a, b) and further implicated in not only modification 
but also in initial assembly of the ECM (Collighan and Griffin 2009). 
During cellular stress, TG2 is exported to the ECM, binds FN, and in that heterocomplex 
is deposited into the wound area (Jonhson et al., 1999; Verderio et al., 2004). However, 
once deposited, it can also interact with heparan sulfate proteoglycans chains that are 
located at the cell surface (Verderio et al., 2003). This process has implications in the 
adhesiveness functions of the enzyme which will be detailed in chapter 5. The affinity 
between TG2 and HS (heparan sulfate), which are known ECM components, has already 
been suggested (Verderio et al., 2003; Telci et. al., 2008). Predominantly one of the HS 
proteoglycans receptors localised at the cell surface of osteoblasts and fibroblasts 
(syndecan-4[S4]) has been indicated as a TG2 binding partner that together with the 
enzyme plays an important role in the cell adhesion process (Verderio et al., 2003, Telci et 
al., 2008; Scarpellini et al., 2007). Although S4 has been suggested to be the main HSPGs 
that TG2 binds to, the interactions between enzyme and other family members cannot be 
disqualified. Studies by Zehe et al. (2006) revealed a possible involvement of cell surface 
HSPGs in the trafficking and localisation of FGF-2 at the plasma membrane. FGF-2 is 
another molecule that similar to TG2 was suggested to be secreted via an unconventional 
pathway from cells (Shäffer et al., 2003; Beckhaus et al., 2003). Thus it is of importance to 
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establish if HSPGs can by some means influence the localisation of the TG2 at the cell 
surface as well as its deposition into the ECM. 
The initial objective of this chapter is to gain a deeper insight into the influence of how 
specific mutations of TG2 can affect the association of the enzyme with the cell surface 
and to clarify the importance of the association of TG2 with its extracellular binding 
partners in its translocation into the ECM. A further objective is to establish the 
physiological importance of the two distinct peptide sequences within the N-terminal 
domain of the enzyme on its interaction with FN (Gaudry et al., 1999a; Hang et al., 2005). 
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4.2 METHODS 
 
4.2.1 Biotinylation of cell surface TG2 and TG2 mutants 
 
The association of the wild type enzyme and its constructs with the plasma membrane 
of HEK293/T17 cells and NIH3T3 cells was verified by the  cell surface biotinylation of 
proteins  using 0.8mM sulfo-NHS-LC-biotin (Sigma Aldrich, UK) dissolved in PBS, pH 8.0 
(Materials and Methods section 2.2.10.1). Following three washes with 50mM Tris-Cl, pH 
8.0 transfected cells were then lysed in 1% SDS (w/v) in PBS pH 8.0 and the amount of 
protein in each cell extract was estimated as detailed in the Materials and Methods 
(2.2.3.7). The amount of 200μg of proteins from each lysate was then pre-incubated 
overnight with 50μl of NeutrAvidin-Agarose resin. Next day to eliminate any possibility of 
non-specific intracellular protein binding, beads were washed three times with PBS pH 8.0 
and further dissolved in 2xLaemmli buffer prior to denaturation. Equally prepared 
proteins were resolved by SDS-PAGE electrophoresis and the presence of TG2 antigen 
bound to the cell surface was verified by Western blotting as described in section (2.2.4 
and 2.2.5).  
 
4.2.2 Deposition of TG2 and TG2 constructs into the ECM 
 
To verify whether the wild type enzyme and its constructs are distributed into the 
ECM, transiently transfected NIH3T3 cells (1 x 106 cells ) were incubated for 72 hours at 
37°C which included serum starvation using DMEM supplemented with 1% FBS (v/v) for 
48 hours post-transfection as detailed in the general Materials and Methods (2.2.10.2). 
After discarding the medium, cells were detached with 2mM EDTA in PBS pH 7.4 and 
collected into the eppendorf tubes. Following two washes, with 2mMEDTA in PBS, pH 7.4 
deposited matrix was further incubated with 0.1% (w/v) deoxycholate in PBS, pH 7.4 in 
order to eliminate all soluble ECM fractions and uncollected cells. Following one more 
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wash with PBS, pH 7.4, insoluble ECM fractions, were dissolved in 50μl of 2x Laemmli 
buffer and after denaturating were separated by SDS-PAGE electrophoresis using 8% 
resolving gels. The presence of TG2 antigen deposited into the ECM was then analysed by 
Western blotting as described under sections (2.2.4 and 2.2.5). 
 
4.2.3 Detection of TG2 in the culture medium  
 
After 72 hours incubation of NIH3T3 cells transfected with the wild type TG2 and TG2 
constructs namely HS2 and the N-terminal mutant, as detailed under Materials and 
Methods (Section 2.2.3.5) the reaction was stopped.  The medium was removed from 
every single well and checked for the presence of secreted TG2. Collected medium was 
centrifugated at 300xg to eliminate any dislodged cells. The proteins present in the 
medium were then precipitated in 300µl ice cold 10% (w/v) TCA by incubating the 
samples on ice for 30 minutes. Following centrifugation at 13000g for 10 minutes, protein 
pellets were washed once with ice cold 10% (w/v) TCA, ethanol-acetone (1:1) and 
acetone and left for 20 minutes at room temperature to dry out. Obtained pellets were 
then resuspended in 30 µl Laemmli loading buffer (2x concentrated), and then checked 
for the presence of TG2 antigen by SDS-PAGE electrophoresis and Western blot analysis 
using anti-TG2 antibody as described in section (2.2.5). 
 
4.2.4 Detection of TG2 expression level in cell extracts 
 
To verify the expression level of wild type TG2 and all TG2 mutants, transfected 
HEK293/T17 and NIH3T3 cells (See Materials and Methods 2.2.3.5) were lysed, denatured 
and then equal amounts of protein were resolved by SDS-PAGE electrophoresis and 
analysed for the presence of TG2 by Western blot as stated in Materials and Methods 
(2.2.4 and 2.2.5). 
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4.2.5 Measurememnt of TG2 activity on the cell surface, Biotin-X-cadaverine 
incorporation into fibronectin 
 
This TG2-activity assay is based on measuring the incorporation of biotin-X-cadaverine 
into fibronectin as described by Jones and his collaborators (Jones et. al., 1997). Briefly, 
wells of a 96-well plate were coated with 5 µg/ml of fibronectin in  50mM Tris-Cl, pH 7.4 
and incubated overnight at 4°C. Trypsinized cells, transfected as described before in 
section (2.2.3.5) were resuspended in a serum free medium containing 0.132mM biotin X-
cadaverine and 10mM DTT at a concentration of 1 x 105 cells/ml. The total volume of 100 
µl was added into the each well of 96-well plate and incubation was allowed to proceed 
for 2 hours at 37°C. In order to stop the reaction, the 96 well plate was three times 
washed with 2mM EDTA in PBS pH 7.4. Further to eliminate remaining cells, 0.1% (w/v) 
sodium deoxycholate in PBS pH 7.4 containing 2mM EDTA was added into the plate which 
was then gently agitated for 10 minutes at room temperature. After discarding the 
supernatant, the remaining fibronectin layer was washed three times with 50mM Tris-
HCl, ph 7.4. To eliminate any non-specific binding, 100µl per well of a blocking solution 
composed of 3% BSA (w/v) in Tris-Cl, pH 7.4 was used. After three washes with 50mM 
Tris-Cl pH 7.4 buffer as described before, the incorporated biotin X-cadaverine was 
detected by incubation for 1 hour at 37°C with 100µl extravidin-peroxidase (Sigma-
Aldrich, UK) diluted 1:5000 in 3% (w/v) BSA in TBS, pH 7.4. Following another wash, the 
TG2 activity was analysed using Sigma Fast OPD, tablets dissolved in 20ml of distilled H20. 
The colour development was stopped by addition of 2.5M H2SO4 and the absorbance was 
read at 490nm using an Absorbance microplate reader ELx808TM.  
 
4.2.6 Measurememnt of TG2 activity in the total cell lysate, Biotin-X-cadaverine 
incorporation into fibronectin 
 
This assay is based on a measuring the incorporation of biotin-X-cadaverine into 
fibronectin as described by Jones and his collaborators (Jones et. al., 1997). Briefly, wells 
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of 96-well plate were coated with 5 µg/ml of fibronectin in a 50mM Tris-Cl, pH 7.4 and 
incubated overnight at 4°C. After three washes with 50mM Tris-Cl, pH 7.4, any possibility 
of non-specific interactions was eliminated by blocking the 96 wells plate in a blocking 
solution composed of 3% (w/v) BSA in 50mM Tris-Cl pH 7.4 for 30 minutes at 37°C.  
Following three washes, 100 µl per well of cell extracts containing 50-60µg of proteins 
obtained from transfected cells as described before in section (2.2.3.5) were resuspended 
in  50mM Tris-Cl pH 7.4 buffer containing 5mM CaCl2, 10mM DTT, 0.132mM biotin X-
cadaverine  and then added in a triplicate into 96-well plate. The activity of all mutants 
was compared to the wild type TG2, which under the test conditions was considered to 
be a positive control. The immobilisation of wild type TG2 and TGase mutant to 
fibronectin was allowed to proceed for 2 hour at 37°C. In order to stop the reaction, 96 
wells plate was three times washed with 2mM EDTA in PBS pH 7.4. Further 0.1% (w/v) 
sodium deoxycholate in PBS pH 7.4 containing 2mM EDTA was added into the plate which 
was then gently agitated for 10 minutes at room temperature. After discarding the 
supernatant, the remaining fibronectin layer was washed three times with 50mM Tris-Cl, 
ph 7.4. Afterwards the incorporated biotin X-cadaverine was detected by incubation for 1 
hour at 37°C with 100µl extravidin-peroxidase (Sigma-Aldrich, UK) diluted 1:5000 in 3% 
(w/v) BSA in TBS, pH 7.4. Following another washing, the TG2 cross-linking activity was 
analysed using Sigma Fast OPD, tablets dissolved in 20ml of distilled H20. The colour 
development was stopped by addition of 2.5M H2SO4 and the absorbance was read at 
490nm using an Absorbance microplate reader ELx808TM. Results were expressed as 
change in absorbance with time per mg of protein. 
 
4.2.7 Measurement of recombinant human TG2 ability to bind to two FN amino 
terminal fragments as well as full length FN 
 
To detect the saturation point of recombinant human TG2 (rhTG2) when bound to 
three different lengths of human plasma FN an ELISA was performed. The solid binding 
phase assay was conducted with a high binding affinity plate (Nunc, Thermo Fisher 
Scientific, Denmark) coated overnight with the three different fragments of fibronectin: 
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45kDa of fibronectin (54μg/ml), 70 kDa fibronectin (45μg/ml) and full length fibronectin 
(5μg/ml) (Sigma-Aldrich, UK) (Verderio et al., 2003) in a 50mM Tris-Cl, pH 7.4. To reduce 
the possibility of non specific reactions, the wells were blocked as detailed under 
Materials and Methods section (2.2.6.2). Following washing with PBS, pH 7.4, 100μl/well 
of the increasing concentration of rhTG2 (1μg/ml, 2.5μg/ml, 5μg/ml, 10μg/ml, 15μg/ml, 
20μg/ml, 30μg/ml) was added into the wells of coated plates, and immobilisation of the 
enzyme on FN was allowed to proceed for 1 hour at room temperature. After three 
washes with PBS pH 7.4 plates were incubated for 2 hours with anti-TG2 monoclonal 
antibody (CUB 7402) diluted 1:1000 in the same blocking buffer followed by incubation 
with secondary antibody (See section 2.2.6.2). The colorimetric reaction between the  
peroxidase conjugated secondary antibody and Sigma Fast OPD substrate was stopped by 
addition of 2.5M H2SO4  and then amount of bound rhTG2 to FN was analysed 
spectrophotometrically at 490nm. 
 
4.2.8 Competition between human recombinant TG2 and AEELVLERCDLELE (P4) and 
WTATVVDQQDCTLSLQLTT (P5) peptides for the binding to fibronectin  
 
ELISA was performed in a high binding 96-well nunc microtiters plate. Microtiter plates 
were coated overnight with 50μl/well of the three different lengths of fibronectin: 45kDa 
of fibronectin (54μg/ml), 70 kDa fibronectin (45μg/ml) and full length fibronectin (5μg/ml) 
(Sigma-Aldrich, UK) (Verderio et al., 2003). The wells were then blocked for 30 min at RT 
with blocking buffer (1% BSA (w/v) in 1xTBS pH 7.6). After two washes with 0.05% Triton 
X-100 in TBS ph 7.6 and one wash with 1xTBS, 100μl per well of the peptides (P4, P4s and 
P5) diluted in 2mMEDTA in PBS pH 7.4 were added to the wells at 0.1μmM – 1mM 
concentrations and incubated for 1 hour at RT. Following three washes, 100μl per well of 
purified human recombinant TG2 was added to the same wells at a final concentration of 
2μg/ml and incubated for 1 hour at room temperature. Bound TG2 was measured by a 2 
hour incubation at room temperature with CuB7402 (diluted 1:1000 in blocking buffer) 
followed by 2 hour incubation at room temperature with peroxidase conjugated goat ant-
mouse IgG antibody (diluted 1:1000 in blocking buffer). After three washes, Sigma Fast 
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OPD substrate was added into the wells, and after few minutes the amount of bound TG2 
was assayed spectrophotometrically at 490nm.  
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4.3 RESULTS 
 
4.3.1 Detection of the wild type TG2 and TG2 mutants at the HEK293T cell surface 
 
To explore the extracellular localisation of the wild type TG2 as well as TG2 constructs 
(HS1, HS2, GTP1, GTP2, FN1, N, and C) in transiently transfected HEK293T cells, cell 
surface proteins were biotinylated using sulfo-NHS-LC-biotin. This particular reagent is 
characterised by the presence of sulfonate groups and is unable to penetrate the cell 
membrane. Following labelling, biotinylated cells were cleared by centrifugation, lysed 
and 200μg of proteins were subjected to incubation with NeutrAvidin Agarose-resins. The 
proteins present in the whole cell lysate and the resin bound proteins were then analysed 
by SDS-PAGE and Western blotting for the presence of TG2 antigen.  
The wild type enzyme and most of the TGase mutants but excluding the N-terminal 
deletion (Δ1-15TG2) could be found at the plasma membrane of HEK293T cells when 
analysed by Western blotting (Fig. 4.3.1). There is a detectable but a very small amount of 
the wild type enzyme found on the surface which could be due to its weaker expression 
by the cells when compared to the expression level of the other TG2 mutants (HS1, HS2, 
GTP2, C). As shown in Fig. 4.3.1 the HS1 mutant (K600A, R601A, K602A) which still bound 
to heparin (see chapter 3 section 3.3.13) appears to be present at the cell surface of 
HEK293T cells in a much greater amount in comparison to the HS2 mutant K205A, R209A 
(the novel heparan sulfate binding site on the TG2 molecule) even though both of these 
mutant proteins are similarly, expressed by cells.  Additionally both of the GTP defective 
binding site mutants (GTP1 and GTP2) the FN1 mutant which is characterised by reduced 
affinity to FN and the C-terminal deletion mutant (Δ594-687TG2) are found in a greater 
amount on the plasma membrane. However when the visible differences in their 
expression level is taken into account the data suggests the lack of importance of each of 
these mutated or deleted TG2 regions in the localisation of TG2 at the cell surface.  
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Figure 4.3.1 Detection of cell surface TG2 antigen in HEK293/T17 cells transfected with 
wild type TG2 and TG2 mutants via biotinylation. HEK293/T17 cells were transiently 
transfected with the wild type enzyme and TG2 mutant constructs then cell surface 
proteins labelled with sulfo-NHS-LC-biotin (Sigma-Aldrich, UK), further lysed with 1% SDS 
(w/v) in PBS pH 8.0 as described under 2.2.10.1 section in the Materials and Methods 
chapter. After denaturation in gel loading buffer and discarding of the membrane and 
cellular debris, by centrifugation, 200μg of proteins calculated per each sample were 
incubated overnight with NeutrAvidin-Agarose resins (Thermo-Fisher Scientific, UK). In 
addition to determining the cell surface presence also the expression level of the wt TG2 
as well as each of the particular mutant TG proteins present in the whole cell lysate (WCL) 
was measured. A Proteins were separated by SDS-PAGE electrophoresis using equal 
protein loadings and the TG2 antigen bound to the resin was detected by Western 
blotting using anti-TG2 antibody (CUB 7402) followed by the incubation with secondary 
anti-mouse IgG conjugate as described under Materials and Methods (2.2.4 and 2.2.5). B 
Densitometry of the TG2 bands representing the expression level of TG2 as well as TG2 
mutants in a whole cell lysate were normalised to the equal loading marker α-tubulin and 
measured using the ImageJ analysis software. Likewise cell surface levels of TG2 and TG2 
constructs were normalised to the relative expression levels which was calculated from 
the densitometric analysis of Western blots.  
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The fact that the N-terminal product is not detectable at the cell surface but is present in 
the whole cell lysate suggests that the first 15 residues of the N-terminus of the enzyme 
are very important for its distribution to the cell surface (Fig. 4.3.1). Due to negligible 
amounts of endogenous TG2 in the vector transfected HEK293T cells the enzyme could 
not be found either at the cell surface or in the cell lysate. 
 
4.3.2 Cellular localisation of the wild type TG2 and TG2 mutants in NIH3T3 cells 
 
To investigate the cell surface distribution of TG2 and TG2 mutants in NIH3T3 cells, 
transfected cells were labelled with sulfo-NHS-LC-Biotin and isolated by extraction and 
binding to NeutrAvidin-coated beads as described before in the Materials and Methods 
(2.2.10.1) and the amount of TG2 antigen was detected using SDS-PAGE followed by 
Western blotting. Performed analysis showed that the wild type enzyme can be found on 
the cell surface of NIH3T3 cells in a greater amount when compared to the HS2, GTP1 and 
N-terminal mutant and smaller amounts when compared to HS1 (K600A, R601A, K602A), 
GTP2 (K173L), FN1(D94A, D97A) and C-terminal mutant (Δ594-687TG2). Mutants that 
could be found in greater amounts on the cell membrane when normalised to that found 
in the cell lysate included the HS1, GTP2, FN1 and C-terminal deletion products (Fig.4.3.2). 
All these mutants were expressed at the similar level by cells when compared to the wild 
type as determined by densitometry analysis. Additionally the expression level of the HS2 
(K205A, R209A) mutant was similar to the previously described mutations however its 
distribution level at the cell surface was remarkably smaller strongly suggesting that 
heparan sulfate proteoglycans are involved in the translocation of the enzyme to the cell 
surface as proposed by (Verderio et al., 2009; Scarpellini et al., 2009). On the other hand, 
the N-terminal mutant (Δ1-15TG2) could not be found at the cell surface, which stays in 
agreement with the previous result (Fig. 4.3.1) however the fact that the GTP1 (S171E) 
mutant is almost undetectable on the  cell surface of NIH3T3 cells, contradicts the result 
obtained with the HEK293T cells.  
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Figure. 4.3.2 Localisation of wt TG2 and TG2 mutants at the cell surface of NIH 3T3 cells. 
The presence of the wild type enzyme and TG2 mutants at the cell surface of fibroblasts 
was determined via cell surface biotinylation. After 48 hours post-transfection, 
transfected NIH 3T3 cells were biotinylated with sulfo-NHS-LC-biotin (Sigma-Aldrich, UK) 
in order to label the cell surface proteins. NIH3T3 cells were then lysed with 1% SDS (w/v) 
and after centrifugation at 14 000g for 20min 200μg of proteins were measured from the 
clarified sample and incubated with NeutrAvidin-Agarose resin (Thermo-Fisher Scientific, 
UK). A Affinity bound proteins  were  separated by SDS-PAGE electrophoresis and the 
amount of TGase in each sample was determined by Western blotting using monoclonal 
anti-TG2 antibody (CUB7402) followed by the incubation with secondary antibody 
conjugated with HRP and revealed by ECL detection system as stated in the  Materials and 
Methods (2.2.4 and 2.2.5). B The expression of total TG2 (WCL) in cell lysates was 
evaluated by Western blotting and compared to the equal loading marker α-tubulin 
(Sigma-Aldrich, UK). The net area value for TG2 bands were normalised against tubulin 
after measurement by densitometry analysis using ImageJ analysis software. The cell 
surface level of wild type and mutant TG2 was then normalised to the relative expression 
levels of wild type and mutant TG2 in the cell lysates, respectively after densitometric 
analysis of Western blots. 
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Likewise HEK293T cells as are NIH3T3 cells are characterised by very low levels of 
endogenous TG2 thus no TG2 band could be found at the cell surface or in the cytosolic 
fraction of untransfected or transfected only with the empty vector pcDNA3.1/CT-GFP 
cells. 
 
4.3.3 Effects of TG2 derived mutants on TG2 transamidating activity in cell lysates of 
transfected HEK293T cells and NIH3T3 cells 
 
To investigate whether the different mutations of TG2 influences its cell surface 
transamidating activity, two cell types including HEK293T cells and NIH3T3 cells were 
chosen as cell models. TG2 intracellular activity was measured in a total cell lysate 
assaying 50-60μg of protein as described under Methods (4.2.6).  The activity of all 
mutants was compared to the wild type TG2, which under the test conditions was used as 
a positive control. Under these conditions, four of the total number of seven TG2 mutants 
showed a decrease in the TG2 activity (change in absorbance over time per 50-60μg of 
cell lysate protein added) in respect to the wild type in both HEK293T and NIH3T3 cell 
lines. As shown in Figure 4.3.3 A, C both the GTP defective binding site forms (S171E and 
K173L) and the TG2 deletion product (Δ1-15TG2) demonstrated a significant reduction in 
the cell lysate activity in comparison to the wild type. This result together with another 
representing specific activity (TG2 activity per TG2 antigen obtained from Western blots) 
of the mutants (Fig. 4.3.3 B, D) indicates that GTP as well as the first 15 amino acids of the 
N-terminal domain of TG2 is important to the transamidating activity of the enzyme. 
Although the  C-terminal deletion mutant (Δ594-687TG2) showed a significant decrease in 
the cell lysate activity in the HEK293T cells (specific activity low), it did not lead to a 
significant decrease in the TG2 activity in the cell lysate of NIH3T3 cells (specific activity 
comparable to wild type TG2) (Fig. 4.3.3 A, B, C, D, respectively). On the other hand, HS1 
(K600A, R601A, K602A), HS2 (K205, R209A) and FN1 (D94A, D97A) mutants showed 
elevated or similar level of activity when compared to the wild type which again was 
observed to be a cell dependent process. These findings indicate that the HSPGs binding 
mutations and the FN binding site mutation site are presumably not implicated in the 
activity of the enzyme.   
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Figure 4.3.3 A, B, C, D Activity of wild type TG2 and TG2 mutants in cell lysate of 
transfected HEK293/T17 cells and NIH3T3 cells. TG2 activity of the wild type enzyme and 
TG2 constructs expressed by A HEK293/T17 cells and C NIH3T3 fibroblasts was analysed 
by biotin-X-cadaverine incorporation into the FN. Transfected with TG2 and TGase 
mutants (HS1, HS2, GTP1, GTP2, FN1, N, and C) cells were lysed as described under 
Materials and Methods (2.2.3.6) and 50-60μg of proteins from cell extracts (WCL) were 
resuspended in a 50mM Tris-Cl, pH 7.4 buffer containing additionally 5mM CaCl2, 10mM 
DTT, and 0.132mM biotin-X-cadaverine on wells of FN coated plate. Incorporated biotin-
X-cadaverine into FN was analysed spectrophotometrically at 490nm using extravidin-
peroxidase. Obtained values are shown as means +/-SD from the three independent 
experiments. The net values of wild type TG2 activity was used as a standard to 
determine the significant difference (* p < 0.05 and • p < 0.001) between the activity of 
wild type enzyme and all TG2 mutants. B, D The specific activity of the wt and TG2 
mutants was assayed by normalisation of cell lysate activity to the normalised cell lysate 
antigen using ImageJ analysis software.  
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4.3.4 Measurement of TG2 derived mutants on TG2 cell surface activity in transfected 
HEK293T and NIH3T3 cells 
 
Knowing that some of the TG2 mutants affect TG2 activity found in the cell lysate it was 
of further interest to examine their influence on the extracellular activity of the enzyme 
using the same epithelial and fibroblast cell models. The activity of cell surface TG2 was 
measured using FN coated plates as stated under Methods (4.2.5) according to the 
previously described method (Jones et. al., 1997). The first part of the experiment (Fig 
4.3.4 A) was performed on HEK293T cells that were transfected with the whole set of 
mutants together with the wild type TG2 as a reaction control. A significantly lower level 
of TG2 transamidating activity was noticed at the cell surface of HEK293T cells which 
expressed GTP defective binding site mutants (GTP1 and GTP2) as well as both N- and C-
terminal deletion mutants (Δ1-15 and Δ594-687) (Fig. 4.3.4 A). In addition when the cell 
surface activity was normalised to that of cell lysate (result not shown), the activity of GTP 
mutants was found to correlate to the mutant activity in the cytosol (less surface activity 
because of smaller amount of activity of mutants in the cytosol). This however was not 
the case for the  N-terminal mutant cell surface activity indicating that its reduced cell 
surface activity may be somehow associated with the smaller amount of protein on cell 
surface. These findings suggest the first 15 amino acids from the N-terminal domain of 
TG2 and the GTP binding mutants are affecting TG2 presentation on the cell surface with 
respect to activity.  
 The level of cell surface TG2 activity when compared to that found in the cell lysate 
was however found to be similar in wild type TG2 and HS1 (K600A, R601A, K602A), HS2 
(K205A, R209A) as well as FN1 (D94A, D97A) mutants. These results indicate that these 
mutations are not able to influence extracellular TG2 activity. Likewise NIH3T3 cells 
transfected with all TG2 mutants (Fig. 4.3.4 B) showed a very similar pattern of TG2 cell 
surface transamidating activity. The only difference refers to the cell surface activity of 
the C-terminal mutant which in NIH3T3 cells showed comparable surface activity to wild 
type TG2, suggesting that the C-terminal domain does not affect the extracellular activity 
of the enzyme in this cell type. 
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Figure. 4.3.4 A, B Measurement of wt TG2 as well as TG2 mutant activity on the cell 
surface by biotin-X-cadaverine incorporation into the FN. A, B Briefly after 48 hours 
post-transfection transfected with wild type enzyme and TGase mutants (HS1, HS2, GTP1, 
GTP2, FN1, N, and C) cells (both HEK293/T17 cells and NIH3T3 cells) at a concentration of 
1x105 cells/ml were resuspended in DMEM only containing 0.132mM biotin-X-cadaverine, 
10mMDTT and seeded into the wells of 96-well plate coated with 5μg/ml FN for 2 hours 
at 37°C. The incorporated biotin-X-cadaverine into FN was determined 
spectrophotoemtrically at 490nm after removal of cells using extravidin-peroxidase as 
described under Methods (4.2.5). TG2 activity is presented as mean values +/- SD of three 
separate experiments. Net values obtained for wild type TG2 were used as control values 
in order to assess significantly different TG2 activity (* p < 0.05 and • p < 0.001) of the 
TG2 mutants.   
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4.3.5 Measurement of the TG2 derived mutants binding affinity to Fibronectin  
 
As previously established (Lorand et al., 1988; LeMosey et al., 1992), TG2 when 
externalised to the ECM was shown to have a high affinity for FN which as further 
reported is independent on the transamidating activity of the enzyme. Therefore to 
estimate the recognition of FN by all TG2 mutants, the ELISA assay was applied. The level 
of binding affinity was compared between all generated mutants (HS1, HS2, GTP1, GTP2, 
FN1, N, and C) and the wild type TG2 using the same amount of protein (60μg of protein 
lysate) obtained from HEK293T cell homogenates as described under general Materials 
and Methods (2.2.6.2) and then normalised to the relative expression level of mutant TG2 
in the cell lysates (result not shown). The ELISA assay shown in Figure 4.3.5 revealed  
remarkable differences in the TG2 antigen level bound to FN especially in relation to FN1 
(D94A, D97A) and N-terminal (Δ1-15TG2) mutants. The statistically significant reduction in 
binding affinity to FN of both of these mutations was expected since they have already 
been characterised in Chapter 3 (Fig.3.14) and one of these mutations has been 
previously described to be important for FN-TG2 interaction (Hang et al., 2005). Likewise, 
FN1 mutant was shown to abolish around 50% binding while the N-terminal mutant 
around 70% of TG2 binding to FN indicating once more that both of these TG2 regions are 
important in its interaction with FN. The C-terminal mutant also showed a reduction in its 
binding strength to FN; however when compared to the mutant expression level, it was 
not significant enough to speculate any involvement of the C-terminal domain on the 
TG2-FN interaction. In contrast, both GTP binding defective forms GTP1 (S171E) and GTP2 
(K173L) but not heparan sulfate binding site mutants HS1 (K600A, R6001A, K602A), and 
HS2 (K205A, R209A) demonstrated a significant increase in affinity for FN suggesting 
influence of any of these mutated TG2 regions on the complex formation between the 
enzyme and extracellularly present FN (Fig. 4.3.5B). 
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Figure 4.3.5 Measurement of wt TG2 and TG2 mutant binding affinity for FN. A Cell 
homogenates containing 50-60μg of proteins obtained from untransfected as well 
transfected with TG2 and TG2 mutants HEK 293/T17 cells were immobilised on a plate 
coated with 5μg/ml FN as described under Materials and Methods (2.2.6.2). After 1 hour 
incubation at 37°C, the amount of enzyme bound to FN was evaluated using anti-TG2 
antibody (CUB7402) followed by HRP-conjugated anti-mouse IgG antibody and further 
determined by spectrophotometry analysis at 490nm as detailed under Materials and 
Methods (2.2.6.2). B  The expression of total TG2 in cell lysates was evaluated by Western 
blotting and compared to the equal loading marker α-tubulin by densitometry analysis 
(result not shown). The binding strength to FN of wild type and mutant TG2 was then 
normalised to the relative expression levels of wild type and mutant TG2 in the cell 
lysates, respectively after densitometric analysis of blots. The results are presented as a 
mean value +/- SD of three separate experiments. The mean value for wild type TG2 was 
established as a standard for determining the significant difference (* p < 0.05 and • p < 
0.001) of values represented by TG2 mutants. 
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4.3.6 Distribution of TG2 mutants in the extracellular matrix 
 
The effect of TG2 mutants on the deposition of the enzyme into to the ECM was 
measured by a Western blot analysis. Knowing that HEK293T cells do not lay down large 
amounts of ECM, NIH3T3 were chosen as an initial cell model for this particular 
experiment. Transfected with the wild type TG2 and all the TG2 mutants, cells were 
incubated for 24 hours in DMEM containing 10% (v/v) serum and then serum starved for 
another 48 hours in order to detect of ECM associated TG2. The presence of TG2 antigen 
in the ECM of NIH3T3 cells was compared to that found in the whole cell lysate (WCL). In 
Figure 4.3.6 it is shown that every mutation affected TG2 deposition in a different way. 
There is a detectable however not particularly large amount of deposited TG2 antigen in 
the ECM by the wild type enzyme. In contrast there is a noticeably much greater amount 
of the antigen deposition compared to the wild type TG2 in the HS1 (K600A, R6001, 
K602), GTP1 (S171E), GTP2 (K173L) and FN1 (D94A, D97A) mutants indicating that none of 
these TG2 regions play an important role in the distribution of the enzyme into the ECM. 
In addition the C-terminal mutant (Δ594-687TG2) which could be found in similar 
amounts in the ECM to the wild type is also considered to be insignificant in that process. 
However as further shown in Figure 4.3.6 TGase deposition into the ECM was altered 
by the two mutants, the HS2 mutant (K205A, R209A) which happens to represent a novel 
HSPGs binding site on the TG2 molecule and the N-terminal deletion product (Δ1-15TG2) 
that lacks the first 15 amino acids from the first TG2 domain. Both of these mutations 
were shown to inhibit the deposition of TG2 antigen into the matrix indicating the 
importance of HSPGs as well as the presence of an intact N-terminal FN binding site in the 
distribution of the enzyme into the matrix. 
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Figure 4.3.6 Effect of TG2 mutations on the distribution of the enzyme into the 
extracellular matrix (ECM). NIH3T3 cells were transiently transfected with wild type TG2 
and TG2 mutants using DMEM supplemented with 10% (v/v) serum which after 24 hours 
post-transfection was replaced with 1% (v/v) serum. The incubation was allowed to 
proceed for another 48hours and afterwards transfected cells were detached leaving the 
deposited  matrix which was further washed with 0.1% (w/v) deoxycholate in PBS, pH 7.4 
to remove of all remaining soluble fractions (Materials and Methods 2.2.10.2). After 
denaturation, insoluble ECM fractions were separated by SDS-PAGE electrophoresis using 
8% resolving gels and the presence of TG2 antigen in the ECM was detected by Western 
blot using anti-TG2 antibody CUB 7402 as described under Materials and Methods (2.2.4 
and 2.2.5). In addition the expression level of the wild type TG2 and TG2 mutants present 
in cell lysates was determined using the same Western blot method as described above. 
The TG2 bands showed on the blot were further normalised to α-tubulin as a marker of 
equal protein loading using ImageJ analysis software. In addition the level of TG2 in the 
ECM was normalised to the relative expression levels of TG2 found in the cell lysates. The 
blots represent one standard experiment.   
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4.3.7 Detection of the TG2, HS2 mutant and N-terminal deletion product in the cell 
growth medium 
 
In the previous experiment two different TG2 mutants (HS2 and N-) have been shown 
to impair the distribution of the enzyme into the ECM. Since the wild type TG2 secreted 
from NIH3T3 cells transfected with HS2 (K205, R209A) and N-terminal (Δ 1-15TG2) is not 
deposited into the ECM it may localise in the cell culture medium. Hence it was of most 
importance to investigate the presence of these two particular mutants in medium of 
NIH3T3 cells. So far this method has been shown difficult to apply (Gaudry et al., 1999a) 
however as described in the later publications (Balklava et al., 2002) not impossible.  To 
minimize the possibility of TG2 interaction with FN which is known to be present in serum 
and to obviate the problems caused by the large amount of albumin in the SDS gels , after 
24 hours post-transfection for which 10% (v/v) serum was required, cells were further 
incubated for another 48 hours in medium containing 1% (v/v) serum. After that the 
medium was collected, proteins were precipitated with TCA and the presence of TG2 
antigen was detected by SDS-PAGE followed by Western blotting as described under 
Materials and Methods (2.2.4 and 2.2.5). Additionally to control the test conditions, 1ng 
of recombinant human TG2 (Zedira, Germany) was applied into to the medium collected 
from untransfected cells and after precipitation with TCA, the presence of purified TG2 
was then analysed by Western blotting.  
As shown in Figure 4.3.7, the positive control, represented by purified recombinant 
human TG2 showed a very strong band indicating that the method is efficient enough to 
detect TGase antigen present in the growth medium of NIH3T3 cells. Further analysis 
allowed detection of two weak bands indicating the presence of TG2 antigen in the 
medium of the NIH3T3 cells transfected with HS2 and N-terminal mutants. In contrast 
TG2 band could not be detected in the medium of cells transfected with the wild type 
enzyme as well as in the medium of untransfected cells which were used as a negative 
control. This could result from the fact that TG2 shows high affinity for ECM proteins, 
especially to associated with cell surface FN (Upchurch et al., 1991) which when bound to 
the enzyme could retain it at the cell surface and in the matrix further prevent its release 
into the cell growth medium. 
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Figure 4.3.7 Detection of wild type TG2, HS2 (K205A, R209A) mutant and N-terminal 
deletion product (∆1-15TG2) in the medium of cultured NIH3T3 cells. The Western blot 
result shows the presence of wt TG2 and TG2 mutants (HS2 and N) in a DMEM 
supplemented with 1% (v/v) serum following 72 hours incubation and  compared  to 1ng 
of human recombinant rhTG2 (Zedira, Germany) added to the wt cells  a positive control 
as seen in (Methods section  4.2.3). The presence of protein was determined after 
precipitation with 10% (w/v) TCA and analysed by SDS-PAGE and western blotting using 
monoclonal antibody (CUB 7402) directed against TG2 antigen as stated in the Materials 
and Methods (2.2.4 and 2.2.5). Additionally the expression of total TG2 in cell lysates was 
estimated using Western blot analysis and then normalised against tubulin.  
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4.3.8 Detection of TG2 bound to the two amino terminal fragments of FN and full length 
of FN 
In order to assess the optimum concentration of TG2 bound to FN, a solid binding 
assay was applied. The assay was based on using increasing concentration of recombinant 
human TG2 (rhTG2) (1μg/ml, 2.5μg/ml, 5μg/ml, 10μg/ml, 15μg/ml, 20μg/ml, 30μg/ml) on 
a high binding plate coated with 45kDa (54μg/ml), 70kDa (45μg/ml) and full length 
(5μg/ml) of FN as described under Methods section (4.2.7) (Verderio et al., 2003).  
As shown in Fig 4.3.8, the full length from human plasma showed the highest affinity 
for rhTG2, with the net values not greatly higher when compared to the 45 kDa and 70 
kDa amino terminal fragments of FN. The 70 kDa and 45 kDa FN fragments revealed no 
significant difference in binding strength when increasing concentrations of rhTG2 were 
applied even though the 70kDa fragment bound TG2 with a higher affinity in comparison 
to the 45 kDa FN fragment FN. 
The ELISA revealed that the saturation level of TG2 bound FN was estimated to be 
10μg/ml for full length FN , 15μg/ml for 45 kDa FN fragment and 20μg/ml for 70kDa FN 
fragment, respectively. 
 
4.3.9 Localisation of P4 (2AEELVLERCDLELE15) and P5 (88WTATVVDQQDCTLSLQLTT106) 
peptides on the TG2 molecule 
 
The NΔ1-15 and D94A, D97A mutants were assessed for their ability to bind to 
fibronectin in a solid phase binding assay utilising purified FN and transfected HEK293T 
cell lysates as detailed previously in Chapter 4 (Fig. 4.3.5). Both of the mutations were 
shown to reduce binding of the enzyme to FN compared to wild type TG2. Thus it was of 
importance to generate two peptides that will correspond to the deleted or mutated FN 
binding site on the TG2 molecule. As shown in Figure 4.3.9, the first peptide was 
generated at the N-terminus of TG2 (2AEELVLERCDLELE15) while the second peptide was 
found to be present in distinct part of the same domain (88WTATVVDQQDCTLSLQLTT106) 
as previously described by (Hang et. al., 2005).  
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Figure 4.3.8 ELISA detection of the relative amounts of recombinant human TG2 bound 
to the full length and two amino terminal fragments of FN (45kDa, 70kDa). The relative 
levels of human recombinant TG2 (rhTG2) (1μg/ml-30μg/ml) bound to the three different 
fragments of immobilised FN was determined using monoclonal anti-TG2 antibody CUB 
(7402) as stated in Methods (4.2.7). Data are expressed as mean +/-SDS absorbance at 
490nm and was taken from three separate experiments, each performed in triplicate. The 
*, ₀, and ◊ represent the statistical difference (p < 0.05) for the increasing levels of TG2 
when compared to the background (PBS + 2mMEDTA) level. 
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Figure 4.3.9 Illustration of 3D fragment of TG2 structure pointing out possible FN 
binding sites with corresponding peptides localised on TG2 molecule kindly provided by 
Dr Russell Collighan from Aston University. 
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4.3.10 The involvement of the N-terminus of TG2 in its interaction with FN 
 
Competitive peptides were synthesised corresponding to both mutations i.e. 
88WTATVVDQQDCTLSLQLTT106 (P5) for D94A, D97A FN binding site according to Hang 
et.al., (2005)  and 2AEELVLERCDLELE15 (P4) for Δ1-15 TG2 which undergoes N terminal 
post-translational modification of the N-terminal methionine (Gaudry et. al., 1999) and 
further tested for their ability to inhibit wild type TG2 binding to FN in the same assay. 
The solid binding assay was based on using three different types of FN, including its two 
amino terminal fragments (45kDa and 70kDa) and full length of protein. Initially, P4 
peptide, it’s negative control, scrambled peptide (P4s) and P5 peptide were added to the 
wells at increasing concentrations (10μM – 1mM) and pre-incubated on a FN coated 
plate, before immobilisation of TG2 which has been initiated as described under Methods 
(4.3.8). Interestingly, as shown in Figure 4.3.10 C peptide P5 when used in a test to check 
if it will compete for TG2 (assuming 100% binding of TG2 to the FN) did not cause any 
alteration of TG2 binding to FN, whereas peptide P4 resulted in a moderate inhibition of 
binding at the higher concentrations of the peptide (Figure 4.3.10A). This suggested that 
the N-terminal residues 1-15 of TG2 are important for FN binding, in addition to D94A, 
D97A. However, only the peptide directed against residues 1-15 was capable of inhibiting 
TG2 binding to FN, suggesting that a larger structural unit may be involved in FN binding. 
As expected no inhibition was noticed when P4s peptide the negative control for P4 
peptide was used (Figure 4.3.10B). 
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Figure 4.3.10 Effect of soluble FN binding site peptides (P4 and P5) on TG2 interaction 
with FN.  Interaction of A P4 peptide (2AEELVLERCDLELE15), B P4s peptide 
(EECRLAEELLEDVL) C P5 peptide (88WTATVVDQQDCTLSLQLTT106) with the two fragments 
(45kDa and 70kDa) and full length FN. The interaction between TG2 derived peptides and 
FN was tested by a solid phase binding assay using increasing concentrations of the 3 
different peptides (10μM, 100μM, 250μM, 500μM, 750μM, 1mM) pre-incubated on a TCP 
plated coated with three different types of FN as described under Methods (4.2.8) The 
presence of TG2 bound antigen was further developed by incubation with anti-TG2 CUB 
7402 monoclonal antibody, followed by secondary antibody as described under Methods 
(4.2.8) and colour development measured spectrophotometrically at 490nm. Each data 
represent the mean values +/- SD from three different experiments each performed in 
triplicate. The statistically significant differences of net values are shown as *, and • and 
calculated by means of student-t test when p< 0.05 and p < 0.001, respectively and 
compared to that of the wild type TG2 as the control.  
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4.4 DISCUSSION 
 
Although tissue type transglutaminase (TG2) lacks the signal peptide, indirect evidence 
regarding its externalisation into the ECM and its association with the cell surface of 
different cells has been provided by many researchers (Martinez et al., 1994; Jones et al., 
1997; Verderio et al., 1998; Gaudry et al., 1999a, b; Akimov and Belkin, 2001; Verderio et 
al., 2009; Scarpellini et al., 2009). Once released TG2 has been shown to further co-
localise at the cells plasma membrane with fibronectin, however its functions has also 
been implicated in interaction with other transmembrane receptors (integrins or HSPGs) 
which like FN have been reported to be high affinity binding partners for the enzyme 
(Lorand et al., 1988; Gaudry et al., 1999a, b; Akimov and Belkin, 2001; Telci et al., 2008; 
Verderio et al., 2009; Scarpellini et al., 2009). Despite available data indicating its broad 
occurrence in the extracellular environment of tissues (Upchurch et al., 1991; 
Aeschlimann and Paulson, 1991; Schittny et al., 1997; Johnson et al., 1999) and its 
deposition by different cells (Martinez et al., 1994; Verderio et al., 1999; Lorand and 
Graham 2003) limited knowledge has been presented regarding the exact fate of TG2 
externalisation as well as the involvement of its binding partners in that process with very 
little mention of the mechanism of its externalisation although the mechanism for its 
endocytosis has been suggested by Zemskov et al., (2007) to be likely involved in the 
regulation of the turnover of extracellular TG2. The present literature suggests that cells 
surface TG2 forms direct complexes with integrins and HS chains of HSPGs (Gaudry et al., 
1999b; Akimov et al., 2000; Scarpellini et al., 2009) which may not be mediated by cell 
surface FN. However when localised in the extracellular environment TG2 non-covalently 
interacts with FN (Turner and Lorand, 1989) which targets the enzyme to the ECM 
compartments. Based on these findings investigations were undertaken to explore the 
influence of TG2 high affinity binding partners on the presence of the enzyme at the cell 
surface and its deposition into the ECM. The importance of the conformational state of 
TG2 for its translocation and further targeting into the ECM has also been investigated 
(Balklava et al., 2002). Since some proteins (FGF-2) that undergo unconventional 
secretion pathway have been suggested to be secreted in a folded state it was of 
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importance to assess how GTP- defective binding sites mutants GTP1 (S171E) and GTP2 
(K173L) of which one (GTP1), is known to lock TG2 in an extended form, affects the 
extracellular  distribution of the enzyme. Since previous discoveries indicated that the 
extracellular Ca2+ bound TG2 is in an open conformation and a recent publication 
showed that the closed GTP-bound form (Johnson and Terkeltaub, 2005) may also be 
found in the ECM it was of interest to find out what conformational state the enzyme 
adopts when present outside the cell which is known from its low-GTP and high calcium 
concentration.  
To be able to gain a more in depth view on the subject a human cell model 
(HEK293/T17cells) and mouse cell model (NIH3T3 cells) were applied in the experimental 
system as previously described. The initial experiment undertaken was to determine the 
cell surface localisation of the wild type TG2 and TG2 constructs (HS1, HS2, GTP1, GTP2, 
FN1, N-, C-) by cell surface biotinylation using sulfo-NHS-LC-biotin which in principle 
allows it to bind and biotinylate only proteins present at the plasma membrane without 
affecting the intracellular ones. Cell surface biotinylation of transiently transfected 
HEK293/T17 and NIH3T3 cells showed some discrepancy in the pattern of TG2 cell surface 
expression (Fig. 4.3.1 and Fig. 4.3.2). Of the two TG2 mutants generated at distinct  
possible heparan sulfate binding sites the one found to be the novel HSPGs binding site 
HS2 (K205A, R209A) mutant, did not appear to greatly impair the association of the 
enzyme with the surface of HEK293 cells. However because of its noticeably smaller 
amount on the cell surface of NIH3T3 it strongly suggested the involvement of HSPGs in 
trafficking of the enzyme to the cell surface in a cell dependent mechanism. This might be 
the case since the only available studies regarding TG2 – HSPGs interaction, identified 
syndecan-4 as one of the HSPGs transmembrane receptors of HSPGs as a fundamental 
binding partner for cell surface binding and translocation at the cell surface (Scarpellini et 
al., 2009; Telci et al., 2008). The cell-surface association of the enzyme has also been 
shown to be unaffected by one of the FN binding site mutants of TG2 -FN1 (D94A, D97A) 
which suggests that FN is not involved in this process. However as shown by previous 
studies, FN may interact with TG2 possibly at two distinct sites located within the N-
terminal domain of the enzyme (Jeong et al., 1995; Gaudry et al., 1999a; Hang et al., 
2005) thus its involvement on TG2 localisation to the cell membrane cannot be ruled out 
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categorically. In fact it was confirmed by the N-terminal deletion product (Δ1-15TG2) 
which completely abolished cell surface TG2 indicating that the intact N-terminus of TG2 
is required for the cell surface TG2-FN co-localisation (Fig 4.3.5) (Gaudry et al., 1999a). No 
effect on the localisation of the enzyme at the cell surface was shown by C-terminal 
mutation indicating that the C-terminal domain is not important in this process. However, 
a recent publication suggesting that integrin binding sites are located in the N-terminal 
domain rather than C-terminal domain (Hang et. al., 2005) does not rule out their 
involvement in TG2 secretion and matrix localisation. Furthermore the fact that GTP1 
mutant (S171E) (open conformation) was found on the cell surface of NIH3T3 cells in 
much smaller amounts whereas the GTP2 mutant (K173L) (uncharacterised conformation) 
was secreted in much larger amounts in a both cell types suggests that externalisation of 
the enzyme is also dependent on its conformation rather than GTP-binding.  
A series of studies have revealed that TG2 possesses transamidation activity which is 
important for the cross-linking of many ECM proteins. This enzymatic, calcium dependent 
activity of the enzyme however was shown not to be required for its interaction with FN, 
integrins, and syndecans when mediating the cell-matrix interactions (Lorand et al., 1988; 
LeMosey et al., 1992; Akimov et al., 2000; Telci et al., 2008; Collighan and Griffin, 2009). 
To investigate the role of HSPGs, FN, integrins as well as GTP on the cell surface cross-
linking activity of TG2 in living cells and further in the cell lysates a well known assay 
based on biotin-X-cadaverine incorporation into FN was applied (Jones et al., 1997; 
Balklava et al., 2002). In this study we showed that the effect of some mutations e.g.  HS1 
(K600A, R601A, K602A), HS2 (K205A, R209A), FN1 (D94A, D97A) did not reduce TG2 
activity within the cellular compartment or at the cell surface of both cell types. In 
contrast significantly lower activity was obtained in both GTP-defective binding mutants 
and the N-terminal mutant both at the cell surface and in the cell lysate suggesting the 
importance of these GTP binding sites and TG2 intact N-terminal tail for the extra- as well 
as intracellular activity of the enzyme. However the findings regarding the activity of the 
GTP mutants that lose their  GTP binding function is inconsistent with previous results 
(Ismaa et al., 2000) which indicated that impairment in GTP binding caused by 
substitution of glutamate in S171 and leucine with K173 did not affect TG2 activity. However 
these disagreements may be due to the fact that the authors were using purified proteins 
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whereas in this approach cell lysates were used from transiently transfected living cells. 
Moreover, visualisation of in situ activity of the enzyme in the absence of the novel 
heparan sulfate binding site (K205, R209A) and in one of the TG2 FN binding site (D94A, 
D97A) mutants indicated that the HSPGs and FN binding domains are presumably not 
implicated in determining TG2 cross-linking when associated with the cellular or 
membrane compartments. However the engagement of HSPGs cannot be left out 
completely since no experiments have been done to estimate the interaction strength 
between the HS2 mutant and the syndecan-4 molecule. In addition the discovered HSPGs 
binding site within the TG2 structure might be one of a few (as with FN) present on the 
TG2 molecule as previously suggested by Verderio et al., (2009) therefore may not be 
directly involved in TG2 syndecan-4 interactions and therefore able to influence TG2 
activity. Although a visible discrepancy between the TG2 cell-surface and cell lysate 
activity in both cultured cells was observed when the activity of the C-terminal mutant 
(Δ594-687TG2) was assayed, the influence of the C-terminal domain on the activity of the 
enzyme cannot be completely disqualified.  
Given that the different TG2 mutations can affect TG2 distribution in different ways at 
the cell surface as well as influencing its activity and being consistent with previous 
findings indicating that impairment in the TG2 active site and also the need for special 
conformation requirements can affect its localisation into the ECM, it was of interest to 
stimulate further investigation as to how every single mutation influences deposition of 
the enzyme into the ECM. Since TG2 has been suggested to localise into the ECM in 
complex with FN (Upchurch et al., 1991; Griffin et al., 2002) which was shown to be 
important in this process, all of the mutants were first analysed for their ability to bind FN 
(Fig 4.3.5). Only two of them FN1 (D94A, D97A) and the N-terminal (Δ1-15TG2) that has 
already been characterised as FN binding regions significantly reduce binding to FN. When 
verified for its interaction with FN, mutants were tested for their ability to localise into 
the ECM. In this particular experiment NIH3T3 fibroblasts were used since only these cells 
from both cell models were able to lay down ECM. No impairment in TG2 deposition was 
observed by HS1 (K600A, R601A, K602A), both the GTP-defective binding site mutants 
and the FN1 mutant indicated that neither GTP nor FN binding are required for that 
process. No alteration in the distribution of the C-terminal mutant could also be found 
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suggesting no involvement of the last TG2 domain in ECM deposition. The most significant 
change resulting in negligible levels of TG2 deposition were by the HS2 (K205A, R209A) 
and the N-terminal (Δ1-15TG2) mutants suggesting that HSPGs as well as the intact N-
terminal TG2 domain contributes to the distribution of the enzyme into the ECM. This 
novel discovery was further investigated by analysing the presence of these two 
particular mutants in the culture medium where they were both present in increased 
amounts when compared to the wild type enzyme. This finding stays in agreement with 
the hypothesis that HSPGs can act across all cells and binds associated cell surface ligands 
(as shown here for TG2) which further could contribute to the binding of these ligands by 
distinct ECM components thus for example being involved in increasing the local 
concentration of TG2 in the ECM (Bishop et al., 2007; Verderio et al., 2009). Additionally it 
throws light on the importance of the intact N-terminal FN binding site of TG2 that was 
previously shown by Gaudry et  al., (1999a) to be necessary for the TG2-FN interaction. 
To further explain the disagreement between the importance of the so far two 
described TG2 motifs responsible for its interaction with FN, two peptides were applied. 
In vitro binding studies have already located the putative high affinity binding sites for 
human TG2 at the N-terminus, gelatin binding site of FN (LeMosey et al., 1992; Radek et 
al., 1993). As shown by Verderio et al., (2003) the putative high affinity binding sites on 
FN including the 70kDa (heparin and gelatine binding site) and 45 kDa (gelatin binding 
site) can substitute for the full length FN. Hence it was decided to use these FN fragments 
in a FN binding ELISA system. The concentration of FN fragments was chosen according to 
Verderio et al., (2003). The immobilisation of the relative levels of rhTG2 showed a 
saturation point around 10-20 μg/ml of the enzyme dependently on length of the FN 
fragments. However because of the conditions of the experiment the saturation of the 
enzyme was not the most important issue. Sufficient interaction between TG2 and the FN 
fragments was seen with a concentration of rhTG2 of 2.5μg/ml which was selected for 
further investigation. 
The purpose was to determine whether any of synthetic peptides generated from the N-
terminal tail of TG2 (P4, P4s) or its β5/β6 hairpin (P5) affect the interaction between the 
enzyme and FN. The peptide P4, representing intact N-terminal site 2AEELVLERCDLELE15, 
but excluding its scrambled analogue was able to moderately inhibit the interaction of 
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TG2 with the different FN fragments indicating once more the importance of that N-
terminal fragment for their complexation. However no inhibition was noticed when P5 
peptide, 88WTATVVDQQDCTLSLQLTT106 was used in the same experimental system. In 
general this result could suggest the unimportance of that particular TG2 binding site for 
FN but this would be in disagreement with a previous finding (Hang et al., 2005). Despite 
that result, the final conclusion cannot be formed since the authors encountered 
unexpected resistant of synthesised P5 peptide for its dissolution in DMSO and further 
suggested hydrophilic solutions.  
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5.1 INTRODUCTION 
 
Cell phenotype is characterised by a multitude of events which may include 
communication with and composition of the extracellular matrix (ECM). So far much has 
been revealed about the organisation and assembly of this complex network through 
studying the interactions of matrix macromolecules with themselves and with distinct 
molecules that are present at the cell surface. Assembly is a difficult process that was 
shown through analysis of one of the most abundant ECM proteins fibronectin (FN) which 
requires the cooperation of extracellular and intracellular mediated signalling pathways. 
Once initiated the soluble dimers of FN are deposited into a dense fibrillar FN network 
which provides a dynamic environment for cell adhesion, migration, growth, survival and 
differentiation (Wierzbicka-Patynowski and Schwarzbauer, 2003). As previously indicated, 
under physiological conditions, FN assembly into the ECM takes place on the surface of 
particular cells in vitro (Mosher, 1993) and expands during pathological circumstances like 
wounding or commonly during tumorigenesis and fibrosis (Gailit and Clark, 1994). FN 
matrix assembly and the interaction of cells with pericellular FN do however require the 
presence of additional components. The main cell surface receptors that fibronectin binds 
to are integrins, mainly the α5β1 integrins. This interaction takes place through the  III8-
III10 modules present on FN, although the most important integrin binding site on FN has 
been mapped to the Arg-Gly-Asp (RGD) sequence that is localised within module III10 
(Mosher, 1984). FN however is not an exception, other extracellular proteins including 
fibrinogen, vitronectin, laminin, osteopontin, collagens also possess RGD recognition 
motifs (Rouslahti and Pierschbacher, 1987). Hence this particular sequence has been 
speculated to play an important role in regulating cell-matrix interactions which was 
further confirmed by many investigators. 
However integrin presence is not the only factor that is required for FN matrix 
assembly and the subsequent formation of focal cell adhesions. The role of heparan 
sulfate proteoglycans in cell adhesion on FN has been brought to attention by initial 
studies on two HSPGs mutant cell lines characterised by lack or impairment in HSPGs 
expression (Couchman et al., 1988; LeBaron et al., 1988). Also earlier data indicated the 
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importance of heparan sulfate activity in the formation of focal contacts by fibroblasts, 
which suggests that in addition to their role in cell adhesion HSPGs are also involved in 
cell spreading (Woods et al., 1986). This was further confirmed by studies on fibroblasts 
indicating that these cells were able to spread in the presence of fibronectin containing 
RGD motifs; however could not form well defined focal contacts in the absence of 
glycosaminoglycan (GAG) binding domains (Burridge et al., 1992). There are two main 
heparin-binding sites localised within the FN domain structure, the Hep I site situated at 
the N-terminal tail and the HepII binding site situated near the C-terminal tail of FN 
(Barkalow and Schwarzbauer, 1991; Lin et al., 2000). Although HepII was initially 
suggested to be the main heparin binding site, Lin and collaborators (2000) revealed the 
HepI played a crucial role in this interaction as well. However as later demonstrated, 
soluble heparin-binding peptides derived from the Hep II (WQPPRARI) were shown to 
significantly reduce the formation of focal adhesions on FN indicating the importance of 
this particular binding site in mediating cell-matrix adhesions (Chon et al., 2001).  
So far syndecans have been characterised as the major cell surface transmembrane 
proteoglycan possessing affinity for FN. Thus it is not surprising, that some of the family 
members have been implicated in the regulation of FN-matrix assembly and cell-matrix 
interactions (Woods et al., 1988).  There are four different receptors among the syndecan 
subfamily of HSPGs, from which two have been shown to affect matrix assembly. 
Syndecan-2 a major proteoglycan receptor of fibroblasts when expressed by stably 
transfected Chinese Hamster ovary (CHO) cells in a full length had no affect on matrix 
formation. However when expressed in a truncated state, lacking residues from the 
cytoplasmic tail, it was shown to negatively regulate assembly of FN and laminin matrices 
indicating its indirect role in this process (Klass et al., 2000). The other major proteoglycan 
receptor, Syndecan-4, widely distributed within different cell types that forms cell 
adhesions, has been shown to influence fibrillogenesis of FN in a more direct way. Studies 
on fibroblasts seeded on the cell-binding domain of FN (CBD), the one that comprises only 
RGD and the PHSRN binding motifs demonstrated that cells were able to attach however 
failed to form focal adhesions or actin stress fibres (Woods et al., 1986; Saoncella et al., 
1999). Only when treated with antibodies against the extracellular domain of syndecan-4 
did cells form mature focal adhesions and stress fibres thus indicating syndecan-4 as the 
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main HSPGs involved in the assembly process (Saoncella et al., 1999). Further analysis 
showed formation of focal adhesions and stress fibres is promoted by the cooperation of 
syndecan-4 with integrin α5β1 which has been shown to act via a Rho-dependent 
mechanism (Saoncella et al., 1999). In addition studies on syndecan- null fibroblasts when 
compared to wild type cells suggested syndecan-4 was able to increase phosphorylation 
of focal adhesion kinase FAK Tyr(397), a condition that has been shown to favour FN 
matrix assembly (Wilcox-Adelman et al., 2002; Telci et al., 2008). Further indication of 
Syndecan-4 in this process has also been associated with activation of protein kinase 
Calpha  (PKCalpha ) which was shown to localise with focal adhesions in fibroblasts (Barry 
and Crichtley, 1994). The activity of this kinase is persistently regulated (Keum et al., 
2004) in the downstream pathway directly influencing Rho kinases (RhoA) (Dovas et al., 
2006), which can mediate stress fibre formation and focal adhesion assembly through 
phosphorylation of myosin II and myosin phosphatase (Pellegrin and Mellor, 2007).  
Studies assaying the interaction of human osteoblasts with fibronectin revealed that 
both the RGD binding sequence and the heparin-binding domain of FN plays an important 
role in osteoblast attachment (Verderio et al., 1998; Verderio et al., 2000; Sim et al., 
2004). Additionally during cell binding, fibronectin has been shown to be a substrate and 
binding protein for different enzymes externalised from cells into the extracellular matrix. 
The ability of TG2 to co-localise with FN at the cell surface or pericellular matrix has been 
widely described (LeMosey et al., 1992; Gaudry et al., 1999a; Hang et al., 2005). The 
cross-linking activity of the enzyme has been believed to play a role in enhancing the 
attachment and spreading of various cell types (Chau et al., 2005). However TG2 has also 
been presented as a novel cell adhesion protein which does not require its transamidating 
activity to promote cell adhesion (Akimov et al., 2000). Association of the enzyme with 
fibronectin and its deposition in FN-complex into the ECM was found to be greater during 
wounding (Telci et al., 2006). Therefore it is not surprising that many investigators 
decided to explore the effect of FN-bound TG2 matrix on mediating cell adhesion. Early 
data on HOB cells and Swiss 3T3 fibroblasts indicated that TG2 binds to FN with high 
affinity and when bound promotes RGD-independent cell adhesion (Verderio et al., 2000; 
Verderio et al., 2003). However further suggestions of the possible influence of heparan 
sulfate proteoglycans on FN-TG2 mediated cell adhesion resulted from applying 
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glycosaminoglycan-degrading enzymes into the experimental system (heparinase and its 
control chondroitinase) which demonstrated that only heparinase that digest cell surface 
heparan sulfate was able to significantly reduce RGD-independent cell adhesion on a FN-
TG2 matrix indicating the importance of HSPGs (Verderio et al., 2003). Among members 
of the HSPGs family, syndecan-4 has been suggested to be involved in TG2 mediated cell 
adhesion. Thus it was not surprising when Telci et al., 2008 revealed that the binding of 
the TG2-FN complex to the chains of syndecan-4 promotes RGD-independent cell 
adhesion.  
However TG2 is not an exception with respect to its high affinity for HSPGs. As stated 
before, fibronectin possesses two heparin binding sites which could compete with TG2 for 
binding to HSPGs. As reviewed by Verderio et al., (2009) even treatment with a peptide 
that impairs immobilisation of TG2 on FN (Hang et al., 2005) did not reduce the amount of 
TG2 in syndecan-4 immunoprecipitates thus indicating a direct interaction between TG2 
and S4. Knowing that TG2 interacts directly with syndecan-4, and this interaction need 
not require the presence of FN it was of most importance to investigate how TG2 binds to 
HSPGs and how this affects the influence of the enzyme on cell adhesion. Therefore the 
work contained in this particular chapter was focused on looking at the effects on cell 
adhesion of different peptides where the amino acid residues were mapped to the newly 
found potential heparin binding site of TG2. This included a long peptide P1 
(NPKFLKNAGRDCSRRSS) and two short peptides: P2 (NPKFLKNA) and P3 (GRDCSRRSS) 
which were used in the experimental cell model using HOB cells (Verderio et al., 2000; 
Heath et al., 2001; Verderio et al., 2003 ). 
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5.2 METHODS 
 
5.2.1 Docking studies 
The crystal structures 1KV3 and 2Q3Z were downloaded as pdb files from the Protein 
Data Bank (http://www.rcsb.org/) and opened in the software CAChe WorkSystem Pro 
version 7.5.0.85 (Fujitsu Ltd). Hydrogens were added and water and ions were deleted. 
Docking sites were defined by selecting all the amino acid residues within either 5 Å or 8 
Å of residues K202, K205, R209, R213 and R222. Both structures contained missing 
residues but these were far enough away from the defined docking sites such that their 
absence would not interfere with the docking studies. Using the same software, three 
ligand structures (a dimer, a pentamer and a hexamer) were defined by taking residues 2-
3, 2-6 and 2-7 respectively from the glycosaminoglycan structure 1HPN.pdb.  
Using the ProjectLeader module and the ActiveSite docking component of the same 
software, the three ligands were each docked three times into the defined docking sites 
of both proteins using the flexible ligand and flexible active site side chain options. Other 
parameters and options included: Use Amber van der Waals; population size 50; 
maximum generations 3000; crossover Rate 0.8; mutation Rate 0.2; elitism number 5; 
local search rate 0.06; maximum iterations local search 300. 
 
5.2.2 Cell adhesion and spreading assay 
 
 
Wells of TCP were coated with 5μg/ml of human plasma fibronectin in Tris-Cl, pH 7.4 
overnight at 4°C and then blocked for 30 min with 3% (w/v) marvel in PBS. Exponentially 
growing HOB cells were trypsinised and then washed in serum free medium in which they 
were further incubated for 20 min at 37°C with increasing concentrations (100-500μg/ml) 
of  long (P1) and two short (P2, P3) peptides corresponding to the newly discovered 
heparan sulfate TG2 binding site and their analogue P1s peptide. Additionally to find out 
the effect of the RGD containing peptide on HOB cell adhesion, 150µg/ml of RGD peptide 
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was also added into the cell suspension that contained the different concentrations of the 
previously described peptides. Pre-treated cells were then seeded into the FN coated 
wells with and without immobilised guinea pig TG2 (used at a concentration of 20µg/ml) 
and allowed to adhere for 30 minutes at 37°C to minimize the externalisation of any 
endogenous proteins (Verderio et al., 2003). Attached cells were washed once with PBS, 
pH 7.4 and then fixed with 3.7% paraformaldehyde, further permeabilised with 0.1% (v/v) 
Triton-X in PBS, and co-stained with May-Grunwald and Giemsa stain as described under 
Materials and Methods (Section 2.2.9). Images of stained cells from non-overlapping 
fields were visualized by digital camera at 20 x magnification and analyzed using the 
Image analysis program written at the National Institutes of Health. 
 
 5.2.3 Competition between long (P1), and short peptide (P3) mapped to HS2 mutant 
binding site and the wild type enzyme for binding to heparin 
 
   The resulting supernatants (total cell lysates) (~150µl containing 4mg/ml of TG2) 
obtained from HEK293/T17 cells transfected with wtTG2 as described before (Section 
2.2.3.5) were dissolved in around 450 µl of 50mM Tris-Cl, 1mM EDTA, 1mM DTT, pH 7.5 
buffer and further pre-incubated on ice with P1, P1s, and P3 peptides to a final 
concentration of 1mg/ml.  After 15 minutes pre-incubation of the heparin sepharose 
column with the desired peptide, such prepared supernatants were applied to the 1ml 
bed volume Heparin sepharose column (Amersham Biosciences, Sweden) equilibrated in 
50mM Tris-Cl, 1mM EDTA, 1mMDTT pH 7.5 buffer only. The column was eluted at 
2ml/min with the same buffer using a peristaltic pump at room temperature. The column 
was then washed with 15ml of the same buffer before linear gradient elution with salt 
(1M NaCl in 50mM Tris-Cl, 1mM EDTA, and 1mM DTT, pH 7.5) was initiated. Both flow-
through and resulting fractions were collected into 96 well microtiter plates. Content of 
the resulting fractions were verified by SDS-PAGE  electrophoresis and Western blotting 
using anti-TG2 monoclonal antibody for the presence of TG2 bands (Materials and 
Methods, Section 2.2.4 and 2.2.5). 
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5.3 RESULTS 
 
5.3.1 A heparin derived oligosaccharide docks into a characteristic heparin binding 
pocket in TG2 
The HS1 and HS2 regions were docked with heparin derived oligosaccharides. An 
iduronic acid-2-sulphate-glucosamine-2, 6-disulphate disaccharide which is the most 
common repeating unit of heparin docked well with the HS2 region of TG2. In addition a 
pentasaccharide (2-6) and hexasaccharide (2-7) consisting of the same repeating units 
were checked for binding affinity to HS2 derived binding pocket localised on TG2 
molecule (Table 5.3.1). However undertaken studies revealed differences in the docking 
scores (kcal/mol) dependently on conformation of the crystal structure of TG2. The more 
negative the score, the better the enthalpy change on binding thus the pentasaccharide 
docked in TG2 which was locked in a close conformation (1KV3) was shown to be most 
effectively bound within the area of the desired binding pocket which was further 
illustrated on a three-dimensional image (Figure 5.3.1). 
 1KV3 5A site 1KV3 8A site 2Q3Z 5A site 2Q3Z 8A site 
IDS – SGN -548 -602 - 574 -627 
2-6 -836 -710 +1407 -349 
2-7 -790 -679 +3706 +9460 
 
Table 5.3.1 Table represents the scores (kcal/mol) of di-, penta-, and hexasaccharide 
docked into, or within the nearest localisation of the novel heparin binding site pocket 
localised on TG2 molecule. Using Cache WorkSystem Proversion 7.5.0.85 (Fujitsu Ltd) 
software, downloaded crystal structures adopted to a close (1KV3) and an open (2Q3Z) 
conformations were treated with IDS-SGN (disaccharide), 2-6 (pentasaccharide) and 2-7 
(hexasaccharide) and further verified for the binding efficiency into the HS2 binding 
pocket by Dr Dan Rathbone from Aston University. The more negative the score, the 
higher binding efficiency. 
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Figure 5.3.1 Three dimension analysis of the novel heparan sulfate binding site pocket 
interaction with pentasaccharide designed and kindly provided by Dr Russell Collighan 
and Dr Dan Rathbone from Aston University. Illustration represents the electrostatic 
surface potential of TG2 with red indicating negative charges and blue indicating 
positive charges. In addition it points out positively charged amino acid residues (K202, 
K205, R209, R213, K387) surrounding the novel heparin binding site pocket where 
pentasaccharide (carbon is indicated by green; hydrogen by white; oxygen by red;                                                                                                   
sulphur by yellow) was docked.  
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5.3.2 Tissue transglutaminase supports RGD-independent HOB cell adhesion to a FN-
TG2matrix  
 
The TG2-FN interaction and its involvement in promoting cell surface adhesion has 
already been widely described in the literature. As shown by immunogold electron 
microscopy TG2 co-localisation at cell surface of Swiss 3t3 cells could be found in 
association with FN (Gaudry et al., 1999a). Moreover initial investigations in this field 
suggested that binding between the enzyme and human plasma FN can take place 
through the N-terminal tail of TG2 (Radek et al., 1993; Gaudry et al., 1999a) which was 
further confirmed by our studies with N-terminal deletion mutant (Δ1-15TG2) as shown in 
chapter 4. Thus to verify previous findings of Verderio et al., (2003) regarding FN-TG2 
interactions, guinea pig TG2, human plasma FN and soluble RGD peptide were used in an 
experimental system. The saturation point of TG2 when immobilised on FN has already 
been measured by Verderio et al., (2003) and established at 20μg/ml. As an initial cell 
model HOB cells were used because of being rich in the appropriate cell surface integrin 
receptors, which mainly possess RGD-binding β1 subunit linked with different α subunits 
(α1, α2, α3, α5, and αV) (Gronthos et al., 1997). Moreover this particular cell line shows 
increased cell spreading on biomaterials coated with FN-TG2 in comparison to FN alone 
(Heath et al., 2002).  
 HOB cells were grown to 80-90% confluence and when ready were treated with 
increasing concentrations of RGD (GRGDTP) synthetic peptide and its control RAD 
(GRADSP) peptide and further seeded onto FN and FN-TG2 matrices. HOB cell attachment 
and spreading was then visualised by camera (Fig. 5.3.2a). To indicate the differences 
between attached and spread cells colourful arrows were applied on each of the images. 
Cell attachment was shown as the total amount of cells attached to particular matrix, 
while cell spreading was described as the number of cells characterised by an extended 
flattened shape. The results showed visual differences in the amount of cells attached to 
both matrices with no significant difference between cells treated with increasing 
concentrations (up to 150μg/ml) of RAD peptide and only a  small  but significant 
decrease in either cell attachment or cell spreading at concentrations of 200μg/ml and  
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Figure 5.3.2 Adhesion of HOB cells on FN and FN-TG2 matrices influenced by the 
presence of RAD and RGD peptides. A Visualisation of four different images representing 
attachment and spreading of HOB cells treated either with RAD or RGD peptides. 
Examples of differences between attached and spread cells are signified by arrows, black 
points on attached (spread) cells whereas red points on non-spread cells; B effect of RAD 
peptide; C effect of RGD peptide. Analysis of cell attachment and cell spreading was 
performed according to the previously described method (Materials and Methods 2.2.9). 
Each data point representing attached or spread cells on FN or FN-TG2 matrices is shown 
as a mean percentage +/- SD of three separate experiments performed in triplicate. Mean 
number of cells on FN, was used as percentage of control values and established at 100%. 
The mean value of attached cells on FN cells was calculated as 108.3 +/- 1.5 and 
represented 100%. The same rule applied to spread cells. To show any statistical 
differences between obtained data points when compared to the control value they were 
calculated by Mann-Whitney test and shown as * (p < 0.05) including both RAD and RGD 
treatment. 
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250μg/ml RAD peptide on FN-TG2 and FN matrices when compared to the value of 
control cell adhesion on FN. This result is consistent within both data panels (upper and 
lower panels in Fig. 5.3.2b). However differences in cell adhesion were noticeable when 
HOB cells were treated with increasing concentrations of RGD peptide. A significant 
reduction of cell attachment and cell spreading was seen when cells were seeded on both 
matrices when compared to untreated cells. Although, HOB cell treatment with RGD 
peptide caused approximately 20-25% (at 50μg/ml - 250μg/ml of RGD) reduction in 
attachment and spreading of cells on FN-TG2 matrix, it was fairly consistent when 
compared to control values on FN matrix. The decrease observed on FN matrix was much 
greater and varied between 26% - 59% (at 50μg/ml - 250μg/ml of RGD) in cell attachment 
and 35% - 78% (at 50μg/ml - 250μg/ml of RGD) in cell spreading. However there was also 
a significant decrease in attachment and spreading observed between cells when treated 
with the same peptide when seeded on FN in comparison to the FN-TG2 matrix (Fig. 
5.3.2c). Cell attachment to FN-TG2 in the presence of 150μg/ml of RGD was 
approximately 28% higher when compared to cell attachment to FN. Similarly cell 
spreading on FN-TG2 at the same concentration of RGD was 30% higher when compared 
to cell spreading on FN. At higher concentrations RGD peptide there is likely to non 
specific affects since RAD peptide was shown to cause a small reduction in cell adhesion 
starting at concentration of 200μg/ml. Thus 150μg/ml of RGD and its control peptide 
were chosen for further experiments. All together these results indicate the involvement 
of TG2 in promoting RGD-independent cell adhesion when immobilised on FN matrix 
which stays in agreement with previous finding of Verderio et al., (2003) and Telci et al., 
(2008).  
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5.3.3 Effect of P1 (NPKFLKNAGRDCSRRSS) peptide on cell binding to FN and FN-TG2 in 
the presence and absence of RGD peptide  
 
To verify whether cell surface proteoglycans can be involved in mediating cell adhesion 
to FN-TG2, HOB cells were subjected to treatment with P1 peptide 
(NPKFLKNAGRDCSRRSS) which corresponds to a binding pocket in the core domain of TG2 
where the novel heparan sulfate binding site has been found. Previous studies have 
shown that TG2 when bound to FN can compensate for the loss of integrin-mediated cell 
adhesion in the presence of RGD peptides in a process requiring cell surface heparan 
sulfate chains, but not requiring the transglutaminase enzymatic activity (Verderio et al., 
2003). It has also been shown that the cell surface proteoglycan syndecan 4 is critical in 
this process (Telci et al., 2008). Since TG2 can interact with both FN and HSPGs, the HSPG 
binding properties of TG2 are most likely involved in this process Telci et al., (2008). 
Therefore the P1 peptide was tested for its ability to interfere with TG2-mediated RGD-
independent binding of HOBs to FN in a simple adhesion and spreading assay. To initiate 
the experimental procedure HOB cells when ready were treated separately with 
competitive concentrations of the P1 peptide or in parallel with the same P1 peptide 
supplemented with 150μg/ml of RGD peptide and then plated on FN and FN-TG2 matrices 
in the presence of the peptides. For clarity only images representing two distinct 
concentrations of P1 peptide (100μg/ml and 500μg/ml) has been chosen for visualisation. 
As seen in Figure 5.3.3a P1 peptide did not influence the morphology of the cells, which 
when attached showed a round form whereas when spread displayed a flat extended 
shape. This appearance was however changed by additional treatment with RGD peptide, 
which caused impairment in cell spreading in particular on the TG2-FN matrix. Once 
incubated with P1 peptide at a concentration of 100μg/ml, cells showed no significant 
differences in adhesion (both attachment and spreading) whether seeded on FN or TG2-
FN matrices when compared to the control value on FN (Figure 5.3.3b upper and lower 
panel). In the presence of 200μg/ml of P1 peptide cell attachment and spreading was 
slightly reduced to around 11% when compared to that of FN-TG2, whereas a significant 
reduction of 17% was seen on the FN matrix. Additionally at the concentration of 
300μg/ml of P1 peptide a significant reduction of 24% to 20% of cell attachment and 25% 
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to 21% of cell spreading was observed on FN-TG2 and FN alone, respectively. However a 
great impairment in cell attachment and spreading was noticed with 400μg/ml and 
500μg/ml concentration of P1 peptide. At concentration of 400μg/ml, P1 peptide led to 
reduction of 48% to 30% of cell attachment and 50% to 32% of cell spreading on TG2-FN 
and FN alone, respectively. At concentration of 500μg/ml, P1 peptide caused even greater 
reduction of 60% to 44% of cell attachment and 65% to 45% of cell spreading on TG2-FN 
and FN alone, respectively (Fig. 5.3.3b). Hence at these higher concentrations P1 peptide 
may work non-specifically. The reduction of cell adhesion and spreading could also be 
seen in the additional presence of RGD peptide. On the FN-TG2 matrix, at 100μg/ml 
concentration of P1 and 150μg/ml of RGD HOBs showed an approximately 20% decrease 
in cell attachment and spreading whereas no significant difference was noted in cell 
adhesion on FN when compared to the untreated control on FN. At concentration of 
200μg/ml of P1 peptide and in the presence of RGD peptide, the reduction of around 25% 
of cell attachment and 29% of cell spreading on FN-TG2 was noticed. The significant 
decrease to approximately 20% in cell attachment and spreading was also observed on FN 
alone when compared to the FN control. Greater reduction in cell adhesion has been 
noticed with higher concentrations of P1 peptide supplemented with RGD peptide both 
on FN-TG2 and FN alone. At concentrations of 300μg/ml and 400μg/ml of P1 peptide 
HOBs cells showed around 35% to 40% and 50% to 55% decrease in cell attachment and 
spreading on FN-TG2, respectively. In addition at these concentrations of P1 peptide and 
in the presence of RGD peptide also 22% to 25% reduction in cell attachment and 
spreading on FN alone was observed. However at 500μg/ml concentration of P1 in the 
presence of 150μg/ml of RGD, cells showed a 60% to 32% decrease in cell attachment and 
64% to 34% in cell spreading on TG2-bound FN and FN matrices, respectively. The data 
therefore indicates that peptide NPKFLKNAGRDCSRRSS reduces cell adhesion and 
spreading on FN-TG2 independently of the presence or absence of RGD peptide in a dose 
dependent manner. In addition it suggests that P1 peptide is able to compensate for the 
RGD induced loss of adhesion on FN alone (even at the lowest concentrations) and seems 
to be substituting for the heparin binding site and compensation itself.  
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Figure 5.3.3 Effect of P1 peptide on attachment and spreading of HOB cells on FN and 
FN-TG2 matrices. A Illustration of attachment and spreading of HOB cells treated with 
two distinct (100μg/ml and 500μg/ml) concentrations of P1 peptide without and with the 
presence of RGD peptide; B effect of P1 peptide alone and in the presence of RGD. 
Adhesion and spreading of HOB cells on FN and FN-TG2 matrices was analysed in the 
presence of 100µg/ml to 500µg/ml P1 peptide in the presence or absence of 150μg/ml 
RGD peptide. Cells were preincubated with the peptides and incubated in the presence of 
the peptides on the different matrices as previously described under (Methods 5.2.2). Cell 
adhesion (attachment and spreading) is expressed as a mean percentage of attached or 
spread cells +/- SD, respectively and shown as a mean of triplicate measurements.  Total 
amount of cells from a control sample (cells on a FN matrix) established as 100% was 
assessed as 129.47 +/- 2.95 for attached cells and 126.86 +/- 4.2 for spread cells. The * 
symbol represents statistical significance between the control sample and each data point 
corresponding to attached and spread cells in the presence of P1 synthetic peptide alone 
or with RGD peptide. The significant different cell adhesion values were evaluated by 
Mann-Whitney test with (p<0.05). In addition to indicate significant differences between 
the single data points symbol ◊ (p< 0.05) was used. 
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5.3.4 Effect of P2 (NPKFLKNA) peptide on cell binding to FN and FN-TG2 in the presence 
and absence of RGD peptide 
 
Since P1 (NPKFLKNAGRDCSRRSS) peptide was shown to inhibit the cell adhesion 
pathway mediated by TG2 bound to fibronectin it was of further interest to investigate 
whether this pathway could be differently influenced by two small peptides randomly 
generated from the P1 peptide. The first short peptide named P2 (NPKFLKNA) was 
synthesised from the first eight amino acids within P1 peptide thus containing the first 
residue (Lys205) that was substituted with Ala within the TG2 HS2 mutant. The second 
short peptide P3 (GRDCSRRSS) was synthesised containing the ninth to the seventeenth 
residue of the P1 peptide and in contrary to the P2 peptide consisted of the second amino 
acid (Arg209) residue that was substituted with Ala within the same TG2 HS2 mutant.   
To explore the possibility that cell adhesion to FN-TG2 may be mediated by one of the 
two short peptides, first P2 (NPKFLKN) peptide was applied into the experimental system 
using a similar approach to the one that was previously described with the longer P1 
peptide. Exponentially growing HOB cells when confluent were trypsinised, washed with 
serum free medium as described under Materials and Methods (Section 2.2.9.3) and 
further 2.5 x 105 cells/ml cell suspension was incubated with increasing concentrations 
(100μg/ml - 500μg/ml) of P2 peptide alone or complemented with 150μg/ml RGD 
peptide. Cell adhesion of the HOB cells was then compared on FN-TG2 and FN matrices. 
Due to clarity only images representing two most distinct concentrations (100μg/ml and 
500μg/ml) of P2 peptide in the absence or presence of RGD peptide are shown in this 
section. When seeded, HOB cells were analysed for attachment and changes in their 
morphology. As seen in Figure 5.3.4a the P2 peptide did not influence the appearance of 
the cells which when spread on either FN-TG2 or FN matrices presented extended shapes 
with a dark nucleus in the middle and bright cytoplasm surrounding this. Following 
treatment with RGD, cells adopted more round shape that was much more evident on FN. 
When visualised, cells were counted and the influence on cell adhesion of the P2 peptide 
with or without RGD on FN-TG2 and FN matrices was compared to the control value of 
untreated cells on FN.  On the FN-TG2 matrix, HOB cells treated with 150μg/ml of RAD 
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(control peptide) showed increase of around 14% to 8% in cell attachment and spreading 
when compared to the control value on FN alone. In addition small significant difference 
in the amount of adhered cells was noticed in the presence of 150ug/ml RGD peptide 
when compared to that of FN alone supporting once more the hypothesis of the 
importance of FN bound TG2 in RGD-independent cell adhesion. In the presence of 
100μg/ml and 200μg/ml of P2 peptide attachment and cell spreading appeared to be 
slightly (8% to 10%) greater than that of TG2-FN control (Figure 5.3.4.b) whereas no effect 
was seen on the FN matrix. When treated with 300μg/ml and 400μg/ml of P2 peptide, cell 
adhesion (attachment and spreading) of HOBs remained almost unchanged on FN-TG2, 
however was significantly reduced to around 25% and 33% of cell attachment and 28% to 
36% of cell spreading on FN alone, respectively. Additionally at the concentration of 
500μg/ml of P2 no difference was observed in cell adhesion on FN-TG2, while on FN, cell 
adhesion (attachment and spreading) was significantly reduced to around 55% of that of 
control cell adhesion to FN. This result could suggest that like P1, P2 peptide when used 
at high concentration may work none specifically. Further treatment of HOB cells with 
100μg/ml and 200μg/ml of P2 peptide and 150μg/ml of RGD peptide resulted in no 
significant difference on cell attachment and spreading on FN-TG2, but significant 
decrease of around 42% to 38% of cell attachment and 47% to 42% of cell spreading 
when cells were plated on FN, respectively. At concentration of 300μg/ml of P2 peptide 
and in the presence of RGD peptide approximately 17% decrease in cell attachment and 
23% decrease in cell spreading on TG2-FN and around 40% decrease in cell attachment 
and spreading on FN alone was noted. In addition in the presence of 400μg/ml of P2 
peptide supplemented with RGD approximately 22% decrease in cell attachment and 25% 
in cell spreading was noticed on TG2-FN, whereas 37% reduction in cell attachment and 
around 40% in cell spreading was observed on FN alone when compared to the control 
FN. When P2 was used at concentration of 500μg/ml in the presence of RGD peptide this 
caused a significant decrease in cell attachment and spreading estimated at 20 - 22% on 
TG2-FN and 46% - 59% on FN matrix, respectively. This result could suggest the 
involvement of P2 peptide in promoting TG2 mediated RGD-independent cell adhesion. 
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Figure 5.3.4 Adhesion of HOB cells on FN and FN-TG2 matrices in the presence of P2 
synthetic peptide. A Visualization of 8 different images representing HOB cell adhesion in 
the presence of two different concentrations of P2 peptide alone or/and in the presence 
of RGD peptide respectively. Images of non overlapping fields were captured by digital 
camera at 20x magnification and further analysed by a Scion Image program as outlined 
in the experimental procedures (Materials and Methods 2.2.9); B effect of P2 peptide in 
the absence or presence of RGD peptide on the attachment and spreading of HOB cells. 
Prior to the cell adhesion, cells were pre-incubated for 20 min with 150µg/ml RGD 
peptide and/or  100µg/ml to  500µg/ml P2 peptide respectively and the assay was 
performed in the absence of serum using FN and FN-TG2 matrices as stated in the 
Materials and Methods (5.2.2). Each data points corresponds to the mean percentage of 
attached cells (cell attachment) or the mean percentage of spread cells (cell spreading). 
Mean values presented as the percentage of control (attached or spread cells on FN) +/- 
SD of triplicate measurements were taken as 100%. The mean percentage attachment 
value +/- SD normalised to 100% was 129.47 +/- 2.95 while the mean percentage 
spreading value +/- SD was 126.86 +/- 4.2. The statistically significant difference was 
shown as * (p<0.05) in the presence or absence of the RGD peptide in the test conditions. 
The ◊ symbol indicates the statistically different cell adhesion values (p<0.05) of points 
representing P2 treated cells with or without RGD peptide on FN-TG2 and FN matrices. 
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5.3.5 Effect of P3 peptide on cell binding to FN and FN-TG2 in the presence and absence 
of RGD peptide  
 
So far the effect of both P1 (NPKFLKNAGRDCSRRSS) and P2 (NPKFLKNA) on RGD-
independent pathway mediated by TG2-FN has been evaluated. Neither of these peptides 
affected cell adhesion on the TG2-FN matrix when RGD was present in the expected 
manner. Therefore it was of importance to test the influence of the second short P3 
(GRDCSRRSS) synthetic peptide on the adhesion of HOB cells using the same experimental 
approach. As previously described, confluent HOB cells were trypsinised and after 
washing were preincubated with increasing concentrations (100 - 500μg/ml) of P3 
peptide alone or P3 peptide substituted with 150μg/ml of RGD peptide.  
The reason for using P3 peptide complemented with RGD peptide was to assess 
whether the P3 peptide can block the adhesion of HOB cells on FN-TG2. The first part of 
the investigation was to explore the effect of P3 peptide on the morphology of HOB cells. 
As seen in images (Figure 5.3.5a), like P1, and P2 peptides, P3 peptide used in a lower 
concentration did not change the appearance of attached cells which was only affected 
by additional presence of RGD peptide. However at the higher concentration of P3 
peptide, cells showed a slightly more rounded appearance. In the absence of P3 and RGD 
peptides, but in the presence of 150μg/ml RAD peptide attachment and spreading 
increased to around 13% to 8% on FN-TG2 when compared to the FN control. Also 
treatment with 150μg/ml RGD peptide resulted in a significant decrease in cell adhesion 
on FN-TG2 but a much greater reduction to around 50% of cell attachment to 60% of cell 
spreading on FN in comparison to the control values. When HOB cells were plated on the 
TG2-FN matrix in the presence of 100μg/ml of P3 peptide they exhibited a 10% increase 
in cell adhesion (cell attachment and spreading) in comparison to the untreated FN 
control. Increase in the P3 concentration to 200μg/ml, and 300μg/ml caused no 
significant effect on cell attachment and spreading on FN-TG2 and FN alone when 
compared to the FN control. Additionally at the concentration of 400μg/ml only moderate 
however no significant decrease in cell adhesion (attachment and spreading) was 
observed on both matrices. When used at the concentration of 500μg/ml P3 peptide 
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caused significant decrease of attachment and spreading to around 36% to 35 on FN-TG2 
and around 20% to 23% on FN alone, respectively. These results suggest that at the 
highest concentration P3 peptide may be non- specific. Additional treatment of HOB cells 
with RGD peptide at the lower concentration of P3 peptide (100μg/ml) did not affect 
attachment and cell spreading on FN-TG2 but led to a significant decrease, estimated as 
26% of cell attachment and 28% of cell spreading on FN alone. In the presence of 
200μg/ml of P3 peptide supplemented with RGD peptide, 12% to 25% decrease in cell 
attachment and 21% to 32%  decrease in cell spreading was observed on FN-TG2 and FN 
alone, respectively. Under the same conditions but at the concentration of 300μg/ml of 
P3 peptide approximately 17% decrease in cell attachment and 26% decrease in cell 
spreading on FN-TG2 and around 26% decrease in cell attachment and 36% in cell 
spreading on FN alone was noted. Notably, RGD peptide did affect cell attachment and 
spreading on FN-TG2 in the presence of the higher concentrations of P3 peptide which 
was observed to decrease to around 38% to 40% (400μg/ml) and 52% to 59% (500μg/ml), 
respectively when compared to that of a control FN. In addition cell adhesion (attachment 
and spreading), in the presence of these higher concentrations of P3 peptide with RGD 
peptide, was also significantly reduced by around 26% (400μg/ml) and 20% (500μg/ml) 
when compared to cell adhesion when cells were incubated with the P3 peptide alone 
but in the absence of RGD on FN-TG2 matrix. The data therefore suggests that HOB cells 
treated with higher concentrations of P3 peptide did not restore the compensatory effect 
of FN-TG2 when cell adhesion was disrupted in the presence of RGD peptide. However P3 
peptide like P1 peptide seemed to restore the loss of cell adhesion induced by the RGD 
peptide on FN alone.  
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Figure 5.3.5 Effect of soluble P3 peptide on the adhesion of HOB cells to FN and FN-TG2 
matrices in the presence of RGD peptide. A Illustration of eight independent images of 
HOB cells on FN and FN-TG2 matrices treated with P3 alone and with the same peptide 
but additionally supplemented with RGD peptide; B effect of P3 peptide on TG2 mediated 
RGD-independent HOB cell adhesion on FN and FN-TG2 matrices. HOB Cells were 
analyzed for attachment and spreading to FN and TG2 immobilised FN matrices as 
indicated under Materials and Methods (Section 2.2.9). Where indicated, cells were pre-
treated with 100µg/ml to 500μg/ml P3 peptide alone or in addition with 150µg/ml RGD 
peptide for 20-25 min and then plated in the presence of these peptides. Each data point 
representing attached or spread cells on FN or FN-TG2 matrices is shown as a mean 
percentage +/- SD of two separate experiments performed in triplicate. The points in the 
upper and lower graphs representing different variables were expressed as percentage of 
control attachment or control spreading to FN +/-SD, respectively which stands for 100%. 
The mean value for cell attachment on FN was calculated as 129.47 +/- 2.95 while the 
mean number of cells spreading on FN +/- SD was 126.86 +/- 4.2 and considered as 100%. 
To show any statistical differences between obtained data points when compared to the 
control point they were calculated by Mann-Whitney test and shown as * (p < 0.05) 
including both the presence and absence of RGD peptide on cell adhesion mediated by P3 
peptide. In addition to indicate significant differences between the single data points 
symbol ◊ (p< 0.05) was applied.  
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5.3.6 P1s (FNRADLKPRCGSSNKSR) peptide does not affect TG2 mediated RGD-
independent cell adhesion on fibronectin 
 
To further confirm any influence of P1, P2, or P3 peptides on FN-TG2 mediated cell 
adhesion, scrambled peptide encompassing the novel heparan sulfate binding site was 
designed. Scrambled peptide P1s (FNRADLKPRCGSSNKSR) was generated from the P1 
peptide, by random combination of amino acids residues within the P1 sequence. This 
peptide was then tested in cell adhesion experiments, as previously described (see 
Section 5.2.2).  After reaching confluence, HOB cells were trypsinised and when ready 
treated with increasing concentrations (100 - 500μg/ml) of P1s alone and/or in the 
presence of 150μg/ml of RGD peptide. However images representing only results 
characterised by the lowest and highest concentrations of P1s peptide were presented in 
this chapter. As for previous peptides (P1, and P2) P1 scrambled did not affect the 
appearance of the cells when attached to either FN-TG2 or FN matrices (Figure 5.3.6a). 
Cell adhesion on both matrices in the presence of RGD peptide and its RAD control 
peptide showed a similar pattern when compared to the untreated control of FN. At all 
concentrations the P1s peptide demonstrated no effect on cell adhesion (attachment and 
spreading) on FN-TG2 and only a moderate decrease in cell attachment (estimated at 
around 10%) when used at the lower concentrations and significant decrease to 
approximately 20% of cell attachment when used at the highest concentration 
(500μg/ml) on FN when compared to the control of FN. In addition at concentrations of 
100μml, 200μg/ml and 300μg/ml the P1s peptide caused no significant difference in cell 
spreading on FN alone; however at higher concentrations of peptide (400μg/ml to 
500μg/ml) cell spreading was significantly reduced to around 20%. When treated with the 
whole range of concentrations (100μg/ml to 500μg/ml) of P1s peptide with the addition 
of 150μg/ml RGD peptide, HOB cells showed no differences in attachment and spreading 
on FN-TG2 when compared to the FN control but demonstrated a significant decrease of 
40% in cell attachment and 46% in cell spreading on FN at the same P1s and RGD peptide 
concentrations.  
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Figure 5.3.6 Effect of P1 scrambled analogue (P1s) on the attachment and spreading of 
HOB cells on FN and FN-TG2 matrices. A Visualisation of different images of HOB cells on 
FN and FN-TG2 in the presence of scrambled peptide alone and with  addition of RGD 
peptide; B effect of P1s on TG2 mediated RGD-independent HOB cells adhesion on both 
matrices. The adhesion experiment and further analysis of obtained images was 
performed according to procedures described under the Materials and Methods (Section 
2.2.9) and Methods (5.2.2). Each data point represents the mean percentage of attached 
cells (cell attachment) or the mean percentage of spread cells (cell spreading) and is 
expressed as the  mean percentage of the control number of cell attachment on FN +/- 
SD, or cell spreading on FN +/- normalised to 100%, respectively. The mean percentage 
for attachment of the two separate experiments was 135.2 +/- 3.475, which was 
considered as 100%. The mean percentage of spreading for the two separate experiments 
was 132 +/- 4.2, which was established at 100%.  The * symbol represents statistical 
significance (p < 0.05) between the control sample and each data point corresponding to 
attached and spread cells in the presence of P1s  synthetic peptide alone or 
supplemented with RGD peptide. In addition to indicate significant differences between 
the single data points symbol ◊ (p< 0.05) was used.  
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The noticeable reduction in cell adhesion when cells were treated with different 
concentrations of scrambled peptide (P1s) in the presence of RGD peptide on FN suggest 
that this peptide does not compensate for the loss of cell adhesion mediated by RGD on 
FN.   
 
5.3.7 P1 peptide does not compete off TG2 from the Heparin binding column 
 
It has already been shown by many investigators (Signorini et al., 1988; Gambetti et al., 
2005; reviewed by Verderio et al., 2009) and further confirmed by our studies that TG2 
has a high affinity for heparin which is an analogue of heparan sulfate. Moreover cell 
binding ECM proteins including fibronectin and vitronectin have been demonstrated as 
heparin binding partners. Since some of the TG2-mediated protein cross-linking is known 
to be enhanced by glycosaminoglyacans (GAGs) such as heparin, it may suggest its 
supportive role in this process (Sane et al., 1990; Verderio et al., 2009). Therefore it was 
of importance to test whether peptides generated within the novel heparan sulfate 
binding site loop were able to interact with heparin and what is even more important 
compete off the wild type TG2 from the heparin column. So far the physiological 
importance of each of the three peptides (P1, P2, and P3) has been tested in cell adhesion 
and spreading assays using HOB cells as the initial cell model. Given that the P2 peptide 
showed to be insignificant for interfering with TG2-mediated RGD-independent cell 
adhesion on fibronectin it was of no importance to verify its affinity for heparin. 
Therefore only the long peptide P1 and short peptide P3 were used on the Heparin 
column. Cell extracts rich in TG2 protein (Materials and Methods 2.2.6.1 A) were applied 
to the 5ml bed volume column prior peptide treatment. For this, P1 peptide (10mg/ml) 
was first diluted into the cell extract to a final concentration of 200μg/ml and incubated 
for 15 minutes. The column was also pre-incubation with the same peptide for 15 min at 
the same concentration, prior to initiation of the experiment by addition of the 
preincubated cell extract to the column.  Bound proteins were eluted with an increasing 
salt gradient (1MNaCl in equilibrating buffer).  
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Figure 5.3.7 
 
Figure 5.3.7 Analysis for competition between the P1 peptide and the wild type TG2 for 
binding to Heparin. All preparations for the experiment were performed as stated under 
Materials and Methods (2.2.6.1 A, B). The only difference was that cell lysate containing 
wt TG2 was pre-incubated for 15 min on ice with 200μg/ml of P1 peptide before loading 
on the 5ml bed volume Heparin column that was also preincubated with peptide before 
being equilibrated in 50mM Tris-Cl, 1mM EDTA, 1mMDTT pH 7.5 buffer. Following 
gradient elution with 1MNaCl in equilibrating buffer, obtained fractions (1-25) were 
assayed for the presence of TG2 antigen by SDS-Page and Western blotting (Materials and 
Methods, Section 2.2.4 and 2.2.5). 
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Once eluted, obtained fractions were resolved by SDS-PAGE electrophoresis followed by 
Western blot analysis as detailed in Materials and Method (2.2.4 and 2.2.5). As shown in 
Figure 5.3.7, TG2 bound to the column with a low and high affinity indicating as 
previously described in chapter 3 the existence of two distinct populations of the enzyme. 
However no big difference in the protein elution pattern was noticed when peptide was 
used. P1 peptide did not compete off the enzyme from the column which bound to it with 
low and high affinity. The only noticeable difference concerned the bands in the flow-
through indicating that some of the enzyme remained unbound to the column. However 
the result was not credible enough to speculate any ability of the P1 peptide to compete 
off the TG2.  
 
5.3.8 Ability of the P3 peptide to compete off TG2 from the Heparin binding column 
 
To explore if the heparan sulfate binding site peptide might be more efficient when 
used in a smaller bed volume of affinity column the 5ml bed volume column was replaced 
with 1ml bed volume column using the same supplier (Amersham Biosciences, Sweden). 
This time, not only P1 peptide but also its scrambled analogue P1s peptide and the P3 
peptide were applied into the experimental system. Peptide solutions were prepared by 
dissolving each of the peptide in the cell extract containing around 4mg/ml of TG2 protein 
mixed with equilibration buffer to a final concentration of peptide 1mg/ml. Such 
prepared peptide solutions were preincubated for 15 min before being applied on the 
Heparin column which was also pre-treated with 1mg/ml of each of the peptide for the 
same period of time. Proteins were eluted using a linear gradient of high salt buffer 
(100mM-1.0M NaCl in equilibrating buffer) at a flow rate of 2ml/min with a 45min 
gradient reaching 35% high salt buffer. All collected fractions (flow-through, wash and 
elution) were assayed for the presence of TG2 antigen using SDS-PAGE followed by 
Western blotting (Materials and Methods, section 2.2.4 and 2.2.5). Initially this linear salt 
gradient elution revealed a big proportion of control sample containing only TG2 with low 
and high binding affinity of enzyme for the column (Figure 5.3.8 A). In contrary to the 
control sample, it showed some remaining unbound proteins in the column  flow-through 
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as well as in the  wash of the sample containing the  P3 peptide (see red arrow on Fig. 
5.3.8 A). The presence of unbound proteins in the wash could suggest P3 is interfering 
with TG2 for binding to Heparin. However due to its very small amount, fractions 
containing these proteins were concentrated by freeze-drying and then once more 
verified for the presence of TG2 by immunoblotting. The same approach was used for the 
P1 peptide and for the control samples containing scrambled peptide and the other 
sample containing only TG2. As seen on every image in Fig. 5.3.8 B none of the peptides 
caused any differences in the TG2 elution pattern when compared to the sample 
containing only the wild type TG2. Each single blot showed bands representing unbound 
proteins in the flow-through fractions, with additional proteins present in the wash and 
proteins which bound to the column with low and high affinity. These results indicate that 
neither the P1 nor P3 peptide has enough binding strength to bind to Heparin and 
compete off the wild type enzyme. However their binding affinity to Heparin cannot be 
ruled out completely since there might be some special conformational requirements 
that are necessary for such a binding. Furthermore heparin-like material still present in 
the cell extract that was initially pre-treated with each of the peptides may possibly 
interfere with binding to Heparin. 
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Figure 5.3.8 A 
 
Figure 5.3.8 A Western blot analysis of TG2 eluted fractions from Heparin sepharose 
column demonstrating negligible competition between the wild type TG2 and the short 
peptide P3 (GRDCSRRSS). Cell extracts (~ 150µl) containing only TG2 and additionally P3 
peptide at a final concentration of 1mg/ml were applied to a 1ml bed volume Heparin 
sepharose column equilibrated in 50mM Tris-Cl, 1mM EDTA, 1mMDTT pH 7.5 buffer and 
run through the column as previously described under Methods (Section 5.2.3). The 
column was however pre-incubated with 1mg/ml of P3 peptide before loading with 
peptide solution was initiated. Proteins were eluted with linear gradient of salt dissolved 
in equilibrating buffer. Both flow-through and resulting fractions (7-16) were assayed by 
SDS-PAGE electrophoresis and Western blotting using anti-TG2 monoclonal antibody 
(CUB 7402) for the presence of TG2 antigen as stated under Materials and Methods (2.2.4 
and 2.2.5). 
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Figure 5.3.8 B Comparison showing TG2 binding to the Heparin Sepharose column in the 
presence of P1 and P3 peptides and the scramled P1 counterpart. Cell lysates from 
transfected with wild type TG2 HEK293/T17 cells mixed with 50mM Tris-Cl, 1mM EDTA, 
1mMDTT pH 7.5 buffer were pre–incubated with P1, P3, and P1s peptide respectively, to 
a final concentration of peptide 1mg/ml and then loaded onto a 1ml Heparin sepharose 
column prepared as described previously (Methods 5.2.3). Proteins were eluted with 
increasing gradient of 1MNaCl in 50mM Tris-Cl, 1mM EDTA, and 1mM DTT, pH 7.5. All 
fractions including flow-through and eluted proteins (7-16) were analysed for the 
presence of TG2 using SDS-PAGE electrophoresis followed by Western blotting as stated 
in Materials and Methods (2.2.4 and 2.2.5). 
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Figure 5.3.8 B 
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5.4 DISCUSSION 
 
It is known that many features of cell behaviour are regulated by the interaction of the 
cell with the extracellular matrix. To provide the integrity and structure of the cell, it is 
essential for it to adhere to the matrix. Since FN is one of the major ECM proteins that 
binds to cells and TG2 has a high affinity for FN it was not surprising  that in vitro cell 
adhesion studies have shown that cell adhesion to FN in some cells is enhanced when in 
complex with TG2 (Akimov et al., 2000; Verderio et al., 2000; Verderio et al., 2003) The 
initial findings on HOB and Swiss 3t3 cells described that TG2 promotes cell adhesion to 
fibronectin through an RGD-independent cell adhesion mechanism (Heath et al., 2002; 
Verderio et al., 2003).  
To verify these findings, an initial experiment with TG2 immobilised on human plasma 
FN, using competitive concentrations of RGD peptide was performed. Peptides when 
assayed for their inhibitory functions, can however cause non specific effects, thus it was 
essential to use in addition to GRGDTP inhibitory hepaxapeptide, an inactive GRADSP 
control hexapeptide (Verderio et al., 2003). In the cell adhesion assay the effect of RGD 
peptide on HOB cells seeded on FN and FN-bound TG2 matrices was studied. As 
suggested by the same investigators Verderio et al., (2003) the incubation of cells with 
RGD peptide should not exceed a certain period of time due to the risk of contamination 
by endogenously secreted ECM proteins, therefore peptide treatment was restricted to 
around 25 minutes. Under these conditions, the RGD peptide caused inhibition of cell 
attachment and spreading on FN, which was however rescued in the presence of TG2. 
These results were in agreement with previous findings, confirming the importance of FN 
bound TG2 as an enhancer of cell adhesion and its involvement in an RGD-independent 
adhesion pathway (Heath et al., 2002; Verderio et al., 2003). 
Although the participation of the integrin binding domain (RGD) has been shown to be 
crucial for cell adhesion to FN, the involvement of the heparin binding domain HepII, has 
also been suggested (Woods et al., 1986). The results from experiments on immobilised 
FN or different FN fragments revealed that the binding of cell-surface proteoglycans to FN 
Chapter V: The role of heparan sulfate proteoglycans in FN-TG2 mediated cell adhesion 
240 
 
is necessary for cell-adhesion (Woods et al., 1986, Saoncella et al., 1999; Park et al., 
2000). Other data presented by Sim et al., (2004) indicated the direct role of cell-surface 
HS in the binding of FN to primary human osteoblasts (HOBS). Recently TG2 was also 
shown to have a high affinity for heparin/HS (Gambetti et al., 2005; Verderio et al., 2009) 
and this TG2-HS interaction was further demonstrated to affect cell-matrix adhesion 
(Verderio et al., 2003; Telci et al., 2008). Till now no detailed information has been 
presented regarding the heparin/HS binding site on the TG2 molecule. However our 
finding with the HS2 mutant allowed us to speculate where such a binding place could be 
localised. As previously described (Verderio et al., 2009; Telci et al., 2008) it is known that 
TG2 can directly interact with the HS chains of syndecan-4. Although HS chains are 
characterised by the high degree of structural diversity, they are classified as dissacharide 
chains (Kirkpatrick and Selleck, 2007). Therefore the interaction between the different 
length saccharides and the proposed heparan sulfate binding loop of TG2 which 
additionally was locked in two distinct conformations was investigated. The docking 
studies reported the pentasaccharide to fit perfectly into the loop surrounded by the 
different positively charged amino acid residues including residues suggested to be 
important for the TG2-HS interaction when the enzyme was adopted in a close 
conformation. Obtained results indicated that this part of TG2 is involved in the binding of 
HS chains and in addition revealed the conformational requirements for efficient binding. 
Since the docking studies supported the discovered novel heparin/HS binding site on 
TG2 it was of importance to generate a P1 peptide containing the possible heparin 
binding consensus sequence (NPKFLKNAGRDCSRRSS) and further evaluate its 
physiological significance in cell adhesion assays. In an attempt to examine whether P1 
peptide will contribute to inhibition of HOB cell attachment and/or spreading on a FN 
bound TG2 matrix, competitive concentrations of this peptide were first tested in the 
experimental system. Additionally to emphasise the inhibitory effect on RGD independent 
cell attachment and spreading the P1 peptide was supplemented with the RGD peptide. 
The data reported here shows a significant and dose-dependent reduction of cell 
attachment and spreading on both FN and FN-bound TG2 matrix in the presence of P1 
peptide. The same results for cell attachment and spreading were also noted on FN-TG2 
when RGD peptide was used in the system. Therefore these data indicates that P1 
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peptide inhibits the TG2-HS interaction thus abolishing the TG2 mediated RGD-
independent cell adhesion; however because of its strong inhibitory effect on cell 
adhesion on FN alone it is possible  that  this peptide is also affecting other elements 
important to cell adhesion.  
To verify whether the length of the peptide could somehow cause it to be non specific, 
two short peptides derived from the P1 peptide were generated and applied in the cell 
adhesion assay. Similar to the previously described approach, increasing concentrations 
of P2 peptide (NPKFLKNA) and P3 peptide (GRDCSRRSS) were applied to FN alone and FN 
matrix with immobilised TG2. The influence of the peptide on HOB cell adhesion either 
alone or in the presence of RGD peptide was examined. The levels of cell attachment and 
spreading when treated with P2 peptide only appeared to be unchanged on FN bound 
TG2 which still retained the same TG2 supportive role in the presence of RGD peptide. 
This finding indicates that this particular part of the peptide does not block the heparin 
binding site on TG2 hence still allowing TG2 to promote cell adhesion on FN 
independently in the presence or absence of RGD. Surprisingly cell adhesion on FN alone 
with higher peptide concentrations showed a significant reduction suggesting the P2 
peptide may be acting by blocking the cell surface heparan sulfate proteoglycan receptors 
thus impairing osteoblasts adhesion to FN when present at high concentrations. However 
the opposite result was noticed when the P3 peptide was used. This peptide when 
incubated with cells seeded on a FN-TG2 matrix supplemented with RGD peptide 
suppressed TG2 mediated cell adhesion on FN in a dose-dependent manner indicating its 
disrupting influence on the interaction between TG2 and cell surface HS. In addition on 
FN alone it brought the loss of cell adhesion induced by RGD peptide.  Firstly these results 
suggest P3 peptide like P1 peptide may be able to mimic the heparin binding site on TG2 
thus representing a novel HS binding motif within the TG2 structure. Secondly it is in 
agreement with previous findings of Verderio et al., (2003) suggesting that TG2 promotes 
RGD-independent cell adhesion on FN, which takes place via interaction of the FN bound 
TG2 with cell surface heparan sulfate proteoglycans.  
As stated earlier to avoid the potential non-specific reduction of cell attachment and 
spreading, control peptide should be applied in the cell adhesion assay. In this chapter, 
scrambled peptide P1s containing a random combination of amino acid residues within 
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the P1 peptide was chosen as control peptide to rule out non-specific effects. P1s did not 
interfere with cell adhesion on a FN bound TG2 matrix. Although the RGD peptide caused 
inhibition of cell adhesion on FN, it was restored when cells were seeded on FN-TG2. 
These results suggest that a relatively small non specific reaction may take place 
especially when used with cells binding to FN alone, however it is not great enough to 
speculate any major influence of the control peptide on cell adhesion.  
In vitro binding studies have identified heparin (heparan sulfate analogue) as a high 
affinity binding partner for tissue transglutaminase (Signorini et al., 1988; Gambetti et al., 
2005). Hence in the initial experiment, the ability of P1 long peptide to bind and further 
compete off TG2 from the Heparin sepharose column was investigated. In the presence of 
P1 peptide, TG2 could still bind to the heparin with low and high affinity indicating P1 
peptide not to have strong enough affinity to displace TG2. Since P3 peptide like P1 was 
shown in a physiological assay to inhibit the heparan sulfate binding site on TG2 it was 
further chosen for its interaction with heparin. In addition as a control for the reaction, 
P1s peptide was applied. It was very surprising when the same or a very similar binding 
pattern was obtained for TG2 when all the peptides used to compete off TG2 were loaded 
onto the column. TG2 was not displaced from the heparin column and TG2 still bound 
with the same affinity. Although these results suggest that P3 peptide does not compete 
for the heparin binding site on TG2, its affinity for heparin cannot be ruled out 
completely. It is possible that it did not displace TG2 because it was bound out by the 
heparin binding -like impurities in a cell extracts containing TG2. The other possibility is 
due to the conformational requirements for binding to the column. As shown in a chapter 
3, TG2 binds tightly to the column and needs to be in a closed conformation; however 
even in an open form it still has affinity for the column. Because of the nature of the 
peptide we cannot confirm what conformation it adopts when it interacts with heparin. In 
addition the P3 peptide is a short peptide thus it could be very easily washed away from 
the column resulting in no effect on TG2 binding to it.  
To sum up a single linear peptide may not compete with a 3 D structure of TG2 which 
may be necessary for binding to Syndecans but not to heparin. 
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6.1 DISCUSSION 
 
Available evidence suggests that tissue transglutaminase is mainly a cytosolic protein 
with around 70-80% of the enzyme localised in the cytoplasm (Griffin et al., 2002; Lorand 
and Graham, 2003). Meanwhile a smaller but significant fraction of membrane associated 
and extracellularly present TG2 has also been reported (Gaudry et al., 1999a, b; Griffin et 
al., 2002; Fesus and Piacentini et. al. 2002; Zemskov et al., 2006). The physiological reason 
for such a location of TG2 is still poorly understood. A variety of different investigations 
have  been undertaken in order to explain how TG2 is targeted to the cell surface and 
further into the ECM since it has no leader sequence and is not glycosylated. Some 
suggest that the presence of the enzyme outside the cell is due to the cell damage 
(Upchurch et al., 1991; Kawai et al., 2008) while the others showed that TG2 can be 
externalised from the healthy cells (Vederio et al., 1998; Gaudry et al., 1999). Although, 
limited information is available in this field, some findings indicate the potential 
involvement of TG2 binding partners in the targeting of the enzyme to the cell 
membrane. Depending on its subcellular localisation, TG2 has been shown to interact 
with different molecules that are considered to be enzyme substrates. They may include 
GTP in the intracellular environment  and in the extracellular environment cell surface 
receptors such as integrins and HSPGs (heparan sulfate proteoglycans), and the most 
ubiquitous ECM molecule, fibronectin (Achyutan and Greenenberg, 1987; Akimov et al., 
2000; Verderio et al., 2009; Lorand et al., 1988; LeMosey et al., 1992). It is therefore 
possible that the alterations in TG2 binding sites corresponding to some of these proteins 
could have implications in targeting and further subsequent fate of its externalisation. In 
order to define a role of known TG2 binding partners, one of the aims of this thesis was to 
generate specific TG2 mutants and further evaluate their role in the cell secretion of the 
enzyme to the cell surface and its subsequent deposition into the ECM.  
 Defining the binding sites for all TG2 binding partners was not straight forward. So far 
only GTP binding sites as well as possible FN binding sites have been mapped within the 
structure of the enzyme (Ismaa et al., 1997, 2000; Liu et al., 2002; Begg et al., 2006a; 
Hang et al., 2005). Thus it was not surprising, that two main GTP binding site residues 
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localised within the core domain and two main FN binding site amino acids within the N-
terminal site including the first 15 amino acids of the same TG2 N-terminal tail were 
chosen for mutagenesis (Ismaa et al., 2000; Gaudry et al., 1999a; Hang et al., 2005). The 
binding sites for both integrins and HSPGs within the structure of TG2 are still not 
mapped. With the major focus on discovering a novel heparan sulfate binding site for 
TG2, examination of the crystal structure of TG2 was undertaken using the consensus 
sequence XBBXBX. As a result two likely candidates such as 590KIRILGEPKQKRK602 (HS1) 
localised at the C-terminal tail of TG2 and 202KFLKNAGRDCSRRSSPVYVGR222 (HS2) 
restricted to the core domain of enzyme were chosen. The findings presented in this 
thesis reveal for the first time a potential novel heparan sulfate binding site which is 
localised within the catalytic core domain of TG2 where the HS2 mutant (K205A, R209A) 
was generated. 
Inside the cell where the calcium concentration is low, TG2 binds GTP (Achyutan and 
Greenberg, 1987). This interaction is independent of the enzyme active site and can link it 
to a signalling pathway via the binding of alpha 1-adrenergic receptors (Nakaoka et al., 
1994). The binding of GTP forces conformational changes of TG2 which when in its GTP-
bound form adopts a closed conformation (Smethurst and Griffin, 1996; di Venere et al., 
2000). In contrast calcium binding is essential for TG2 to allow access to the catalytic triad 
at the active site thus facilitating the transamidating activity of the enzyme to take place. 
It is therefore possible that modulation of conformational changes, provoked by TG2-GTP 
interactions, may be important in the regulation of TG2 presence either at the cell surface 
or outside the cell.  So far GTP binding sites have been mapped within the structure of the 
enzyme. A number of reports identified different residues to be important for GTP-
binding and hydrolysis in rat and human TG2 (Ismaa et al., 1997, Ismaa et al., 2000; Begg 
et al., 2006). Residues Ser171 and Lys173 localised within the catalytic core domain and 
Arg580 present within the barrel 1 have been indicated to be important for GTP binding 
(Ismaa et al., 2000; Begg et al., 2006). Unlike other investigations, this study was based on 
using two TG2–GTP defective binding forms GTP1 (S171E) and GTP2 (K173L) to provide 
insights into the translocation pattern of the enzyme released at the cell surface and into 
the ECM. Both GTP mutants reduced the activity of the enzyme either on the cell surface 
or in cell lysates suggesting that TG2 activity is destabilised by these GTP mutations. This 
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finding is not necessarily consistent with early reports (Ismaa et al., 2000) which indicated 
that impairment in GTP binding caused by S171E and K173L did not affect TG2 activity. 
Further investigations of Antonyak et al., (2001) on transiently tranfected NIH3T3 cells 
revealed however that the human S171E mutant is poorly expressed and significantly 
reduces TG2 activity suggesting that TG2 activity is critically dependent on the presence 
of this GTP binding site. Ser171 does not seem to interact directly with GTP (Begg et al., 
2006a); therefore the lack of activity may be peculiar to that mutation rather than its 
ability to bind GTP. The poor expression of GTP1 and the almost undetectable level of the 
mutant at the NIH3T3 cell surface was shown to be opposite to the result obtained with 
HEK293 cells. Nevertheless the GTP1 mutant (open conformation) was found in smaller 
amounts on the cell surface of both cell types and was deposited less into the ECM, when 
compared to GTP2 mutant (uncharacterised conformation). However the GTP2 seemed to 
be secreted in much larger amounts. These findings suggest that externalisation of the 
enzyme is affected by the conformational changes caused by substitution of Ser with 
Glutamic acid rather than a lack in GTP binding. 
Despite lacking a typical ER targeting signal peptide and the characteristics of a 
cytoplasmic molecule, TG2 presence was detected in the membrane fractions (Griffin et 
al., 1978; Barnes et al., 1985; Tyrrell et al., 1985) and in the ECM (Aeschlimann and 
Paulsson 1994, Jones et al., 1997; Johnson et al., 1997 and 1999; Verderio et al., 1998). It 
is known that different cell types express a variety of transmembrane proteins and 
receptors such as integrins, selectins and CAMs (cell adhesion molecules) as well as 
HSPGs (heparan sulfate proteoglycans) (Akimov et al., 2000; Zemskov et al., 2006) . Some 
of them are recognized from their ability to directly or indirectly associate with TG2 and 
are thus believed to be involved in targeting of the enzyme to the cell membrane. So far 
both integrins and HSPGs were suggested to be high affinity binding partners of TG2 
(Gaudry et al., 1999b; Akimov et al., 2000; Johnson et al., 2008; Verderio et al., 2009). 
Therefore applying the suggestions of previous investigators (Akimov et al., 2000) 
regarding a possible integrin binding site within the β-barrel 2 domain of TG2, the C-
terminal deletion mutant (C) was generated. Analysis of the lysates of HEK293 and 
NIH3T3 cells transfected with the C-terminal deletion mutant revealed the expression 
level of this mutant to be greater than that of the wild type TG2 or comparable to it. 
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Although the C-terminal deletion mutant showed a significantly reduced activity than that 
of the wild type TG2 on the cell surface of HEK293 cells, and a comparable activity to the 
wild type enzyme on the cell surface of NIH3T3 cells it was still secreted to the cell surface 
of both cell types and further distributed into the ECM. This result could suggest that the 
C-terminal domain of TG2 is not implicated in the enzyme externalisation process. 
However, a recent publication suggesting that the integrin binding sites are likely to be 
located within the N-terminal domain of TG2 (Hang et al., 2005) does not rule out their 
involvement in TG2 secretion and its localisation within the ECM.  
Moreover this study has also provided insight into the expression of the two novel 
mutants HS1 (K600A, R601A, K602A) and HS2 (K205A, R209A) identified as possible TG2 
heparan sulfate binding mutants. The Ala substitution in the amino acids consensus of 
HS1 and HS2 mutants was considered likely to disturb the protein folding according to the 
protein structure viewed by a modeling program. Indeed, analysis of lysates expressing 
both of the mutants revealed their expression level to be comparable or greater than that 
of wild type. However to verify whether any of these mutants were folded correctly, their 
interaction with heparin was examined. There is evidence indicating high affinity between 
heparin which is considered to be an analogue of heparan sulfate and TG2 (Signorini et 
al., 1988; Gambetti et al., 2005). Experiments with Heparin Sepharose columns have 
shown that the binding of the enzyme to heparin does not interfere with the enzymatic 
activity of TG2 but protects it from thermal unfolding and proteolytic degradation 
(Gambetti et al., 2005). In keeping with these findings, this study demonstrated a high 
and low affinity of the wild type enzyme to heparin. Further examination revealed that 
this affinity to heparin is conformation dependent and is much greater when TG2 is in a 
GTP-bound form than in the open conformation when bound to the irreversible inhibitor 
of TG2 activity. It is also greater than that of the inactive Cys277 mutant form which 
stabilises the enzyme in an open conformation. Moreover no difference in the binding 
pattern to heparin between the HS1 and wild type enzyme suggested this particular 
mutation is not involved in TG2-HSPGs interactions. However, great discrepancies in the 
binding pattern of the HS2 mutant to that of wild type indicated the HS2 mutation site to 
represent a novel heparan sulfate binding site on TG2. Additional verification of the 
mutants’ activity confirmed that the low affinity of HS2 for the column resulted from the 
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substitution of two distinct amino acids with Ala and not from protein degradation. 
Further analysis of the triple and double mutants revealed that both of them had no 
greater influence on TG2 activity either at the cell surface or in the cell lysates. In addition 
the HS2 mutant was found in much smaller amounts than that of wild type enzyme when 
released to the cell surface or distributed into the ECM suggesting once more that this 
particular binding site is involved in the enzyme’s association with HS given earlier data 
(Verderio et al., 2009).  
Since the enzyme is known to be deposited into the ECM under normal physiological 
conditions (Verderio et al., 1998) as well as during the stress or inflammation caused by 
damage to the cell (Johnson et al., 1999; Upchurch et al., 1991) it’s affinity for the matrix 
proteins especially for FN, which is abundant at wound sites and the most ubiquitous 
component of the ECM is not surprising. Thus a number of reports have analysed the 
possible FN binding sites on TG2 and revealed that the likely intact N-terminal tail of TG2 
(Gaudry et al., 1999a) and the two residues encompassing Asp94 and Asp97 (Hang et al., 
2005) are involved in TG2-FN interactions. The deletion of the first 15 amino acids (Δ1-15) 
from the TG2 N-terminus and substitution of these two amino acids with Ala (FN1 D94A 
and D97A) resulted in either poor or good expression of the mutated TG2 in the HEK293 
and NIH3T3 cells, respectively. The double point mutant FN1 and the Δ1-15 N-terminal 
deletion mutant (N) both showed reduced binding to FN. However a greater reduction of 
binding to FN was caused by the Δ1-15 N-terminal deletion (N) when compared to the 
double point mutant (FN1). The FN1 mutation did not affect enzyme activity either 
intracellularly or at the cell surface. It is evident that although FN1 was suggested to be 
the main FN binding site on TG2 (Hang et al., 2005), the mutation has retained a similar 
distribution pattern to the wild type whether it was released at the cell surface or 
distributed into the ECM. Conversely, the N-terminal deletion mutant (N) had decreased 
TG2 activity on the cell surface and in cell lysates and was detected in greatly reduced 
amounts at the cell surface and in the ECM (Figure 6.1). In addition when compared to 
the FN1 mutant it was characterised by a low capacity to interact with Heparin an 
analogue of HSPGs which are present at the cell surface and in the ECM. All together 
these results suggest that the first 15 amino acids of the N-terminal tail of TG2 are 
important for both enzyme activity and its distribution on the cell surface and into the 
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matrix. In support of this hypothesis, previous data has demonstrated that TG2 when 
released from cells co-localises at the cell surface in association with FN, and that the 
intact N-terminus of TG2 mediates this interaction. Early experiments with SDS-
denaturated TG2 fragments identified the first seven amino acids to be important in this 
process (Jeong et al., 1995) which was further confirmed using expression vectors 
encoding truncated TG2 lacking these amino acids from the N-terminal tail of TG2 
(Gaudry et al., 1999a). Furthermore Hang et al., (2005) designed a synthetic peptide 
mapped to the first 12 amino acids from the N-terminal tail and additionally produced a 
TG2 deletion mutant with the first 15 amino acids deleted. Given that no direct binding of 
the synthetic peptide to fibronectin took place and the removal of the first 15 amino acids 
of TG2 did not appear to significantly reduce the interaction between truncated TG2 and 
the 42kDa FN fragment, the new fibronectin binding site on TG2 encompassing 
88WTATVVDQQDCTLSLQLTT106 was proposed. However according to results presented in 
this thesis, the truncated TG2 lacking the first 15 amino acids greatly inhibited its binding 
to human plasma fibronectin. Therefore in an attempt to explain these discrepancies the 
synthetic peptide 2AEELVLERCDLELE15 based on the proposed truncation was generated 
and examined for its ability to reduce and/or further compete with the enzyme for 
binding to fibronectin. Additionally for the scrambled peptide 2EECRLAEELLEDVL15 it was 
necessary to use the synthetic peptide 88WTATVVDQQDCTLSLQLTT106 as a control, so any 
changes in TG2-FN interaction could be attributed to the 2AEELVLERCDLELE15 peptide. The 
peptide P4, 2AEELVLERCDLELE15, but not its scrambled analogue and other control 
peptide was able to moderately inhibit interaction between the enzyme and fibronectin. 
This moderate inhibition could result from the fact that only the small fragment of this 
peptide is extended beyond the N-terminal domain and its second part is localised within 
the β-sheet and further partially covered α-helix, thus it makes it hard for it to be fully 
accessable by the fibronectin molecule. All together these results suggest that the first 15 
amino acids of the N-terminal tail of TG2 represents a recognition motif on the TG2 
molecule involved in the interaction of the enzyme with fibronectin.  
Understanding how TG2 can have so many pleiotropic functions in cells remains a 
challenging assignment. TG2 is believed to associate with many molecules present in the 
different cellular compartments which in turn influence cellular behaviour and its 
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physiology. Once externalised from cells, TG2 is removed from the cell surface and 
localised within the ECM, where it was shown to play a role in the cross-linking and 
stabilisation of matrix proteins (Aeschlimann and Paulson 1991; Raghunath et al., 1996; 
Zemskov et al., 2006). The extracellular matrix is an insoluble, adhesive complex 
supported by various structural and functional proteins released by cells themselves. 
These adhesive molecules associated with the solid matrix include, laminin, vitronectin, 
fibronectin and collagens, from which fibronectin have been particularly shown to be a 
good substrate for TG2 (Lorand and Turner, 1988; LeMosey et al., 1992; Gaudry et al., 
1999a; Hang et al., 2005). 
 
 
Figure 6.1 Cellular distribution of wild type TG2 and TG2 constructs including HS1 
(K600A, R601A, K602A), HS2 (K205A, R209A), GTP1 (S171E), GTP2 (K173L), FN1 (D94A, 
D97A), N (Δ1-15), and C (Δ594-687). 
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When outside the cell, TG2 interaction with FN may be mediated via the cross-linking 
activity of the enzyme (Jones et al., 1997; Verderio et al., 1998) or via  TG2 binding to FN 
(Balklava et al., 2002; Verderio et al., 2003) in a manner independent of its 
transamidating activity leading to increased cell attachment to the ECM. Thus later 
studies revealed that TG2 may  act as a novel adhesion receptor for cell surface FN 
(Akimov et al., 2000; Belkin et al., 2001; Kabir-Salmani et .al., 2005; Zemskov et al., 2006) 
and this association was shown to be further involved not only in adhesion of cells to the 
matrix (Akimov et al., 2000; Akimov and Belkin, 2001) but also in cell migration, signalling 
pathways and matrix assembly (Akimov et al., 2000; Belkin et al., 2001; Akimov and Belkin 
2001; Akimov and Belkin, 2001; Verderio et al., 2003).  
Consistent with findings that TG2 is not only released from healthy cells but also in 
response to cell damage or injury (Upchurch et al., 1991; Haroon et al., 1999; Johnson et 
al., 1999) which causes up-regulation and enhanced deposition into the ECM where it 
associates with FN fibrils or plasma FN (LeMosey et al., 1992; Gaudry et al., 1999a; 
Verderio et al., 1998), a cell model based on imitating normal and pathological conditions 
in vivo was generated. This model was based on the hypothesis that the TG2-FN 
association with cell surface heparan sulfate proteoglycans could mediate cell survival 
during matrix turnover when RGD containing peptides are released via proteolysis 
(Verderio et al., 2003). Initial investigations examined the function of TG2-bound FN 
matrix in cell-matrix interactions when inhibition of the classical RGD-dependent 
adhesion mechanisms was initiated. To achieve this the synthetic peptide GRGDTP 
containing an RGD consensus as well as anti-integrin function blocking antibodies 
directed against α5 and β1 subunits on osteoblasts were applied. The results were 
straightforward, obstructed RGD cell binding motifs on a FNIII10 domain, prevented its 
interaction with cell surface α5β1 integrins and further cell-matrix interaction, which 
however was restored upon the seeding of cells on a TG2-FN matrix (Verderio et al., 
2003). In support of previous findings, the data presented in this thesis confirm that TG2 
can support RGD-independent osteoblast adhesion when bound to FN. In addition the 
examination of other cell types including mouse 3T3 fibroblasts and the epithelial-like 
cells ECV-304 revealed the same restoration effect verifying once more the adhesive 
function of TG2 (Verderio et al., 2003). 
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Available data also suggested that the FN-bound TG2 RGD-independent cell adhesion, 
could not take place through other integrin receptors localised at the cell surface 
(Verderio et al., 2003; Telci et al., 2008) since the involvement of α4β1 integrins, that are 
found in negligible amounts in osteoblasts (Gronthos et al., 1997) and which are not 
involved in the formation of stress fibres (Sechler et al., 2000) seemed unlikely. Initial 
studies on the distribution of transglutaminase, demonstrated that TG2 in rat lung is 
strongly connected with its insoluble matrix which was found to contain high levels of 
heparan sulfate (Cocuzzi and Chung, 1986). Further investigations based on using the 
competitive substrate (mono-dansylcadaverine), demonstrated the formation of high 
molecular weight dermatan sulfate proteoglycans in bovine aortic endothelial cell 
cultures (Kinsella and Wight, 1990). Additionally by using in vitro purification techniques 
for TG2 involving  Heparin sepharose columns (Gambetti et al., 2005) and more 
physiological assay such as surface plasmon resonance (SPR) (Scarpellini et al., 2007) the  
affinity of TG2 to heparin, an analogue of heparan sulfate (Signorini et al., 1988) was 
confirmed. Moreover the treatment of HOB cells with heparinase and chondroitinase ABC 
revealed that only digestion of HSPGs with heparinase but not digestion of chondroitin 
sulphates with chondroitinase ABC, reduced FN-bound TG2 mediated RGD-independent 
cell adhesion. This indicated that HS chains are particularly important in supporting cell 
attachment to the ECM by TG2 (Verderio et al., 2003). Even though a vast amount of 
information has been revealed regarding TG2-HSPGs interactions, so far the binding site 
for HSPGs on the TG2 structure has not been found. Such a binding site has however been 
mapped within fibronectin, indicating that the HepII/IIICS region was mainly involved in 
its interaction with HSPGs and integrins and implicated in the cell adhesion process 
(Woods et al., 2001; Chon et al., 2001). In addition the effect of GAGs and FN fragments 
on cell attachment to FN coated surfaces showed that the binding to cell surface 
proteoglycan receptors was necessary for successful cell adhesion (Woods et al., 1986; 
Saoncella et al., 1999; Woods et al., 2000; Park et al., 2001; Sim et al., 2004). Although 
HSPGs have been shown to be necessary, they are not fully engaged in the cells binding to 
FN alone. Thus it was not surprising when Verderio et al., 2003 observed in HOB and 
Swiss 3T3 cells that the additional presence of TG2 and its possible interaction with HSPGs 
caused increased cell binding to the FN matrix (Verderio et al., 2003).  
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Given that the supported mechanism of adhesion was shown to be TG2, FN and HSPGs 
dependent, it was hypothesised that the heparin-binding peptide derived from TG2 could 
significantly impair interaction between TG2 and the common high-affinity binding sites 
on the heparan sulfate chain thus reducing FN-bound TG2 mediated RGD-independent 
adhesion mechanism. Since in this thesis a clear indication of such a binding site within 
the TG2 molecule has been proposed, it was of interest to generate a synthetic peptide 
encompassing the novel heparin binding site. However to generate such a peptide, 
protein modeling studies using three dimensional TG2 structures were undertaken. The 
data presented previously, showed osteoblast cell lines to be commonly used in adhesion 
experiments (Gronthos et al., 1997; Heath et al., 2002; Verderio et al., 2003) because of 
possessing a well defined pattern of integrin receptors, mainly β1 integrins and HS 
receptors (Verderio et al., 2003; Sim et al., 2004). It was therefore sensible to use this cell 
line as a cell model. Our results suggest that the possible heparin-binding peptide 
200NPKFLKNAGRDCSRRSS216 derived from the indicated sequence within the catalytic core 
domain of TG2 may act non specifically thus decreasing cell attachment not only to the 
FN bound TG2 matrix but also to the FN matrix alone as assessed by the physiological 
assay. These findings were consistent with an observed dose-dependent decrease in cell-
matrix adhesive strength (See chapter 5). In addition it was noticed that the capacity of 
the heparin-binding peptide to reduce cell adhesion on FN-TG2 was not changed in the 
presence of RGD synthetic peptide.  Such a strong inhibition by the generated peptide can 
only suggest its indirect effect on cell surface heparan sulfate proteoglycan receptors thus 
altering osteoblasts adhesion to FN which also takes place when integrin receptors are 
blocked by the presence of RGD peptide. Recent observations have identified one of the 
HS proteoglycans, syndecan-4 as the only member of the syndecan family that is able to 
enhance focal adhesion assembly (Woods and Couchman, 1994; Saoncella et al., 1999; 
Woods et al., 2000) and to interact through its heparan sulfate chains with integrins 
during focal adhesion formation (Woods and Couchman 1994; Couchman 2003). The 
influence of syndecan-4 and integrins on cell adhesion to fibronectin domains involves a 
series of downstream signalling pathways including the activation of tyrosine kinases by 
the integrins. In addition, the syndecan-4 cytoplasmic domain was shown to bind 
phospahtidylinositiol 4, 5, biphosphate thus initiating conformational changes that could 
lead to activation of the protein kinase PKCα (Shin et al., 2001; reviewed by Xian et al., 
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2010) further promoting cell spreading. Cell attachment and spreading studies suggested 
syndecan-4 as the possible co-receptor for the TG2 adhesive functions (Verderio et al., 
2003). As shown by Telci et al., (2008) fibronectin associated TG2 can interact with 
syndecan-4 heparan sulfate chains thus promoting RGD-independent cell adhesion and 
further activating PKCα leading to its interaction with β1 integrins and downstream 
signalling pathways. Therefore it is plausible that in addition to the targeted inhibition of 
TG2 heparan sulfate interactions by soluble P1 peptide, it’s possible interaction with the 
cell surface syndecan-4 heparan sulfate chains could lead to strong (> 50%) impairment of 
osteoblast attachment to FN possibly via the HEP II binding site. Such a non specific 
binding of the peptide with syndecan-4 chains could further affect β1 integrin-mediated 
cell adhesion to the RGD cell binding motif on FN thus leaving it unaffected by the 
additional presence of RGD peptide as shown in the experimental system.   
Hence to avoid this unwanted interaction, the long peptide was divided into two 
fragments. Further work presented in this thesis revealed that one of the short peptides 
derived from the 200NPKFLKNAGRDCSRRSS216 effectively reduces cell attachment and 
spreading to the FN bound TG2 matrix without having additional large non specific effects 
on cell adhesion to FN alone. The P3 peptide 208GRDCSRRSS216 but not its scrambled 
longer analogue showed a dose-dependent decrease, in the cell adhesion to FN-TG2 in 
the presence of the RGD peptide. Interestingly the P3 peptide also showed a 
compensation of the RGD induced loss of cell adhesion on FN alone possibly by mimicking 
the heparan sulfate binding site on TG2. The results presented here for the first time 
strongly suggest that this specific peptide is able to mimic the heparin binding site on TG2 
hence representing the novel heparan sulfate binding motif on enzyme. This discovery is 
in agreement with the previous presumptions of Verderio et al., (2009) indicating clusters 
rich in Lys and Arg residues as possible TG2 heparan sulfate binding motifs. In addition the 
fact that two positively charged residues within the P3 peptide (Arg 209 and Arg 213 from 
which one was selected to generate the HS2 mutant), are conserved within different 
species (human, monkey, bovine, mouse, rat) and are not just specific for human TG2 
(Figure 6.2) also supports this finding. 
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Figure 6.2 TG2 sequence alignment. Alignment is showing conserved (green) positively 
charged amino acids in position 202, 205, 209, 213, 222, and 387 among different species 
expressing TG2 as well members of transglutaminase family. Non-conserved residues are 
indicated by red.  
 
An unresolved aspect of these findings is the lack of the ability of the long peptide 
200NPKFLKNAGRDCSRRSS216 and the short 208GRDCSRRSS216 peptide capacity to bind and 
further compete off the wild type TG2 from the Heparin Sepharose column. Since both 
peptides consisted of clusters of positively charged amino acids, namely Arg and Lys, they 
were considered to be able to easily interact with the negatively charged GAG chains of 
heparin. However their limited association with the column could result from the fact that 
both sequences of the long and short peptides did not contain the putative heparin –
binding motif (XBBXB consensus) characterised previously by Cardin and Weintraub, 
(1989) as important for association of heparan sulfate derived peptides with heparin. In 
addition previous studies indicated that synthetic peptides may represent a small part of 
a bigger contiguous binding motif therefore be frequently less active than the intact 
protein they were derived from (Rouslahti and Pierschbacher, 1987; Mooradian et al., 
1992). This might be the case since results with the Cys277 mutant indicated the active 
site conformation of TG2 to play an important role for its interaction with Heparin. 
Moreover during synthesis changes of secondary structure can appear (Rouslahti and 
 
   
           ↓  ↓   ↓   ↓        ↓            ↓ 
Human TG2  190DICLILLDVNPKFLKNAGRDCSRRSSPVYVGRVVSGMVNCND232  382GDLSTKYDAPF392 
Monkey TG2  213DICLILLDVNPKFLKNAGRDCSRRSSPVYVGRVVSGMVNCND255  405GDLSTKYDAPF415 
Bovine TG2  190DICLMLLDVNPKFLRNAGRDCSRRSSPVYVGRVVSGMVNCND232  382GDLSTKYDAPF392 
Guinea pig TG2 190DICLMLLDTNPKFLKNAGQDCSRRSRPVYVGRVVSAMVNCND232  382GHLNVKYDAPF392 
Mouse TG2  190DTCLMLLDMNPKFLKNRSRDCSRRSSPIYVGRVVSAMVNCND232  382GDLSTKYDAPF392 
Rat TG2  190DACLMLLDVNPKFLKDRSRDCSRRSSPIYVGRVVSGMVNCND232  382GDLSTKYDASF392 
Chicken TG2  199AICLEMLDINPKFLRDQNLDCSRRNDPVYIGRVVSAMVNCND241  392GDLQVQYDIPF402 
 
Human TG1  299DACLYILDR-------RGMPYGGRGDPVNVSRVISAMVNSLD334  483GLVYMKYDTPF503 
Human TG3  186SICLSILDRSLNFRRDAATDVASRNDPKYVGRVLSAMINSND228  378GDVQLNFDMPF388 
Human TG4  190DCCISLLTE-------SSLKPTDRRDPVLVCRAMCAMMSFEK225  374GDIFIVYDTRF384 
Human TG5  191DICLKLLDKSLHFQTDPATDCALRGSPVYVSRVVCAMINSND233  384GEVDLNYDTPF394 
Human F13A  266DTCLYVMDR-------AQMDLSGRGNPIKVSRVGSAMVNAKD301  450GHVCFQFDAPF460 
Human B4.2  220DLSLRLLSK--------DKQVEKWSQPVHVARVLGALLHFLK254  404GTLGLTPAVSD414 
202 205 209 213 222 387 
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Pierschbacher, 1987) thus causing significant alterations to the stabilisation of the protein 
folding and reduced association with the column which enables it to compete off the 
parental protein. Additionally the limited interaction with the column may be due to the 
competition between the peptide and HSPGs that could be still present in HEK 293T cell 
extract (Schoefield et al., 2003).  
Consistent with the data presented in previous reports, our findings suggest that TG2 
through its interaction with FN and HSPGs contributes to maintaining cell-matrix 
interactions. Moreover identification of an intact N-terminal tail as a key element 
involved in TG2 association with cell surface FN and a novel HS binding site within the TG2 
structure further indicated the conformational requirements necessary for this enzyme 
interaction with Heparan sulfates and with heparin.  
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